Datasets:

ravistech

/

clinical-trial-llm-CAR-T-CELL-V1

like 0

Follow

ravistech 6

{ "NCT_ID" : "NCT02813252", "Brief_Title" : "Long-Term Follow-up Study for Patients Previously Treated With JCAR015", "Official_title" : "Long-Term Follow-up Protocol for Subjects Treated With JCAR015", "Conditions" : ["Acute Lymphoblastic Leukemia"], "Interventions" : ["Genetic: JCAR015"], "Location_Countries" : ["United States"], "Study_Design" : { "Study_Type" : "OBSERVATIONAL", } }

#Study Description Brief Summary This study will provide long-term follow-up for patients who have received treatment with JCAR015 in a previous clinical trial. In this study, patients will be followed for up to 15 years after their last dose of JCAR015 for evaluation of delayed adverse events, presence of persisting JCAR015 vector sequences, and survival. #Intervention - GENETIC : JCAR015 - No study drug is administered in this study. Patients who received JCAR015 in a previous trial will be evaluated in this trial for long-term safety and efficacy.

#Eligibility Criteria: Inclusion criteria: * Patients who have received at least one dose of JCAR015 in a previous treatment protocol. * Patients who have provided informed consent for the long-term follow-up study prior to study participation. Exclusion criteria: * None. All patients who have previously received JCAR015 treatment are eligible for this long-term follow-up study. Sex : ALL Ages : - Minimum Age : 18 Years - Age Group (Child: birth-17, Adult: 18-64, Older Adult: 65+) : ADULT, OLDER_ADULT Accepts Healthy Volunteers: No

{ "NCT_ID" : "NCT05130489", "Brief_Title" : "CAR T Cell Therapy Related Cardiovascular Outcomes", "Official_title" : "Chimeric Antigen Receptor (CAR) Cell Therapy Related Cardiovascular Outcomes", "Conditions" : ["Cardiovascular Diseases", "B-cell Acute Lymphoblastic Leukemia", "B-cell Lymphoma Refractory", "B-cell Lymphoma Recurrent", "Primary Mediastinal Large B-cell Lymphoma (PMBCL)", "Diffuse Large B Cell Lymphoma", "Cardiotoxicity", "Cardiovascular Complication"], "Location_Countries" : ["United Kingdom"], "Study_Design" : { "Study_Type" : "OBSERVATIONAL", } }

#Study Description Brief Summary This will be a cohort study of all patients receiving Cluster of Differentiation 19 (CD19)-specific CAR T cell therapy for relapsed/refractory B cell haematological malignancies. Patients will receive cardiac assessment and have serum cardiac biomarkers, ECG, transthoracic echocardiogram and cardiac magnetic resonance imaging performed at baseline prior to CAR T cell therapy, 7 days post CAR T cell infusion, and 3 months post CAR T cell infusion. Abnormalities in these cardiac investigations will be used to demonstrate cardiac injury and identify which patients are most at risk of developing cardiac injury related to CAR T cell therapy. Detailed Description CD19-specific chimeric antigen receptor (CAR) T cells are a novel therapy for relapsing or refractory blood cancers, which have delivered a significant improvement in the rates of complete and partial remission. However, they are associated with toxicities, with some of early evidence suggestive of cardiovascular involvement. Despite this, the full extent of cardiovascular toxicity is poorly understood. This research study seeks to understand the cardiac safety of CAR T cells in patients who receive this therapy as part of standard care for relapsed/refractory B-cell blood cancer. They will be assessed for cardiovascular risk factors via history, blood biomarkers, and cardiac imaging tests. These parameters will be repeated at 7 days following administration of the CAR T cells or if there are signs of cardiovascular deterioration, and again at 3 months follow up. The aim is to predict the cohort most at risk of cardiovascular toxicity, and demonstrate evidence of cardiac injury on the cardiac imaging scans.

#Eligibility Criteria: Inclusion Criteria: * Patients with capacity, (aged 16 and older) * Undergoing CAR T cells for treatment for relapsing or refractory haematological malignancies Exclusion Criteria: * Patients under 16 years Sex : ALL Ages : - Minimum Age : 16 Years - Age Group (Child: birth-17, Adult: 18-64, Older Adult: 65+) : ADULT, CHILD, OLDER_ADULT Accepts Healthy Volunteers: No

{ "NCT_ID" : "NCT03726515", "Brief_Title" : "CART-EGFRvIII + Pembrolizumab in GBM", "Official_title" : "Phase 1 Study of EGFRvIII-Directed CAR T Cells Combined With PD-1 Inhibition in Patients With Newly Diagnosed, MGMT-Unmethylated Glioblastoma", "Conditions" : ["Glioblastoma"], "Interventions" : ["Biological: Pembrolizumab", "Biological: CART-EGFRvIII T cells"], "Location_Countries" : ["United States"], "Study_Design" : { "Study_Type" : "INTERVENTIONAL", "Phase" : ["PHASE1"], "Primary_Purpose" : "TREATMENT", "Allocation" : "NA", "Interventional Model" : "SINGLE_GROUP", "Masking" : "NONE" } }

#Study Description Brief Summary This is an open-label, phase 1 study to assess the safety and tolerability of EGFRvIII T cells in combination with pembrolizumab (PD-1 Inhibitor) in patients with newly diagnosed, EGFRvIII+, MGMT-unmethylated glioblastoma. #Intervention - BIOLOGICAL : CART-EGFRvIII T cells - autologous T cells that have been engineered to express an extracellular Humanized single chain antibody (scFv) with specificity for EGFRvIII linked to an intracellular signaling molecule comprised of a tandem signaling domain of the 4-1BB and TCRζ signaling modules. - BIOLOGICAL : Pembrolizumab - humanized monoclonal immunoglobulin (Ig) G4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immune checkpoint inhibitory and antineoplastic activities. - Other Names : - Keytruda

#Eligibility Criteria: Inclusion Criteria: * One of the following diagnoses of GBM: a. Newly diagnosed glioblastoma multiforme that is histologically confirmed by pathology review of surgically resected tissue; OR b. An integrated molecular/pathologic diagnosis of diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV. This diagnosis requires patients have one of the following: i. High-level amplification of EGFR; OR ii. Combined whole chromosome 7 gain and whole chromosome 10 loss (+7/-10); OR iii. TERT promoter mutation. * Undergone tumor resection. * No prior systemic therapies, radiation, tumor-treating fields, or intratumoral therapeutic agents including Gliadel wafers are allowed. Tumor resection must be the only tumor-directed treatment that the patient has received for glioboblastoma. * Tumor tissue is positive for EGFRvIII expression, as performed by either the University of Pennsylvania's in-house fusion transcript panel (RNA-based assay using Illumina HiSeq platform) or NeoGenomics Laboratories (quantitative RT-PCR assay). * Tumor tissue is negative for MGMT promoter methylation (i.e. the tumor is MGMT-unmethylated), as performed by either the University of Pennsylvania's in-house pyrosequencing protocol or NeoGenomics Laboratories. * Patients >= 18 years * ECOG performance status 0 <= age <= 1 * Provides written informed consent * Must have adequate organ function as measured by: 1. White blood count >= 2500/mm3; platelets >= 100,000/mm3, hemoglobin >= 9.0 g/dL; without transfusion or growth factor support 2. AST, ALT, LDH, alkaline phosphatase within 2.5 x upper normal limit, and total bilirubin <= 2.0 mg/dL 3. Serum creatinine < 1.5 x upper limit of normal 4. Adequate cardiac function (LVEF >= 45%) * Subjects of reproductive potential must agree to use acceptable birth control methods. Exclusion Criteria: * Pregnant or lactating women * Inadequate venous access for or contraindications to leukapheresis. * Active Hepatitis B, hepatitis C, or HIV infection, or other active, uncontrolled infection * History of allergy or hypersensitivity to study product excipients (human serum albumin, DMSO, and Dextran 40) * History of severe hypersensitivity reactions to other monoclonal antibodies which in the opinion of the investigator may post an increased risk of serious infusion reactions. * Requirement for immunosuppressive agents including but not limited to cyclosporine, MMF, tacrolimus, rapamycin, or anti-TNF agents within 4 weeks of eligibility confirmation by the physician-investigator. * Subjects with a history of known or suspected, severe or uncontrolled autoimmune or connective tissue disease. Patients with vitiligo, controlled type 1 diabetes mellitus (on stable insulin dose), residual autoimmune-related hypothyroidism (due to autoimmune condition only requiring hormone replacement), or psoriasis (not requiring systemic treatment), or conditions not expected to recur in the absence of an external trigger, are permitted to enroll. * Known history or current interstitial lung disease or non-infectious pneumonitis * Prior allogenic bone marrow or solid organ transplant * Any uncontrolled active medical or psychiatric disorder that would preclude participation as outlined. * Severe, active co-morbidity in the opinion of the physician-investigator would preclude participation in this study, including but not limited to the following: * Unstable angina within 6 months prior to eligibility confirmation by the physician-investigator * Transmural myocardial infarction within the last 6 months prior to eligibility confirmation by the physician-investigator * New York Heart Association grade II or greater congestive heart failure requiring hospitalization within 12 months prior to eligibility confirmation by the physician-investigator. * Serious and inadequately controlled cardiac arrhythmia * Serious or non-healing wound, ulcer, or history of abdominal fistula, gastrointestinal perforation, intra-abdominal abscess major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to eligibility confirmation by the physician-investigator, with the exception of the craniotomy for tumor resection. 13. Patients with tumors primarily localized to the brain stem or spinal cord. Sex : ALL Ages : - Minimum Age : 18 Years - Age Group (Child: birth-17, Adult: 18-64, Older Adult: 65+) : ADULT, OLDER_ADULT Accepts Healthy Volunteers: No

{ "NCT_ID" : "NCT04938115", "Brief_Title" : "Cell Therapy for CD7 Positive Acute Myeloid Leukemia or Mixed Lineage Leukemia", "Official_title" : "Cell Therapy for CD7 Positive Acute Leukemia or Mixed Lineage Leukemia Except Those Who Are Diagnosed With T-ALL/T-LBL Using CD7-Specific CAR-T Cells", "Conditions" : ["Leukemia, T Cell"], "Interventions" : ["Biological: CD7 CART"], "Location_Countries" : ["China"], "Study_Design" : { "Study_Type" : "INTERVENTIONAL", "Phase" : ["NA"], "Primary_Purpose" : "TREATMENT", "Allocation" : "NA", "Interventional Model" : "SINGLE_GROUP", "Masking" : "NONE" } }

#Study Description Brief Summary This is an open, single-arm, clinical study to evaluate efficacy and safety of anti CD7 CAR-T cell in the treatment of CD7 Positive acute leukemia or mixed lineage leukemia except those who are diagnosed with T-ALL/T-LBL Detailed Description The CARs consist of an anti-CD7 VHHs, a portion of the human CD137（4-1BB） molecule, and the intracellular component of the human CD3ζ molecule. Prior to CAR-T cell infusion, the patients will be subjected to preconditioning treatment. After CAR-T cell infusion, the patients will be evaluated for adverse reactions and efficacy. The Main research objectives: To evaluate the safety and efficacy of CD7 CAR-T cells in patients with CD7 Positive acute leukemia or mixed lineage leukemia except those who are diagnosed with T-ALL/T-LBL The Secondary research objectives: To investigate the cytokinetic characteristics of CD7 CAR-T cells in patients with CD7 Positive acute leukemia or mixed lineage leukemia except those who are diagnosed with T-ALL/T-LBL #Intervention - BIOLOGICAL : CD7 CART - Biological: CD7 CAR-T; Drug: Cyclophosphamide,Fludarabine; Procedure: Leukapheresis

#Eligibility Criteria: Inclusion Criteria: * Diagnosis of refractory or relapsed CD7+ acute myeloid leukemia or mixed lineage leukemia was made according to the NCCN 2019.V2 guideline. Refractory AML is defined as a patient who has failed to achieve complete remission after induction therapy. Relapsed AML is defined as the reappearance of blasts (5%) in either peripheral blood or bone marrow. Patient diagnosed with AML should be treated and whose disease failed with at least 2 prior lines of therapies. Patients whose tumor burden >=5% blasts, or who have persistent positive minimal residual disease (MRD), or have reappearance of extramedullary lesions are also considered eligible; * CD7+ expression on tumor cells (CD7 positive blasts >=50% by flow cytometry); * Life expectancy greater than 12 weeks; * KPS or Lansky score>=60; * HGB>=70g/L (can be transfused); * oxygen saturation of blood>90%; * Total bilirubin (TBil)<=3 × upper limit normal, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <= 5×upper limit of normal; * Informed consent explained to, understood by and signed by patient/guardian Exclusion Criteria: * Any of the following cardiac criteria: Atrial fibrillation/flutter; Myocardial infarction within the last 12 months; Prolonged QT syndrome or secondary prolonged QT, per investigator discretion. Cardiac echocardiography with LVSF (left ventricular shortening fraction)<30% or LVEF(left ventricular ejection fraction)<50%; or clinically significant pericardial effusion. Cardiac dysfunction NYHA(New York Heart Association) III or IV (Confirmation of absence of these conditions on echocardiogram within 12 months of treatment); * Has an active GvHD; * Has a history of severe pulmonary function damaging; * With other tumors which is/are in advanced malignant and has/have systemic metastasis; * Severe or persistent infection that cannot be effectively controlled； * Merging severe autoimmune diseases or immunodeficiency disease; * Patients with active hepatitis B or hepatitis C([HBVDNA+]or [HCVRNA+]); * Patients with HIV infection or syphilis infection; * Has a history of serious allergies on Biological products (including antibiotics); * Clinically significant viral infection or uncontrolled viral reactivation of EBV(Epstein-Barr virus), CMV(cytomegalovirus), ADV(adenovirus), BK-virus, or HHV(human herpesvirus)-6; * Presence of symptomatic disorders of the central nervous system, which include but not limited to uncontrolled epilepsy, cerebrovascular ischemia/hemorrhage, dementia, and cerebellar disease, etc.; * Have received transplant treatment for less than 6 months in prior to enrollment; * Being pregnant and lactating or having pregnancy within 12 months; * Any situations that the researchers believe will increase the risks for the subject or affect the results of the study Sex : ALL Ages : - Minimum Age : 2 Years - Maximum Age : 70 Years - Age Group (Child: birth-17, Adult: 18-64, Older Adult: 65+) : ADULT, CHILD, OLDER_ADULT Accepts Healthy Volunteers: No

{ "NCT_ID" : "NCT01865617", "Brief_Title" : "Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia", "Official_title" : "Phase I/II Study of Immunotherapy for Advanced CD19+ Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia/Lymphoma and Non-Hodgkin Lymphoma With Defined Subsets of Autologous T Cells Engineered to Express a CD19-Specific Chimeric Antigen Receptor", "Conditions" : ["CD19-Positive Neoplastic Cells Present", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Chronic Lymphocytic Leukemia", "Recurrent Diffuse Large B-Cell Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Non-Hodgkin Lymphoma", "Recurrent Small Lymphocytic Lymphoma", "Refractory Acute Lymphoblastic Leukemia", "Refractory Chronic Lymphocytic Leukemia", "Refractory Diffuse Large B-Cell Lymphoma", "Refractory Mantle Cell Lymphoma", "Refractory Non-Hodgkin Lymphoma", "Refractory Small Lymphocytic Lymphoma"], "Interventions" : ["Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes"], "Location_Countries" : ["United States"], "Study_Design" : { "Study_Type" : "INTERVENTIONAL", "Phase" : ["PHASE1", "PHASE2"], "Primary_Purpose" : "TREATMENT", "Allocation" : "NON_RANDOMIZED", "Interventional Model" : "SINGLE_GROUP", "Masking" : "NONE" } }

#Study Description Brief Summary This phase I/II trial studies the side effects and best dose of laboratory treated T cells to see how well they work in treating patients with chronic lymphocytic leukemia, non-Hodgkin lymphoma, or acute lymphoblastic leukemia that have come back or have not responded to treatment. T cells that are treated in the laboratory before being given back to the patient may make the body build an immune response to kill cancer cells. Detailed Description PRIMARY OBJECTIVES: I. To evaluate the feasibility and safety of adoptive T cell therapy using ex vivo expanded autologous CD8 positive (+) and CD4+ CD19 chimeric antigen receptor (CAR)-T cells for patients with advanced CD19+ B cell malignancies. SECONDARY OBJECTIVES: I. To determine the duration of in vivo persistence of adoptively transferred T cells, and the phenotype of persisting T cells. II. To determine if adoptively transferred T cells traffic to the bone marrow and function in vivo. III. To determine if the adoptive transfer of CD19 CAR-T cells results in depletion of CD19+ B cells in vivo as a surrogate for functional activity. IV. To determine if the adoptive transfer of CD19 CAR-T cells has antitumor activity in patients with measurable tumor burden prior to T cell transfer. V. To determine if the adoptive transfer of CD19 CAR-T cells is associated with tumor lysis syndrome. OUTLINE: This is a phase I, dose-escalation study of autologous CD19 CAR T-cells followed by a phase II study. Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells intravenously (IV) over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity. DOSE DENSE EXPANSION COHORT: An additional cohort will receive a second anti-CD19-CAR lentiviral vector-transduced autologous T cell infusion without additional lymphodepleting chemotherapy 10-21 days after the first infusion if adequate CD19 CAR-T cells can be produced and appropriate criteria are met. After completion of study treatment, patients are followed up for at least 15 years. #Intervention - BIOLOGICAL : Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes - Given IV

#Eligibility Criteria: Inclusion Criteria: INCLUSIONS FOR SCREENING AND LEUKAPHERESIS * Patients with CD19 expressing acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL) or non-Hodgkin lymphoma (NHL) * Ability to understand and provide informed consent * Not human immunodeficiency virus (HIV) infected INCLUSIONS FOR CAR-T CELL THERAPY * Patients with: * CLL who are beyond first remission and who have failed combination chemoimmunotherapy with regimens containing a purine analogue and anti-CD20 antibody or who were not eligible for such therapy; patients with CLL for whom ibrutinib is now standard first line therapy, must have progressed on ibrutinib; patients with fludarabine refractory disease are eligible; patients may be treated following allogeneic hematopoietic cell transplant (HCT); for the concurrent ibrutinib cohort, patients must agree to continue on or be restarted on ibrutinib and must not have had prior intolerance to ibrutinib that would prevent this; patients managed with prior dose reductions for toxicity will continue at the reduced dose for the remainder of this study * Indolent NHL or mantle cell NHL who are beyond first remission and previously treated with chemoimmunotherapy or who were not eligible for such therapy; patients who have relapsed following autologous or allogeneic HCT are eligible * Aggressive NHL such as diffuse large B-cell lymphoma (DLBCL), who have relapsed or have residual disease following treatment with curative intent; patients should have relapsed following, or not be eligible for high-dose therapy and autologous HCT; patients with chemotherapy refractory disease or marrow involvement or comorbidities precluding successful autologous HCT are eligible; patients may be treated following allogeneic HCT * Patients with CD19 expressing, relapsed or refractory ALL * Patients with one of the above diagnoses whose disease state does not qualify but who have prognostic indicators that suggest a high risk of progression of disease may be screened and undergo leukapheresis; enrollment for T cell therapy would require meeting the full disease state eligibility * Confirmation of diagnosis * Evidence of CD19 expression by immunohistochemistry or flow cytometry on any prior or current tumor specimen or high likelihood of CD19 expression based on disease histology * Karnofsky performance status >= 60% * All patients of childbearing potential must be willing to use a contraceptive method before, during, and for at least two months after the T cell infusion * Ability to understand and provide informed consent Exclusion Criteria: EXCLUSIONS FOR CAR-T CELL THERAPY * Patients requiring ongoing daily corticosteroid therapy at a dose of > 15 mg of prednisone per day (or equivalent); pulsed corticosteroid use for disease control is acceptable * Active autoimmune disease requiring immunosuppressive therapy is excluded unless discussed with the Principal Investigator (PI) * Serum creatinine > 2.5 mg/dL * Serum glutamic oxaloacetic transaminase (SGOT) > 5 x upper limit of normal * Bilirubin > 3.0 mg/dL * Patients with clinically significant pulmonary dysfunction, as determined by medical history and physical exam should undergo pulmonary function testing; those with a forced expiratory volume in one second (FEV1) of < 50 % of predicted will be excluded * Diffusing capacity of the lung for carbon monoxide (DLCO) (corrected) < 40% will be excluded * Significant cardiovascular abnormalities as defined by any one of the following: New York Heart Association (NYHA) class III or IV congestive heart failure, clinically significant hypotension, uncontrolled symptomatic coronary artery disease, or a documented ejection fraction of < 35% * Uncontrolled active infection Sex : ALL Ages : - Minimum Age : 18 Years - Age Group (Child: birth-17, Adult: 18-64, Older Adult: 65+) : ADULT, OLDER_ADULT Accepts Healthy Volunteers: No

{ "NCT_ID" : "NCT03068416", "Brief_Title" : "CD19-targeting, 3rd Generation CAR T Cells for Refractory B Cells Malignancy", "Official_title" : "CD19-targeting, 3rd Generation CAR T Cells for Refractory B Cells Malignancy - a Phase II Trial.", "Conditions" : ["B-cell Leukemia", "B-Cell Lymphoma"], "Interventions" : ["Biological: CAR T cells"], "Location_Countries" : ["Sweden"], "Study_Design" : { "Study_Type" : "INTERVENTIONAL", "Phase" : ["PHASE2"], "Primary_Purpose" : "TREATMENT", "Allocation" : "NA", "Interventional Model" : "SINGLE_GROUP", "Masking" : "NONE" } }

#Study Description Brief Summary Treatment of patients with B cell lymphoma or leukemia with two doses of CD19-targeting chimeric antigen receptor (CAR) T cells to evaluate for safety and efficacy. Detailed Description Treatment of patients with B cell lymphoma or leukemia with two doses of CD19-targeting chimeric antigen receptor (CAR) T cells to evaluate for safety and efficacy. The CAR consists of a CD19 targeting antibody scFv with three intracellular signaling domains derived from CD3 zeta, CD28 and 4-1BB. Autologous T cells will be gene engineered with the CAR gene using a retrovirus vector. Prior to T cell infusion, the patients will be subjected to preconditioning treatment. After the second infusion patients will be subjected to immunomodulatory treatment. After T cell infusion, the patients will be evaluated for 24 months for adverse reactions, persistence of CAR T cells and efficacy. Primary outcome: - Registration of the safety profile such as inflammation, fever, pain, changes in blood pressure, pulse and other adverse events. Weekly for the first 6 weeks, then at 3, 6, 9, 12, 15, 18, 21 and 24 months. Secondary outcome: Tumor response, CAR T cell persistence and immunological profile * Determination of tumor size and the tumor marker CD19. * Determination of the levels of circulating B cells. * Determination of the level of CAR T cells (mRNA and cells) in blood and biopsies. * Determination of activation markers on CAR T cells such as CD107a. * Determination of the presence of immunological markers in blood and biopsies. At 1 and 3 weeks then at 3, 6, 9, 12, 15, 18, 21 and 24 months. #Intervention - BIOLOGICAL : CAR T cells - Autologous CD19-targeting, 3rd generation CAR T cells

#Eligibility Criteria: Inclusion Criteria: * Relapsed or refractory CD19+ B-cell lymphoma or leukemia with no other curative treatment option available. * Measurable disease. * All ages * Performance status ECOG 0 <= age <= 2. * Fertile females/males must consent to use contraceptives during participation of the trial. * Signed informed consent. Exclusion Criteria: * Any significant medical or psychiatric illness that would prevent the patient from giving informed consent or from following the study procedures. * Patients with primary CNS lymphoma. * Known human immunodeficiency virus (HIV) infection. * Active and/or severe infection (e.g. tuberculosis, sepsis and opportunistic infections, active hepatitis B virus (HBV) or active hepatitis C virus (HCV) infection. * Other serious underlying medical conditions, which, in the Investigator's judgment, could impair the ability of the patient to perform the treatment. * Treatment with an investigational product within 30 days prior to enrollment, or at least 5 half-lives of that drug, which is longest. * Pregnancy * Patients that do not consent to that tissue and blood samples are stored in a biobank * Patients whose cells cannot be manufactured. Sex : ALL Ages : - Minimum Age : 0 Years - Maximum Age : 100 Years - Age Group (Child: birth-17, Adult: 18-64, Older Adult: 65+) : ADULT, CHILD, OLDER_ADULT Accepts Healthy Volunteers: No

{ "NCT_ID" : "NCT02976857", "Brief_Title" : "A Phase 1 Study Evaluating Safety and Efficacy of C-CAR011 Treatment in DLBCL Subjects", "Official_title" : "A Phase 1 Single Center, Non-randomized Study Evaluating Safety and Efficacy of Anti-CD19 Chimeric Antigen Receptor T-cell (C-CAR011) Treatment in Subjects With Refractory Diffuse Large B-cell Lymphoma", "Conditions" : ["Refractory Diffuse Large B-Cell Lymphoma"], "Interventions" : ["Biological: C-CAR-011"], "Location_Countries" : ["China"], "Study_Design" : { "Study_Type" : "INTERVENTIONAL", "Phase" : ["PHASE1"], "Primary_Purpose" : "TREATMENT", "Allocation" : "NA", "Interventional Model" : "SINGLE_GROUP", "Masking" : "NONE" } }

#Study Description Brief Summary The trial is a single arm, single-center, non-randomized phase I clinical trial which is designed to evaluate the safety and efficacy of C-CAR011 in treatment of refractory DLBCL Detailed Description The 3x3 dose escalation design will be adopted in order to determine the maximum tolerated dose (MTD). Subjects will be enrolled into low-dose group, medium-dose group and high-dose group as below: Dose CAR+ cells/kg Low 0.8×106 Medium 2.5×106 High 5.0×106 DLT is evaluated within 30 days post C-CAR011 infusion). #Intervention - BIOLOGICAL : C-CAR-011 - lymphocytes will be transduced with lentiviral vector containing CAR-CD19 gene. - Other Names : - CAR-CD19

#Eligibility Criteria: Inclusion Criteria: * Histologically diagnosed as DLBCL according to the NCCN non-Hodgkin's lymphoma Clinical Practice Guidelines (3rd edition 2016) * Refractory DLBCL * All subjects must have received adequate prior therapy including anti-CD20 monoclonal antibody (unless tumor is CD20-negative) and an anthracycline containing chemotherapy regimen. The standardized treatment regimens reference to NCCN non-Hodgkin lymphoma Clinical Practice Guidelines (2016 Version 3) * At least one measurable lesion per revised IWG Response Criteria (the longest diameter of the tumor >= 1.5 cm) * Age 18 <= age <= 70 years, male or female * Expected survival >= 12 weeks * ECOG score 0 <= age <= 1 * Subject's left ventricular ejection fraction (LVEF) is >= 50% and no evidence of pericardial effusion as determined by an ECHO * At least 4 weeks from receiving previous treatment (radiotherapy, chemotherapy, monoclonal antibody therapy or other treatments) * No contraindications of peripheral blood apheresis * Female subjects in childbearing age, their serum or urine pregnancy test must be negative, and must agree to take effective contraceptive measures during the trial measures * Volunteered to participate in this study and signed informed consent Exclusion Criteria: * Have a history of allergy to cellular products * Used any genetically modified T cell therapy * History of allogeneic hematopoietic stem cell transplantation * Severe active infection (uncomplicated urinary tract infections, bacterial pharyngitis allowed) or currently receiving intravenous antibiotic therapy and received intravenous antibiotic therapy within one week. Prophylactic antibiotic, antiviral and antifungal treatment is permissible * Hepatitis B or hepatitis C virus infection (including carriers), as well as acquired, congenital immune deficiency diseases, including but not limited to HIV-infected persons * Patients with class III and IV heart failure according to the NYHA Heart Failure Classifications * A history of QT prolongation * A history of epilepsy or other central nervous system disorders * The patient had a history of other primary cancers, with the following exceptions: Excisional non-melanoma such as cutaneous basal cell carcinoma; Cured in situ carcinoma such as cervical cancer, bladder cancer or breast cancer * Subjects with any autoimmune disease or any immune deficiency disease or other disease in need of immunosuppressive therapy * Used of systemic steroids within two weeks (using inhaled steroids is an exception) * Women who are pregnant or lactating or have breeding intent in 6 months * Participated in any other clinical trial within three months * The investigators believe that any increase in the risk of the subject or interference with the results of the trial Sex : ALL Ages : - Minimum Age : 18 Years - Maximum Age : 70 Years - Age Group (Child: birth-17, Adult: 18-64, Older Adult: 65+) : ADULT, OLDER_ADULT Accepts Healthy Volunteers: No

{ "NCT_ID" : "NCT03310619", "Brief_Title" : "A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies", "Official_title" : "An Exploratory Phase 1/2 Trial To Evaluate The Safety And Efficacy Of JCAR017 Combinations In Subjects With Relapsed/Refractory B-Cell Malignancies (PLATFORM)", "Conditions" : ["Lymphoma, Non-Hodgkin", "Lymphoma, Large B-Cell, Diffuse", "Lymphoma, Follicular"], "Interventions" : ["Drug: Durvalumab", "Drug: CC-122", "Drug: CC-220", "Drug: Relatlimab", "Biological: JCAR017", "Drug: Ibrutinib", "Drug: CC-99282", "Drug: Nivolumab"], "Location_Countries" : ["United States"], "Study_Design" : { "Study_Type" : "INTERVENTIONAL", "Phase" : ["PHASE1", "PHASE2"], "Primary_Purpose" : "TREATMENT", "Allocation" : "RANDOMIZED", "Interventional Model" : "PARALLEL", "Masking" : "NONE" } }

#Study Description Brief Summary This is a global, open-label, multi-arm, parallel multi-cohort, multi-center, Phase 1/2 study to determine the safety, tolerability, PK, efficacy and patient-reported quality of life of JCAR017 in combination with various agents. This protocol is intended to evaluate various drug combinations with JCAR017, as separate arms, over the life of the protocol, using the same objectives. Each combination will be evaluated separately (ie, the intention is not to compare between combinations) for the purposes of the objectives, trial design, and statistical analysis. The following combinations will be tested: Arm A: JCAR017 in combination with durvalumab Arm B: JCAR017 in combination with CC-122 (avadomide) Arm C: JCAR017 in combination with CC-220 (iberdomide) Arm D: JCAR017 in combination with ibrutinib Arm E: JCAR017 in combination with relatlimab and/or nivolumab Arm F: JCAR017 in combination with CC-99282 Additional arms will be added by way of amendment once combination agents have been selected. The study will consist of 2 parts: dose finding (Phase 1) and dose expansion (Phase 2). Dose expansion may occur in one or more arms. Detailed Description During Phase 1, different arms may be opened to test JCAR017 in combination with combination agent(s) in adult subjects with R/R aggressive B-cell NHL. Within each arm, different doses and schedules of JCAR017 and the combination agent(s) may be tested in several cohorts and subcohorts per arm. During Phase 2 of the study, the expansion of any dose level and schedule for any arm that has been shown to be safe may occur. Arm A will test JCAR017 in combination with Durvalumab Arm B will test JCAR017 in combination with CC-122 Arm C will test JCAR017 in combination with CC-220 (iberdomide ) Arm D will test JCAR017 in combination with ibrutinib. Arm E will test JCAR017 in combination with relatlimab and/or nivolumab Arm F will test JCAR017 in combination with CC-99282 All subjects from Phase 1 and Phase 2 will be followed for 24 months following JCAR017 infusion. Post-study follow-up for survival, relapse, long-term toxicity (including new malignancies), and viral vector safety will continue under a separate long-term follow-up (LTFU) protocol for up to 15 years after the JCAR017 dose as per health authority regulatory guidelines. #Intervention - BIOLOGICAL : JCAR017 - Gene modified autologous T cells - DRUG : Durvalumab - Anti-PD-L1 - Other Names : - MEDI4736 - DRUG : CC-122 - Pleiotropic Pathway Modifier - DRUG : Ibrutinib - Ibrutinib - DRUG : CC-220 - CC-220 - DRUG : Relatlimab - Relatlimab - DRUG : Nivolumab - Nivolumab - DRUG : CC-99282 - CC-99282

#Eligibility Criteria: Inclusion Criteria: * Subject is >= 18 years at the time of signing the informed consent form (). * Subject must understand and voluntarily sign an ICF prior to any study-related assessments/procedures being conducted. * Subject is willing and able to adhere to the study visit schedule and other protocol requirements. * Subject must have aggressive B-cell NHL according to 'the 2016 revision of the WHO classification of lymphoid neoplasms', histologically confirmed at last relapse by the treating institution, defined as: 1. Diffuse large B-cell lymphoma (DLBCL) Not otherwise specified (NOS) including transformed indolent Non-Hodgkin lymphoma (NHL) 2. Follicular lymphoma Grade 3B 3. T cell/histiocyte-rich large B-cell lymphoma 4. Epstein-Barr virus (EBV) positive DLBCL, NOS 5. Primary mediastinal (thymic) large B-cell lymphoma 6. High grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with DLBCL histology (double/triple-hit lymphoma) * Subjects disease must have relapsed or be refractory to at least 2 prior lines of therapy. Previous therapy must have included a CD20-targeted agent and an anthracycline. * Subject must have 1. Positron emission tomography (PET)-positive (Deauville score 4 or 5) and computed tomography (CT) measurable disease as per Lugano Classification 2. Sum of product of perpendicular diameters (SPD) of up to 6 index lesions >= 25 cm2 by CT scan (not applicable to Arm A or B or subjects with Richter's transformation) * Eastern Cooperative Oncology Group (ECOG) performance status <= 1 at screening * Adequate organ function * Subjects must agree to not donate blood, organs, sperm or semen, and egg cells for usage in other individuals * Participants must agree to use effective contraception Exclusion Criteria: * Subject has any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study based on investigator´s judgment. * Subject has any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study based on investigator´s judgment. * Subject has any condition that confounds the ability to interpret data from the study based on investigator´s judgment. * Subjects with prior history of malignancies, other than aggressive R/R NHL, unless the subject has been free of the disease for >= 2 years with the exception of the following non-invasive malignancies: 1. Basal cell carcinoma of the skin 2. Squamous cell carcinoma of the skin 3. Carcinoma in situ of the cervix 4. Carcinoma in situ of the breast 5. Incidental histologic finding of prostate cancer (T1a or T1b using the TNM [tumor, nodes, metastasis] clinical staging system) or prostate cancer that is curative. 6. Other completely resected stage 1 solid tumor with low risk for recurrence * Prior treatment with any prior gene therap y product * Prior treatment with any adoptive T cell therapy; prior hematopoietic stem cell transplant (HSCT) is allowed * Allogeneic HSCT within 90 days of leukapheresis * Prior treatment with the combination agent from the assigned arm: 1. Anti PD-1 or PD-L1 (Arm A and E) 2. CC-122 (Arm B) 3. CC-220 (Arm C) 4. Prior treatment with ibrutinib is not exclusionary for subjects on any study arm 5. Anti LAG-3 targeted agent (Arm E) 6. CC-99282 (Arm F) * Presence of acute or chronic graft-versus-host disease (GVHD) * Presence of the following: 1. Active hepatitis B or active hepatitis C infection 2. History of or active human immunodeficiency virus (HIV) infection * Uncontrolled bacterial, viral or fungal infection at the time of leukapheresis, lymphodepleting chemotherapy or JCAR017 infusion * Any history of myocarditis (Arm E); history of any one of the following cardiovascular conditions within the past 6 months: Class III or IV heart failure as defined by the New York Heart Association (NYHA), cardiac angioplasty or stenting, myocardial infarction, unstable angina, or other clinically significant cardiac disease (all arms) * History or presence of clinically relevant central nervous system (CNS) pathology such as epilepsy, seizure, paresis, aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychosis * Subjects with active CNS or cerebrospinal fluid (CSF) involvement by malignancy * Pregnant or nursing (lactating) women. * Subjects with active auto immune disorders/processes or active neurological or inflammatory disorders * For subjects to receive oral combination therapy (Arms B, C, D or F): History of a gastrointestinal (GI) condition or procedure that in the opinion of the investigator may affect oral drug absorption. * Progressive tumor invasion of venous or arterial vessels. * Deep venous thrombosis (DVT)/pulmonary embolism (PE) not managed on a stable regimen of anticoagulation. Sex : ALL Ages : - Minimum Age : 18 Years - Age Group (Child: birth-17, Adult: 18-64, Older Adult: 65+) : ADULT, OLDER_ADULT Accepts Healthy Volunteers: No

{ "NCT_ID" : "NCT04557436", "Brief_Title" : "TT52CAR19 Therapy for B-cell Acute Lymphoblastic Leukaemia (B-ALL)", "Official_title" : "Phase 1, Open Label Study of CRISPR-CAR Genome Edited T Cells (PBLTT52CAR19) in Relapsed /Refractory B Cell Acute Lymphoblastic Leukaemia", "Conditions" : ["B Acute Lymphoblastic Leukemia"], "Interventions" : ["Drug: PBLTT52CAR19"], "Location_Countries" : ["United Kingdom"], "Study_Design" : { "Study_Type" : "INTERVENTIONAL", "Phase" : ["PHASE1"], "Primary_Purpose" : "OTHER", "Allocation" : "NA", "Interventional Model" : "SINGLE_GROUP", "Masking" : "NONE" } }

#Study Description Brief Summary PBLTT52CAR19 modified T cells are allogenic engineered human T cells (defined as TT52CAR19 +TCRαβ-) prepared for the treatment of CD19+ B cell leukaemia. The cells are from healthy adult volunteer donors and are not HLA-matched. They have been transduced to express and anti-CD19 chimeric antigen receptor (CAR19) using a lentiviral vector that also incorporates CRISPR guides for genome editing of CD52 and TRAC loci in the presence of transiently provided Cas9. Recognition by TT52CAR19 T cells mediates eradication of CD19+ leukaemia and other CD19+ B cells through T cell mediated cytotoxicity. This study aims to apply PBLTT52CAR19 T cells to secure molecular remission in children with relapsed/refractory B-ALL ahead of programmed allogeneic stem cell transplantation. The cells are to be used in a time-limited manner for their anti-leukaemia effects and then depleted by standard pre- transplant conditioning. #Intervention - DRUG : PBLTT52CAR19 - gene therapy

#Eligibility Criteria: Inclusion Criteria: * Patients with relapsed (second or subsequent bone marrow relapse or bone marrow relapse after allo-SCT) or refractory (not achieving an initial complete response (CR) after 2 cycles of standard chemotherapy) CD19-positive B-acute lymphoblastic leukaemia * Morphologically confirmed with leukemic blasts in the bone marrow or a quantifiable MRD load of 1x10 <= age <= 4 (by multiparameter flow cytometry and/or quantitative polymerase chain reaction) * Eligible and fit for allogeneic hematopoietic stem cells transplantation with suitable donor available * Estimated life expectancy >= 12 weeks * Lansky (age < 16 years at the time of assent/consent) or Karnofsky (age >= 16 years at the time of assent/consent) performance status >= 50 Eastern Cooperative Oncology Group ECOG performance status < 2 Exclusion Criteria: * Patients/parents unwilling to undergo a follow-up for 15 years * Foreseeable poor compliance to the study procedures * CD19-negative B-cell leukaemia * Evidence of disease progression after cytoreduction * Uncontrollable CNS leukaemia or neurological symptoms defined as CNS grade 3 (per National Comprehensive Cancer National guidelines). Patients developing grade 3 CNS disease at any time after enrolment will be excluded. * Absence of suitable HLA matched or mismatched donor * Weight < 6 kgs * Presence of donor-specific anti-HLA antibodies directed against PBLTT52CAR19 * GvHD requiring systemic therapy * Systemic steroid therapy prednisolone >0.5mg/kg/day * Known hypersensitivity to any of the test materials or related compounds * Active bacterial, fungal, or viral infection not controlled by a standard of care anti-microbial or anti-viral treatment. Uncontrolled bacteraemia/ fungaemia is defined as the ongoing detection of bacteria/fungus on blood cultures despite antibiotic or anti-fungal therapy. * Uncontrolled viraemia is defined as rising viral loads on two consecutive occasions despite antiviral therapy. * Risk of pregnancy or non-compliance with contraception (if applicable). Girls of childbearing potential must have been tested negative in a pregnancy test within 14 days prior to inclusion. * Lactating female participants unwilling to stop breastfeeding * Intrathecal methotrexate within 4 weeks or intrathecal chemotherapy (e.g Ara-C) within 2 weeks of lymphodepletion * Less than 2 half-lives from prior therapy with immune checkpoint pathway modifiers to lymphodepletion * Prior CAR19 therapy known to be associated with >=Grade 3 cytokine release syndrome (CRS) or >=Grade 3 drug-related CNS toxicity Sex : ALL Ages : - Minimum Age : 6 Months - Maximum Age : 18 Years - Age Group (Child: birth-17, Adult: 18-64, Older Adult: 65+) : ADULT, CHILD Accepts Healthy Volunteers: No

{ "NCT_ID" : "NCT03585517", "Brief_Title" : "Safety and Efficacy Evaluation of IM23 CAR-T Cells (IM23CAR-T)", "Official_title" : "Safety and Efficacy Evaluation of IM23 CAR-T Cells On CD123+ AML Patients", "Conditions" : ["AML"], "Interventions" : ["Drug: IM23"], "Location_Countries" : ["China"], "Study_Design" : { "Study_Type" : "INTERVENTIONAL", "Phase" : ["PHASE1"], "Primary_Purpose" : "TREATMENT", "Allocation" : "NA", "Interventional Model" : "SINGLE_GROUP", "Masking" : "NONE" } }

#Study Description Brief Summary Assessment of the Safety and Feasibility of Administering T Cells Expressing an Anti-CD123 Chimeric Antigen Receptor to Patients With CD123+ AML Detailed Description Assessment of the Safety and Feasibility of Administering T Cells Expressing an Anti-CD123 Chimeric Antigen Receptor to Patients With CD123+ AML and determine the best dosage. #Intervention - DRUG : IM23 - T Cells Expressing an Anti-CD123 Chimeric Antigen Receptor

#Eligibility Criteria: Inclusion Criteria: * Patients with CD123+ Refractory or Relapsed AML * To be aged 3 <= age <= 80 * Expression of CD123 in Blast >=90% * ECOG score <=2 * Voluntary participation in the clinical trials and sign the informed consent. Exclusion Criteria: * Intracranial hypertension or unconsciousness * Respiratory failure * CD19 negative * Disseminated intravascular coagulation * ALT /AST>3 x normal value; Creatinine> 1.5 x normal value; Bilirubin >2.0 x -normal value * Hematosepsis or Uncontrolled active infection * Uncontrolled diabetes * Abalienation; * Patients in pregnancy or breast-feeding period * Previously treatment with any gene therapy products * Any uncontrolled medical disorders that the researchers consider are not eligible to participate the clinical trial Sex : ALL Ages : - Minimum Age : 3 Years - Maximum Age : 80 Years - Age Group (Child: birth-17, Adult: 18-64, Older Adult: 65+) : ADULT, CHILD, OLDER_ADULT Accepts Healthy Volunteers: No

{ "NCT_ID" : "NCT04136275", "Brief_Title" : "CAR-37 T Cells In Hematologic Malignancies", "Official_title" : "A Phase I Clinical Trial With CAR-37 T Cells for the Treatment of Patients With Relapsed or Refractory CD37+ Hematologic Malignancies", "Conditions" : ["Hematologic Malignancy", "Leukemia", "Lymphoma", "Lymphoma, B-Cell", "Lymphoma, T-Cell", "Lymphoma, Non-Hodgkin"], "Interventions" : ["Biological: CAR-37 T cells"], "Location_Countries" : ["United States"], "Study_Design" : { "Study_Type" : "INTERVENTIONAL", "Phase" : ["PHASE1"], "Primary_Purpose" : "TREATMENT", "Allocation" : "NON_RANDOMIZED", "Interventional Model" : "PARALLEL", "Masking" : "NONE" } }

#Study Description Brief Summary This research study is studying Chimeric Antigen Receptor (CAR)-37 T Cells (CAR-37 T Cells) for treating people with relapsed or refractory CD37+ hematologic malignancies and to understand the side effects when treated with CAR-37 T Cells. - Chimeric Antigen Receptor (CAR)-37 T Cells (CAR-37 T Cells) is an investigational treatment Detailed Description This is a two-part, non randomized, open label, single site Phase 1 study. Participants who fulfill eligibility criteria will be entered into the trial Chimeric Antigen Receptor (CAR)-37 T Cells (CAR-37 T Cells). This study consists of 2 parts: * Part A (Dose Escalation): The investigators are looking the highest dose of the study intervention that can be administered safely without severe or unmanageable side effects in participants that have relapsed or refractory CD37+ hematologic malignancies, not everyone who participates in this research study will receive the same dose of the study intervention. The dose given will depend on the number of participants who have been enrolled prior and how well the dose was tolerated * Part B (Expansion Cohort): Part B: Expansion Cohort: Participants will be treated at the respective dose (at or below the Maximum Tolerated Dose), as determined during Part A (Dose Escalation). * A total of 18 participants will be enrolled to this trial This research study is a Phase I clinical trial, which tests the safety of an investigational intervention and also tries to define the appropriate dose of the investigational intervention to use for further studies. Investigational' means that the intervention is being studied The U.S. Food and Drug Administration (FDA) has not approved CAR-37 T Cells as a treatment for any disease. This is the first time that CAR-37 T Cells will be given to humans #Intervention - BIOLOGICAL : CAR-37 T cells - CAR-37 is an investigational treatment that uses the participant own immune cells, called T cells, to try to kill the cancerous cells

#Eligibility Criteria: Inclusion Criteria: Voluntarily sign informed consent form. Age >=18 years of at the time of signing informed consent Eastern Cooperative Oncology Group (ECOG) performance status 0 <= age <= 2 Karnofsky >=60%, see Appendix A) * Diagnosis of relapsed/refractory (R/R) CD37+ hematologic malignancy as defined as one of the following: * Mature B cell neoplasms * Follicular Lymphoma (FL) grade 1, grade 2, or grade 3a * RR disease after 2 or more prior lines of therapy AND * 1 of the prior lines of therapy must include an anti-CD20 antibody monotherapy. * Marginal Zone Lymphoma (MZL) nodal or extranodal: * R/R disease after 2 or more prior lines of therapy AND * 1 of the prior lines of therapy must include an anti-CD20 antibody monotherapy * Diffuse large B-cell lymphoma (DLBCL), including transformed follicular lymphoma (FL), primary mediastinal B-cell lymphoma (PMBCL), high-grade B-cell lymphoma and grade 3b Follicular Lymphoma (FL). * R/R disease after 2 or more prior lines of therapy OR * Relapsed following autologous SCT,OR * Ineligible for autologous SCT. * Mantle cell lymphoma * R/R disease as defined by disease progression after last regimen (including autologous SCT), OR Refractory disease as defined as failure to achieve a CR to last regimen. * Prior therapy must include: * Anthracycline or bendamustine-containing chemotherapy AND * Anti-CD20 monoclonal antibody therapy AND * BTKi therapy * Chronic lymphocytic leukemia (CLL) * CLL with an indication for treatment based on iwCLL guidelines and clinical measurable disease (lymphocytosis > 5×109/L and/or measurable lymph nodes and/or hepatic or splenomegaly) * Subjects must have received previous treatment as follows: * Subjects with high-risk features, defined as having complex cytogenetic abnormalities (3 or more chromosomal abnormalities), 17p deletion, TP53 mutation, or unmutated IGHV, must have failed at least 1 line of prior therapy, including a BTKi OR * Subjects with standard-risk features must have failed at least 2 lines of prior therapy, including a BTKi OR * Subjects who are BTKi intolerant and have received < 6 months of BTKi therapy, must have failed at least 1 high-risk line of non-BTKi therapy or 2 standard-risk lines of non-BTKi therapy OR * Subjects who are ineligible for BTKi, must have failed at least 1 (high-risk) line of non-BTKi therapy or 2 (standard-risk) lines of non-BTKi therapy. * Small lymphocytic lymphoma (SLL) * SLL (lymphadenopathy) or SLL (splenomegaly and < 5x 109 CD19+ CD5+ clonal B lymphocytes/L [<5000/μL] in the peripheral blood at diagnosis with measurable disease defined as at least one lesion > 1/5 cm in the greatest transverse diameter that is biopsy-proven SLL) * Subjects must have received previous treatments as follows: * Subjects with high-risk features, defined as having complex cytogenetic abnormalities (3 or more chromosomal abnormalities), or 17p deletion, or TP53 mutation, or unmutated IGHV, must have failed at least 1 line of prior therapy, including a BTKi OR * Subjects with standard-risk features must have failed at least 2 lines of prior therapy, including a BTKi OR * Subjects who are BTKi intolerant and have received < 6 months of BTKi therapy must have failed at least 1 high-risk or 2 standard-risk other lines of non-BTKi therapy OR * Subjects who are ineligible for BTKi, must have failed at least 1 high-risk or 2 standard-risk other lines of non-BTKi therapy. * Mature T cell neoplasms: * Peripheral T-Cell lymphoma (PTCL)/Cutaneous T-Cell Lymphoma (CTCL) * R/R after 2 or more prior lines of therapy OR * Relapse following autologous stem cell transplant OR * T-cell prolymphocytic leukemia (TPLL) --- Diagnosis of TPLL with plan for subsequent therapy. * Evidence of CD37 expression on tumor cells as demonstrated by flow cytometry and/or IHC on fresh biopsy or historic samples. * Subjects must have measurable disease according to appropriate disease specific criteria. * Adequate absolute lymphocyte count (ALC > 100 cells/ul) within one week of apheresis. * Adequate bone marrow function defined by absolute neutrophil count (ANC) >1000 cells/mm3 without growth factor support (filgrastim within 7 days of pegfilgrastim within 14 days) and untransfused platelet count >50,000 mm3. * Left ventricular ejection fraction > 40% * Adequate hepatic function defined by aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) < 2.5 × upper limit of normal (ULN) and direct bilirubin < 1.5 × ULN. * Adequate renal function defined by creatinine clearance >30 ml/min using the Cockcroft-Gault formula. * The effects of CAR-37 T cells on the developing human fetus are unknown. For this reason, women of child-bearing potential and men with partners of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to leukapheresis and until 6 months post CAR-37 infusion. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men with partners of childbearing potential treated or enrolled on this protocol must also agree to use adequate contraception prior to the study and until 4 months after last CAR-37 T cells administration. * Ability and willingness to adhere to the study visit schedule and all protocol requirements Inclusion criteria for lymphodepletion: * Eastern Cooperative Oncology Group (ECOG) performance status 0 <= age <= 2 (Karnofsky >=60%, see Appendix A). * No Active, uncontrolled, systemic bacterial, viral, or fungal infection. If febrile, the patient must be afebrile for 24 hours and blood cultures negative for 48 hours on appropriate antibiotic therapy. * Oxygen saturation >92% on room air while awake. * No additional anti-cancer therapy since leukapheresis excluding steroids at or below physiologic dosing. Exclusion Criteria: * Prior CD37 targeted therapies. * Treatment with an any investigational cellular therapy within 8 weeks prior to apheresis. * Any systemic anti-cancer therapy within 1 weeks of leukapheresis excluding steroids at or below physiologic dosing. * Ongoing treatment with chronic immunosuppressants (e.g., cyclosporine or systemic steroids above physiologic dosing). Intermittent topical, inhaled, or intranasal corticosteroids are allowed. * Ongoing systemic immunosuppression for acute and/or chronic GVH as a result of previous allogeneic bone marrow transplant and at least 12 weeks out from prior allogeneic SCT. * Significant co-morbid condition or disease which in the judgment of the Principal Investigator would place the subject at undue risk or interfere with the study; examples include, but are not limited to, cirrhotic liver disease, sepsis, and/or recent significant traumatic injury. * Active, uncontrolled, systemic bacterial, viral, or fungal infection. * Subjects with a history of class III or IV congestive heart failure or with a history of non- ischemic cardiomyopathy. * Subjects with unstable angina, myocardial infarction, or ventricular arrhythmia requiring medication or mechanical control within the previous 3 months. * Subjects with arterial vascular disease such as history of cerebrovascular accident or peripheral vascular disease requiring therapeutic anti-coagulation. * Subjects with history of a new pulmonary embolism within 6 months of beginning lymphodepletion. * Subjects with second malignancies if the second malignancy has required therapy in the last 3 years or is not in complete remission; exceptions to this criterion include successfully treated non-metastatic basal cell or squamous cell skin carcinoma, or prostate cancer that does not require therapy other than hormonal therapy. * Pregnant or lactating women Sex : ALL Ages : - Minimum Age : 18 Years - Age Group (Child: birth-17, Adult: 18-64, Older Adult: 65+) : ADULT, OLDER_ADULT Accepts Healthy Volunteers: No

{ "NCT_ID" : "NCT03980691", "Brief_Title" : "Effect of Chidamide Combined With CAT-T or TCR-T Cell Therapy on HIV-1 Latent Reservoir", "Official_title" : "Effect of Chidamide Combined With CAT-T or TCR-T Cell Therapy on HIV-1 Latent Reservoir", "Conditions" : ["HIV/AIDS"], "Interventions" : ["Biological: Chidamide with CAR-T or TCR-T cell therapy"], "Location_Countries" : ["China"], "Study_Design" : { "Study_Type" : "INTERVENTIONAL", "Phase" : ["PHASE1"], "Primary_Purpose" : "TREATMENT", "Allocation" : "RANDOMIZED", "Interventional Model" : "PARALLEL", "Masking" : "NONE" } }

#Study Description Brief Summary To study the safety and effectiveness of the combination of Chidamide with Chimeric Antigen Receptor(CAR)-T or T cell receptor(TCR)-T cell therapy on HIV patients based on cART. Detailed Description Despite the advent of combined antiretroviral therapy (cART), the persistence of viral reservoirs remains a major barrier to cure human immunodeficiency virus type 1 (HIV-1) infection. Recently, the shock and kill strategy, by which such reservoirs are eradicated following reactivation of latent HIV-1 by latency-reversing agents (LRAs), has been extensively practiced. It is important to reestablish virus-specific and reliable immune surveillance to eradicate the reactivated virus-harboring cells. Some studies have shown that Chidamide can highly activate the HIV reservoirs. The VC-CAR-T cells effectively induced the cytolysis of LRA-reactivated HIV-1-infected CD4 T lymphocytes isolated from infected individuals receiving suppressive cART. Our previous study demonstrated that the special features of genetically engineered CAR-T cells make them a particularly suitable candidate for therapeutic application in efforts to reach a functional HIV cure. The purpose of this study is to evaluate the safety and efficacy of Chidamide together with Chimeric Antigen Receptor(CAR)-T or T cell receptor(TCR)-T cell therapy based on cART in HIV-infected adults whose plasma HIV has been successfully suppressed after cART. #Intervention - BIOLOGICAL : Chidamide with CAR-T or TCR-T cell therapy - HIV-1 specific therapy

#Eligibility Criteria: Inclusion Criteria: * HIV infection confirmed * Receiving cART more than 12 months. * HIV viral-load < 50 copies/ml and CD4 cell count more than 350 cells/ul. * Without serious liver , heart, liver and kidney diseases. * The subjects know about the study and volunteer to attend the research and sign the informed consent. Exclusion Criteria: * With active HBV or HCV infection, or serious opportunistic infections. * With serious chronic disease such like diabetes, the mental illness,et al * History of suffering from pancreatitis during cART . * Pregnant or breast-fed. * With poor adherence. * Unable to complete follow up. Sex : ALL Ages : - Minimum Age : 18 Years - Maximum Age : 60 Years - Age Group (Child: birth-17, Adult: 18-64, Older Adult: 65+) : ADULT Accepts Healthy Volunteers: No

{ "NCT_ID" : "NCT03792633", "Brief_Title" : "Study of huCART19 for Very High-Risk (VHR) Subsets of Pediatric B-ALL", "Official_title" : "Phase 2 Study of Humanized CD19-directed Chimeric Antigen Receptor-modified T Cells (huCART19) for Very High-Risk Subsets of B Cell Acute Lymphoblastic Leukemia (B-ALL)", "Conditions" : ["Acute Lymphoid Leukemia"], "Interventions" : ["Biological: huCART19"], "Location_Countries" : ["United States"], "Study_Design" : { "Study_Type" : "INTERVENTIONAL", "Phase" : ["PHASE2"], "Primary_Purpose" : "TREATMENT", "Allocation" : "NON_RANDOMIZED", "Interventional Model" : "PARALLEL", "Masking" : "NONE" } }

#Study Description Brief Summary This is a phase 2 study to evaluate humanized CD19 redirected autologous T cells (or huCART19 cells) with CD19 expressing relapsed and refractory B-cell acute lymphoblastic leukemia. This study is targeting pediatric and young adult patients aged 1-29 years with CD19+ B cell malignancies in newly diagnosed B-ALL patients predicted to have an exceedingly poor outcome with conventional chemotherapy, in high-risk first relapse, or and in second or greater relapse in this phase 2 trial. In addition, a second cohort will test the efficacy of huCART19 in patients with poor response to prior B cell directed engineered cell therapy. #Intervention - BIOLOGICAL : huCART19 - huCART19 infusion - Other Names : - huCTL019

#Eligibility Criteria: Inclusion Criteria: * Signed informed consent form must be obtained. * Relapsed or refractory B-cell ALL: a. Cohort A: Patients with newly diagnosed VHR B-ALL or high-risk relapse of B-ALL who meet one of the following criteria: i. Newly diagnosed NCI HR B-ALL with induction failure: M3 marrow (>25% blasts) at end of induction OR ii. First marrow relapse of B-ALL at < 36 months from diagnosis OR iii. 2nd or greater relapse OR iv. Any relapse after allogeneic HSCT and >= 4 months from SCT at enrollment OR v. Refractory disease defined as having not achieved an MRD-negative and/or CSF-negative CR after >= 2 chemotherapy regimens/cycles of frontline therapy or 1 cycle of reinduction therapy for patients in first relapse OR vi. Ineligible for allogeneic SCT because of: * Comorbid disease * Other contraindications to allogeneic SCT conditioning regimen * Lack of suitable donor * Prior SCT * Declines allogeneic SCT as the therapeutic option after documented discussion, with expected outcomes, about the role of SCT with a BMT physician not part of the study team b. Cohort B: Patients previously treated with B cell directed engineered cell therapy who meet one of the following criteria: i. partial response or no response to prior cell therapy ii. CD19+ relapse after prior cell therapy iii. demonstrated early (<=6 months from infusion) B cell recovery suggesting loss of engineered cells c. Patients with prior or current history of CNS3 disease will be eligible if CNS disease is responsive to therapy (at infusion, must meet criteria in Section 5.3 of the protocol) * Documentation of CD19 tumor expression in bone marrow, peripheral blood, CSF, or tumor tissue by flow cytometry at relapse (or a recent sample in the case of refractory disease). If the patient has received CD19-directed therapy, then the flow cytometry should be obtained after this therapy to show CD19 expression. * Adequate organ function defined as: * A serum creatinine based on age/gender * ALT<= 500 U/L * Bilirubin <=2.0 mg/dl * Must have a minimum level of pulmonary reserve defined as <= Grade 1 dyspnea, < Grade 3 hypoxia; DLCO >= 40% (corrected for anemia) if PFTs are clinically appropriate as determined by the treating investigator * Left Ventricular Shortening Fraction (LVSF) >= 28% or Ejection Fraction (LVEF) >= 45% confirmed by ECHO, or adequate ventricular function documented by a scan or a cardiologist. 5. Age 3 months to 29 years. 6. Adequate performance status (Lansky or Karnofsky score >=50). 7. Subjects of reproductive potential must agree to use acceptable birth control methods. Exclusion Criteria: 1. Active hepatitis B or active hepatitis C. 2. HIV Infection. 3. Active acute or chronic graft-versus-host disease (GVHD) requiring systemic therapy. 4. Concurrent use of systemic steroids or immunosuppression at the time of cell infusion or cell collection, or a condition, in the treating physician's opinion, that is likely to require steroid therapy or immunosuppression during collection or after infusion. Steroids for disease treatment at times other than cell collection or at the time of infusion are permitted. Use of physiologic replacement hydrocortisone or inhaled steroids is permitted as well. 5. CNS3 disease that is progressive on therapy, or with CNS parenchymal lesions that might increase the risk of CNS toxicity. 6. Pregnant or nursing (lactating) women. 7. Uncontrolled active infection. 8. Active medical disorder that, in the opinion of the investigator, would substantially increase the risk of uncontrollable CRS or neurotoxicity. Sex : ALL Ages : - Minimum Age : 3 Months - Maximum Age : 29 Years - Age Group (Child: birth-17, Adult: 18-64, Older Adult: 65+) : ADULT, CHILD Accepts Healthy Volunteers: No

{ "NCT_ID" : "NCT02445248", "Brief_Title" : "Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients", "Official_title" : "A Phase II, Single Arm, Multicenter Trial to Determine the Efficacy and Safety of CTL019 in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)", "Conditions" : ["Diffuse Large B-cell Lymphoma (DLBCL)"], "Interventions" : ["Biological: Tisagenlecleucel", "Drug: Lymphodepleting chemotherapy"], "Location_Countries" : ["Italy", "Austria", "Australia", "Canada", "Netherlands", "Germany", "Norway", "France", "Japan", "United States"], "Study_Design" : { "Study_Type" : "INTERVENTIONAL", "Phase" : ["PHASE2"], "Primary_Purpose" : "TREATMENT", "Allocation" : "NA", "Interventional Model" : "SINGLE_GROUP", "Masking" : "NONE" } }

#Study Description Brief Summary This is a multi-center, phase II study to determine the efficacy and safety of CTL019 in adult patients with relapsed or refractory DLBCL. Detailed Description This was a single arm, open-label, multi-center, Phase II study conducted to determine the efficacy and safety of tisagenlecleucel in adult patients with r/r DLBCL. The study consisted of the following sequential periods: Screening, Pre-Treatment, Treatment and Primary follow-up, Secondary follow-up, Survival follow-up. Patients were enrolled in 2 cohorts to receive one tisagenlecleucel infusion as follows: * Main Cohort (patients treated with tisagenlecleucel manufactured at the Novartis manufacturing facility in Morris Plains, US, referred to as 'US manufacturing facility') and * Cohort A (patients treated with tisagenlecleucel manufactured at the Fraunhofer Institut für Zelltherapie, Leipzig, Germany, referred to as 'EU manufacturing facility'). The study enrolled adult patients ≥ 18 years with histologically confirmed relapsed or refractory (r/r) DLBCL after ≥ 2 lines of chemotherapy, with a life expectancy of ≥ 12 weeks and not eligible or not consenting to stem cell transplantation (SCT). Patients had measurable disease at time of enrollment, adequate organ function and zero or one Eastern Cooperative Oncology Group performance status at screening. For each patient, the apheresis product of non-mobilized cells was received and accepted by the manufacturing site. #Intervention - BIOLOGICAL : Tisagenlecleucel - The target dose of CTL019 transduced cells for adult patients consisted of a single infusion of 5 x 10\^8 viable CTL019 transduced cells, which was administered via intravenous infusion. The acceptable dose range was 1 - 5x10\^8 viable CTL019 transduced cells. - Other Names : - CTL019 - DRUG : Lymphodepleting chemotherapy - Prior to CTL019 cell infusion, an additional lymphodepleting chemotherapy cycle was planned. The use of any additional bridging therapy prior to the recommended lymphodepleting chemotherapy was at the discretion of the investigator and dependent on the patient's disease burden. Lymphodepleting chemotherapy was started 14 to 5 days before CTL019 infusion (D1) to allow for at least 48 hours from last dose of lymphodepleting chemotherapy to CTL019 infusion. The lymphodepleting regimen was: Fludarabine (25 mg/m\^2 intravenously \[i.v.\] daily for 3 doses) and cyclophosphamide (250 mg/m\^2 i.v. daily for 3 doses starting with the first dose of fludarabine).

#Eligibility Criteria: Inclusion Criteria: * Written informed consent must be obtained prior to any screening procedures * Histologically confirmed DLBCL at last relapse(by central pathology review before enrolment. .- Relapsed or refractory disease after >=2 lines of chemotherapy including rituximab and anthracycline and either having failed autologous Hematopoietic stem cell transplantation (ASCT), or being ineligible for or not consenting to ASCT * Measurable disease at time of enrollment * Life expectancy >=12 weeks * Eastern Cooperative Oncology Group (ECOG) performance status that is either 0 or 1 at screening * Adequate organ function: * Renal function defined as: * A serum creatinine of <=1.5 x Upper Limit of Normal ULN OR * Estimated Glomerular Filtration Rate (eGFR) >= 60 mL/min/1.73 m^2 * Liver function defined as: * Alanine Aminotransferase (ALT) <= 5 times the Upper Limit of Normal (ULN) for age * Bilirubin <= 2.0 mg/dl with the exception of patients with Gilbert-Meulengracht syndrome; patients with Gilbert-Meulengracht syndrome may be included if their total bilirubin is <= 3.0 x ULN and direct bilirubin <= 1.5 x ULN * Must have a minimum level of pulmonary reserve defined as <= Grade 1 dyspnea and pulse oxygenation > 91% on room air * Hemodynamically stable and Left Ventricle Ejection Fraction (LVEF) >= 45% confirmed by echocardiogram or Multigated Radionuclide Angiography (MUGA) * Adequate bone marrow reserve without transfusions defined as: * Absolute neutrophil count (ANC) > 1.000/mm^3 * Absolute lymphocyte count (ALC) >= 300/mm^3 and absolute number of CD3+ T cells > 150/mm^3 * Platelets >= 50.000//mm^3 * Hemoglobin > 8.0 g/dl * Must have an apheresis product of non-mobilized cells accepted for manufacturing * Women of child-bearing potential (defined as all women physiologically capable of becoming pregnant) and all male participants must agree to use highly effective methods of contraception for at least 12 months following CTL019 infusion and until CAR T cells are no longer present by PCR on two consecutive tests Exclusion Criteria: * Prior treatment with any prior anti-CD19/anti-CD3 therapy, or any other anti-CD19 therapy * Treatment with any prior gene therapy product * Active Central Nervous System (CNS) involvement by malignancy * Prior allogeneic HSCT * Eligible for and consenting to HSCT * Chemotherapy other than lymphodepleting chemotherapy within 2 weeks of infusion * Investigational medicinal product within the last 30 days prior to screening * The following medications are excluded: * Steroids: Therapeutic doses of steroids must be stopped >72 hours prior to leukapheresis and >72 hours prior to CTL019 infusion. However, the following physiological replacement doses of steroids are allowed: < 12 mg/m^2/day hydrocortisone or equivalent * Immunosuppression: Any other immunosuppressive medication must be stopped >=2 weeks prior to leukapheresis and >= 2 weeks prior to CTL019 infusion. This could include check point inhibitors (monoclonal antibodies and small molecule modulators) * Antiproliferative therapies other than lymphodepleting chemotherapy within two weeks of leukapheresis and 2 weeks prior to infusion * Short acting drugs used to treat leukemia or lymphoma (e.g. tyrosine kinase inhibitors, and hydroxyurea) must be stopped > 72 hour prior to leukapheresis and > 72 hours prior to CTL019 infusion * Other cytotoxic drugs, including low dose daily or weekly maintenance chemotherapy, must not be given within 2 weeks prior to leukapheresis and within 2 weeks prior to CTL019 infusion * Fludarabine may be associated with prolonged lymphopenia. This should be taken into consideration when evaluating the optimal timing for leukapheresis collection. * Antibody use including anti-CD20 therapy within 4 weeks prior to infusion or 5 half-lives of the respected antibody, whichever is longer * CNS disease prophylaxis must be stopped > 1 week prior to CTL019 infusion (e.g. intrathecal methotrexate) * Prior radiation therapy within 2 weeks of infusion * Active replication of or prior infection with hepatitis B or active hepatitis C( HCV RNA positive ) * HIV positive patients * Uncontrolled acute life threatening bacterial, viral or fungal infection (e.g. blood culture positive <= 72 hours prior to infusion) * Unstable angina and/or myocardial infarction within 6 months prior to screening * Previous or concurrent malignancy with the following exceptions: * Adequately treated basal cell or squamous cell carcinoma (adequate wound healing is required prior to study entry) * In situ carcinoma of the cervix or breast, treated curatively and without evidence of recurrence for at least 3 years prior to the study * A primary malignancy which has been completely resected and in complete remission for >= 5 years * Pregnant or nursing (lactating) women. NOTE: female study participants of reproductive potential must have a negative serum or urine pregnancy test performed within 24 hours before lymphodepletion * Intolerance to the excipients of the CTL019 cell product * Cardiac arrhythmia not controlled with medical management * Prior treatment with any adoptive T cell therapy * Patients with T-cell rich/histiocyte rich large B-cell lymphoma (THRBCL), primary cutaneous large B-cell lymphoma, primary mediastinal B-cell lymphoma (PMBCL), EBV positive DLBCL of the elderly, Richter's transformation, and Burkitt lymphoma * Patients with active neurological auto immune or inflammatory disorders (e.g. Guillain Barre Syndrome, Amyptrophic Lateral Sclerosis) Sex : ALL Ages : - Minimum Age : 18 Years - Age Group (Child: birth-17, Adult: 18-64, Older Adult: 65+) : ADULT, OLDER_ADULT Accepts Healthy Volunteers: No

{ "NCT_ID" : "NCT04853277", "Brief_Title" : "Patient Reported Outcomes and Patient Education in Cellular Therapy Patients", "Official_title" : "Effect of Patient Education Regarding Emotional Stressors on Patient Reported Outcomes in Patients Undergoing Cellular Therapy (HSCT or CAR-T)", "Conditions" : ["Stem Cell Transplant", "CAR T-Cell Transplant", "CAR T-Cell Therapy", "Cellular Therapy", "Hematopoietic Stem Cell Transplant", "HSCT", "Multiple Myeloma", "Leukemia", "Lymphoma"], "Interventions" : ["Behavioral: Education"], "Location_Countries" : ["United States"], "Study_Design" : { "Study_Type" : "INTERVENTIONAL", "Phase" : ["NA"], "Primary_Purpose" : "PREVENTION", "Allocation" : "NA", "Interventional Model" : "SINGLE_GROUP", "Masking" : "NONE" } }

#Study Description Brief Summary The purpose of this research is to provide an educational visit addressing common emotional stressors involved in the transplant/CAR-T process, and determine if this added education improves levels of anxiety, depression, and fatigue after transplant/CART in comparison to people who do not receive the brief educational visit. Detailed Description Individuals who decide to participate in this study, will be provided with a survey evaluating current symptoms. This survey should take approximately 10 minutes to complete. Individuals will then be scheduled for a 30 minute telephone visit to review common emotional stressors experienced after Stem Cell Transplant/CAR-T therapy as well as strategies to help reduce these symptoms. Participants will be provided with a pamphlet to review during the visit and independently afterwards. This visit will be conducted by telephone to avoid extra travel to the hospital, and will be conducted prior to admission for Transplant/CAR-T. Individuals will then be asked to fill out the same set of surveys at 1 month, 3 months, 6 months, and 12 months after receiving the transplant/CAR-T therapy. These surveys will be conducted during other scheduled clinic visits to avoid additional travel to the hospital. An individual's involvement will be complete at 1 year. If an individual receives post-transplant/CAR-T care at a hospital other than DHMC, surveys will be mailed to the participant to complete and return at the same time points. #Intervention - BEHAVIORAL : Education - Each Patient will undergo a 30 minute telephone visit with a trained Medical Provider outlining the timeline of various common emotional challenges experienced after transplant/CAR-T, as well as coping techniques. A pamphlet with information discussed will also be provided to the patient to review on their own time. The patient will have an opportunity to express any psychosocial/emotional concerns at this time.

#Eligibility Criteria: Inclusion Criteria: * Any patient with an underlying hematologic disease planning to undergo an autologous or allogeneic hematopoietic stem cell transplant (HSCT) or chimeric antigen receptor T-cell (CAR-T) therapy at Dartmouth-Hitchcock Medical Center is eligible. * The patient must be approved for HSCT/CAR-T by the treating transplant physician. This includes completion of their pre-treatment work up and consent as directed by the standard DHMC SOPs. * Age >18 years, and no upper age limit Exclusion Criteria: * Any patient with medical, social, or psychological factors that would prevent the patient from cooperating with the trial and completing surveys at requested intervals. Sex : ALL Ages : - Minimum Age : 18 Years - Age Group (Child: birth-17, Adult: 18-64, Older Adult: 65+) : ADULT, OLDER_ADULT Accepts Healthy Volunteers: No

{ "NCT_ID" : "NCT02765243", "Brief_Title" : "Anti-GD2 4th Generation CART Cells Targeting Refractory and/or Recurrent Neuroblastoma", "Official_title" : "Anti-GD2 4th Generation Chimeric Antigen Receptor-modified T Cells (4SCAR-GD2) Targeting Refractory and/or Recurrent Neuroblastoma", "Conditions" : ["Neuroblastoma", "Effects of Immunotherapy"], "Interventions" : ["Biological: Anti-GD2 CART"], "Location_Countries" : ["China"], "Study_Design" : { "Study_Type" : "INTERVENTIONAL", "Phase" : ["PHASE1"], "Primary_Purpose" : "TREATMENT", "Allocation" : "NA", "Interventional Model" : "SINGLE_GROUP", "Masking" : "NONE" } }

#Study Description Brief Summary Patients with refractory and/or recurrent neuroblastoma have poor prognosis despite complex multimodel therapy and therefore, novel approaches are urgently needed. The investigators are attempt to treat this disease using T cells genetically modified with a 4th generation lentiviral chimeric antigen receptor (CAR) targeting GD2 (4SCAR-GD2). The 4SCAR-GD2-modified T cells can recognize and kill neuroblastoma through the recognition of GD2, a surface protein expressed at high levels on neuroblastoma but not on normal tissues. This study will evaluate the side effects and effective doses of 4SCAR-GD2 T cells in treating refractory and/or recurrent neuroblastoma. Detailed Description Background: Patients with refractory and/or recurrent neuroblastoma have poor prognosis despite complex multimodal therapy; therefore, novel curative approaches are needed. The investigators are attempting to use T cells obtained directly from the patient, which can be genetically modified to express a 4th generation GD2-specific chimeric antigen receptor (4SCAR-GD2). The chimeric antigen receptor (CAR) molecules enable the T cells to recognize and kill neuroblastoma through the recognition of a surface antigen, GD2, which is expressed at high levels in neuroblastoma but not at significant levels on normal tissues. This study will evaluate the side effects and the best dose of a novel 4th generation anti-GD2 CAR T cells to refractory and/or recurrent neuroblastoma. Objectives: 1. Primary: To determine the safety and feasibility of administration of 4SCAR-GD2 T cells to children with neuroblastoma following a cyclophosphamide/fludarabine preparative regimen. 2. Secondary: 1. To determine if the administration of 4SCAR-GD2 T cells can establish an antitumor effects in children with neuroblastoma who receive preparative regimen. 2. To describe the toxicity of administration of anti-GD2 CAR T cells in children with or without high-burden disease. 3. To evaluate the incidence and the treatment effect of cytokine release syndrome (CRS). 4. To determine the expansion and functional persistence of 4SCAR-GD2 T cells in the peripheral blood of patients and the correlation with antitumor effects. Eligibility: Patients 1-14 years of age, at least 10 kg, with neuroblastoma that has recurred after or not responded to standard therapy and is deemed incurable by standard therapy. Design: * Participants will be screened through physical exam and medical history. Blood and urine samples will be collected. Imaging studies or bone marrow aspirates may be performed. * Peripheral blood mononuclear cells (PBMC) will be obtained by apheresis, and T cells will be activated and modified to express the 4SCAR-GD2 gene. * On Day -7, PBMC will be activated and enriched for T cells, which will be followed by 4SCAR-GD2 lentiviral transduction. The total culture time is approximately 5-10 days. * Participants will receive a preparative conditioning regimen comprising cyclophosphamide/fludarabine to prepare their immune system to accept the modified CAR T cells. The preparative regimen is consisted of fludarabine 25 mg/m(2) on days -4, -3 and -2 and cyclophosphamide 300 mg/m(2) on day-4, -3 and -2. * Participants will receive an infusion of the modified 4SCAR-GD2 T cells and closely followed up for treatment related responses. * Participants will have frequent follow-up visits to monitor the outcome of the treatment. #Intervention - BIOLOGICAL : Anti-GD2 CART - Anti-GD2 4th Generation Chimeric Antigen Receptor-modified T Cells

#Eligibility Criteria: INCLUSION CRITERIA: * Patients with neuroblastoma have received standard first-line therapy and been judged to be non-resectable, metastatic, progressive/persistent or recurrent. * The GD2 antigen status of the neuroblastoma will be determined for eligibility. Positive expression is defined by GD2 antibody staining results based on immunohistochemistry or flow cytometry analyses. * Body weight greater than or equal to 10 kg. * Age: >=1 year and <= 14 years at the time of enrollment. * Life expectancy: at least 8 weeks. * Prior Therapy: 1) There is no limit to the number of prior treatment regimens. Any grade 3 or 4 non-hematologic toxicity of any previous therapy must have resolved to grade 2 or less. 2) Must not have received hematopoietic growth factors for at least 1 week prior to mononuclear cells collection. 3) At least 7 days must have elapsed since the completion of therapy with a biologic agent, targeted agent, tyrosine kinase inhibitor or a metronomic nonmyelosuppressive regimen. 4) At least 4 weeks must have elapsed since prior therapy that included a monoclonal antibody. 5) At least 1 weeks since any radiation therapy at the time of study entry. * Karnofsky/jansky score of 60% or greater. * Cardiac function: Left ventricular ejection fraction greater than or equal to 40/55 percent . * Pulse Ox greater than or equal to 90% on room air. * Liver function: defined as alanine transaminase (ALT) <3x upper limit of normal (ULN), aspartate aminotransferase (AST) <3x ULN; serum bilirubin and alkaline phosphatase <2x ULN. * Renal function: Patients must have serum creatinine less than 3 times upper limit of normal. * Marrow function: White blood cell count >=1000/ul, Absolute neutrophil count >=500/ul, Absolute lymphocyte count >=500/ul, Platelet count >=25,000/ul (not achieved by transfusion). * Patients with known bone marrow metastatic disease will be eligible for study as long as they meet hematologic function criteria, and the marrow disease not evaluable for hematologic toxicity. * Patients must have autologous transduced T cells at levels greater than or equal to 2x10e5 cells per kilogram body weight. * For all patients enrolled in this study, their parents or legal guardians must sign an informed consent and assent. EXCLUSION CRITERIA: * Existing severe illness (e.g. significant cardiac, pulmonary, hepatic diseases, etc.) or major organ dysfunction, with the exception of grade 3 hematologic toxicity. * Untreated central nervous system (CNS) metastasis: Patients with previous CNS tumor involvement that has been treated and is stable for at least 6 weeks following completion of therapy are eligible. * Previous treatment with other genetically engineered GD2-CAR T cells. * Active HIV, Hepatitis B virus (HBV), Hepatitis C virus (HCV) infection or uncontrolled infection. * Patients who require systemic corticosteroid or other immunosuppressive therapy. * Patients previously experienced severe toxicity from cyclophosphamide or fludarabine. * Evidence of tumor potentially causing airway obstruction. * Inability to comply with protocol requirements. * Insufficient CAR T cells availability. Sex : ALL Ages : - Minimum Age : 1 Year - Maximum Age : 14 Years - Age Group (Child: birth-17, Adult: 18-64, Older Adult: 65+) : CHILD Accepts Healthy Volunteers: No

{ "NCT_ID" : "NCT05349201", "Brief_Title" : "CAR T Cells Real World Evidence Study Based on the French Hospital Claims Data Source (PMSI)", "Official_title" : "CAR-T Cells - Real Life Study Of Care Pathway And Total Cost Of Care For Patients Under Car T-Cell Treatment Based On The PMSI French Database", "Conditions" : ["Diffuse Large B-Cell Lymphoma (DLBCL)", "Acute Lymphoblastic Leukemia (ALL)"], "Interventions" : ["Other: YESCARTA", "Other: KYMRIAH"], "Location_Countries" : ["United States"], "Study_Design" : { "Study_Type" : "OBSERVATIONAL", } }

#Study Description Brief Summary This was a Retrospective cohort study based on the PMSI data source Detailed Description A retrospective database analysis was performed using the French national hospital claims database (Medicalized Information System Program - PMSI, 2015-2019), which includes discharge summaries for all hospital admissions in France (\~99% of French residents). The patients were identified based on the CAR-T administration hospital stay, between 2017 and 2019. Based on the exhaustivity of the database, all patients treated with CAR-T (since 2018) were identified. The study design included multiple periods of analysis based on the CAR-T process. Three main periods were defined: the historical period, the CAR-T period, and the post CAR-T period. The CAR-T period was divided in 2 sub-periods: pre CAR-T (including the apheresis procedure and 15 days before this procedure) and per CAR-T (including the lymphodepletion and CAR-T cell injection hospital stay until the end at the discharge date related to CAR-T cell injection hospital stay). The follow-up period started at the end of CAR-T hospital stay. CAR-T populations: KYMRIAH® DLBCL cohort: * Adult patients (≥18 years of age) with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. * Patient with a CAR-T administration hospital stay of Kymriah between 2017 and 2019 YESCARTA®DLBCL cohort: * Adult patients (≥18 years of age) with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy: * Patient with a CAR-T administration hospital stay of Yescarta between 2017 and 2019 KYMRIAH® ALL cohort: * Pediatric and young adult patients (≤ 25 years of age) with B-cell acute lymphoblastic leukemia (ALL) that is refractory, in relapse post-transplant or in second or later relapse: * Patient with a CAR-T administration hospital stay of Kymriah between 2017 and 2019 #Intervention - OTHER : KYMRIAH - Patients (≥18 years of age) with (relapsed/refractory diffuse large B cell lymphoma \[R/R DLBCL\]) or Pediatric and young adult patients (≤25 years of age) with B cell acute lymphoblastic leukemia (ALL) refractory, in relapse post transplant or in second or later relapse - OTHER : YESCARTA - Patients (≥18 years of age) with (relapsed/refractory diffuse large B cell lymphoma \[R/R DLBCL\])

#Eligibility Criteria: Inclusion Criteria: * Patients treated with CAR-T cells from 2017 to 2019 and informed as such in the PMSI And * Patients diagnosed with ALL or DLBCL when administering CAR-T cells and * up to 25 years for patients with ALL Exclusion Criteria: * All patients treated outside the two types of indications presented in the inclusion criteria will be excluded Sex : ALL Ages : - Minimum Age : 18 Years - Maximum Age : 30 Years - Age Group (Child: birth-17, Adult: 18-64, Older Adult: 65+) : ADULT Accepts Healthy Volunteers: No

{ "NCT_ID" : "NCT04812691", "Brief_Title" : "CD19-targeted CAR T Cells （JWCAR029） for Primary Refractory Diffuse Large B Cell Lymphoma", "Official_title" : "CD19-targeted CAR T Cells （JWCAR029） for Primary Refractory Diffuse Large B Cell Lymphoma, Phase Ⅰ,Open-label,Single-arm,Muticenter Study", "Conditions" : ["Diffuse Large B Cell Lymphoma"], "Interventions" : ["Biological: JWCAR029 (CD19-targeted Chimeric Antigen Receptor Cells)"], "Location_Countries" : ["China"], "Study_Design" : { "Study_Type" : "INTERVENTIONAL", "Phase" : ["PHASE1"], "Primary_Purpose" : "TREATMENT", "Allocation" : "NA", "Interventional Model" : "SINGLE_GROUP", "Masking" : "NONE" } }

#Study Description Brief Summary This is a phase I, open-label, single-arm, multicenter study to assess the safety and efficacy of JWCAR029 in adult primary refractory DLBCL subjects in China Detailed Description This is a phase I, open-label, single-arm, multicenter study conducted in adult subjects with primary refractory DLBCL in China to evaluate the safety, efficacy, pharmacokinetics(PK), pharmacodynamics(PD) of JWCAR029 and collect immune response after JWCAR029 treatment. One dose level of 1.0 x 10\^8 CAR+ T cells is adopted in this study. All sujects will be followed for 2 years after JWCAR029 infusion. #Intervention - BIOLOGICAL : JWCAR029 (CD19-targeted Chimeric Antigen Receptor Cells) - Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JWCAR029. During JWCAR029 production, subjects will receive a conditioning chemotherapy regimen of cyclophosphamide and fludarabine for the purpose of lymphocytes depletion. After lymphodepletion, subjects will receive 1 x 10\^8 CAR+T cells (JWCAR029) treatment by intravenous (IV) injection.

#Eligibility Criteria: Inclusion Criteria: * >= 18 years; * Sign on the informed consent; * Subject must have histologically confirmed diffuse large B lymphoma and primary refractory with first-line therapy; * Subjects have accessible PET-positive lesion and have measurable CT-positive lesion according to Lugano Classification; * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; * Adequate organ function; * Adequate vascular access for leukapheresis procedure; * Subjects who have previously received CD19 targeted therapy must confirm that lymphoma lesions still express CD19; * Women of childbearing potential must agree to use highly effective methods of contraception for 1 year after the last dose of JWCAR029; * Males who have partners of childbearing potential must agree to use an effective barrier contraceptive method for 1 year after the last dose of JWCAR029 Exclusion Criteria: * Subjects who have received second-line treatment or above * CD19 negative * Primary CNS lymphoma; * History of another primary malignancy that has not been in remission for at least 2 years; * Subjects has HBV, HCV, HIV or syphilis infection at the time of screening; * Deep venous thrombosis (DVT)/Pulmonary embolism (PE), or DVT/PE requires anti-coagulation within 3 months prior to signing the ICF; * Subjects with uncontrolled systemic fungal, bacterial, viral or other infection; * Presence of acute or chronic graft-versus-host disease (GVHD); * History of any serious cardiovascular disease or presence of clinically relevant CNS pathology; * Pregnant or nursing women; * Subjects using of any chemotherapy, corticisteriod, experiment agents, GVHD therapies, radiation, allo-HSCT or any other therapies for lymphoma must go through a specific wash-out period before leukapheresis; * Uncontrolled conditions or unwillingness or inability to follow the procedures required in the protocol; * Received CAR T-cell or other genetically-modified T-cell therapy previously. Sex : ALL Ages : - Minimum Age : 18 Years - Age Group (Child: birth-17, Adult: 18-64, Older Adult: 65+) : ADULT, OLDER_ADULT Accepts Healthy Volunteers: No

{ "NCT_ID" : "NCT04840875", "Brief_Title" : "Phase I Clinical Trial of Autologous CD7-CAR T Cell Therapy for High-risk Acute T-cell Leukemia/lymphoma", "Official_title" : "Phase I Clinical Trial of Autologous CD7-CAR T Cells in the Treatment of High-risk Acute T-cell Leukemia / Lymphoma", "Conditions" : ["T Cell Lymphoma", "T-cell Leukemia"], "Interventions" : ["Biological: chimeric antigen receptor T cell treatment"], "Location_Countries" : ["China"], "Study_Design" : { "Study_Type" : "INTERVENTIONAL", "Phase" : ["PHASE1"], "Primary_Purpose" : "TREATMENT", "Allocation" : "NA", "Interventional Model" : "SINGLE_GROUP", "Masking" : "NONE" } }

#Study Description Brief Summary This is a phase 1 clinical trial of autologous CD7-CAR T cells in the treatment of high-risk acute T-cell leukemia / lymphoma. Twenty subjects will be enrolled. Subjects will be pretreated with chemotherapy prior to infusion of CAR T cells: about 3 days before cells transfusion, the patients who planned to reinfuse CAR T cells were treated with fluorodarabine 30 mg/m2( body surface area) and cyclophosphamide 250 mg/m2( body surface area) for 3 days. Then this study will be using a 3+3 dose escalation approach from dose 1 (DL-1): 5×105 (±20%) to dose 2 (dl-2): 1×106 (±20%). Below the lowest dose was reinfused at the PI's discretion. #Intervention - BIOLOGICAL : chimeric antigen receptor T cell treatment - Subjects will be pretreated with chemotherapy prior to infusion of CAR T cells: about 3 days before cells transfusion, the patients who planned to reinfuse CAR T cells were treated with fluorodarabine 30 mg/m2( body surface area) and cyclophosphamide 250 mg/m2( body surface area) for 3 days. Then this study will be using a 3+3 dose escalation approach from dose 1 (DL-1): 5×105 (±20%) to dose 2 (dl-2): 1×106 (±20%). Below the lowest dose was reinfused at the PI's discretion.

#Eligibility Criteria: Inclusion Criteria: In order to be eligible to participate in this study, an individual must meet all of the following criteria: * Diagnosed as a high-risk acute T-cell leukemia / lymphoma patient with complete remission within 3 months and persistent positive of minimal residual disease, expressing tumor surface antigen CD7 * Refractory or relapsed T-cell acute lymphoblastic leukemia/lymphoma patients with no blasts in peripheral blood by flow cytometry and suspending anti-neoplastic treatment for more than 2 weeks * Male or female, aged 0 <= age <= 70 years * No serious allergic constitution * Eastern Cooperative Oncology Group (ECOG) performance status (Oken et al., 1982) score 0 to 2 * Have life expectancy of at least 60 days based on investigator's judgement * CD7 positive in bone marrow or peripheral blood or immunohistochemistry * Candidates aged 8 <= age <= 70 years need to be sufficiently conscious and able to sign the treatment consent form and voluntary consent form. And Pediatric patients under 8 years could be recruited after signing an informed consent form by a legal surrogate (Guardian) * Minimal residual disease was positive after chemotherapy and there were contraindications of allogeneic hematopoietic stem cell transplantation. Exclusion Criteria: An individual who meets any of the following criteria will be excluded from participation in this study: * Intracranial hypertension or disorder of consciousness * Symptomatic heart failure or severe arrhythmia * Symptoms of severe respiratory failure * Complicated with other types of malignant tumors * Diffuse intravascular coagulation * Serum creatinine and / or blood urea nitrogen >= 1.5 times of the normal value * Suffering from septicemia or other uncontrollable infections * Patients with uncontrollable diabetes * Severe mental disorders * Obvious and active intracranial lesions were detected by cranial magnetic resonance imaging (MRI) * Have received organ transplantation (excluding hematopoietic stem cell transplantation); * Reproductive-aged female patients with positive blood HCG test * Screened to be positive of infection of hepatitis (including hepatitis B and C), AIDS or syphilis Sex : ALL Ages : - Maximum Age : 70 Years - Age Group (Child: birth-17, Adult: 18-64, Older Adult: 65+) : ADULT, CHILD, OLDER_ADULT Accepts Healthy Volunteers: No

{ "NCT_ID" : "NCT03338972", "Brief_Title" : "Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma", "Official_title" : "A Phase I Study of Adoptive Immunotherapy for Advanced B-Cell Maturation Antigen (BCMA)+ Multiple Myeloma With Autologous CD4+ and CD8+ T Cells Engineered to Express a BCMA-Specific Chimeric Antigen Receptor", "Conditions" : ["Recurrent Plasma Cell Myeloma", "Refractory Plasma Cell Myeloma"], "Interventions" : ["Drug: Fludarabine", "Drug: Cyclophosphamide", "Biological: Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143", "Procedure: Leukapheresis"], "Location_Countries" : ["United States"], "Study_Design" : { "Study_Type" : "INTERVENTIONAL", "Phase" : ["PHASE1"], "Primary_Purpose" : "TREATMENT", "Allocation" : "NON_RANDOMIZED", "Interventional Model" : "SINGLE_GROUP", "Masking" : "NONE" } }

#Study Description Brief Summary This phase I trial studies the side effects and best dose of BCMA CAR-T cells in treating patients with BCMA positive multiple myeloma that has come back or does not respond to treatment. T cells are a type of white blood cell and a major component of the immune system. T-cells that have been genetically modified in the laboratory express BCMA and may kill cancer cells with the protein BCMA on their surface. Giving chemotherapy before BCMA CAR-T cells may reduce the amount of disease and to cause a low lymphocyte (white blood cell) count in the blood, which may help the infused BCMA CAR-T cells survive and expand. Detailed Description PRIMARY OBJECTIVE: I. To evaluate the safety of adoptive therapy with ex vivo expanded autologous CD8+ plus CD4+ T cells transduced to express a human B cell maturation antigen (BCMA)-targeting chimeric antigen receptor (CAR) for patients with relapsed or treatment refractory multiple myeloma. SECONDARY OBJECTIVES: I. To determine the duration of in vivo persistence and the phenotype of long lived CAR-T cells. II. To determine the degree to which adoptively transferred T cells traffic to multiple myeloma (MM) cells in the bone marrow (BM) and function in vivo. III. To estimate the antitumor activity of adoptively transferred BCMA-specific CAR-expressing T lymphocytes (BCMA CAR-T cells). OUTLINE: This is a dose-escalation study of BCMA-specific CAR-expressing T lymphocytes. Patients undergo leukapheresis to obtain their immune cells, from which CAR-T cells are produced. A few weeks later, patients then receive cyclophosphamide and fludarabine on days -4 to -2. Beginning 36-96 hours after chemotherapy, patients receive BCMA-specific CAR-expressing T lymphocytes intravenously (IV) over 20-30 minutes on day 0. Patients may receive a second dose of BCMA-specific CAR-expressing T lymphocytes IV with or without additional cytoreductive chemotherapy at the discretion of the principal investigator or their designee (sub-investigator). After completion of study treatment, patients are followed up at 60, 90, 120, 180, and 365 days and then annually up to 15 years. #Intervention - BIOLOGICAL : Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143 - Given IV - Other Names : - Autologous Anti-BCMA-CAR CD4+/CD8+ Cells, Autologous Anti-BCMA-CAR-expressing CD8+ and CD4+ T-lymphocytes, BCMA CAR-CD4+/CD8+ T-cells, BCMA-specific CAR-expressing CD4+/CD8+ T-lymphocytes, FCARH143 - DRUG : Cyclophosphamide - Given IV - Other Names : - (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719 - DRUG : Fludarabine - Given IV - Other Names : - Fluradosa - PROCEDURE : Leukapheresis - Undergo leukapheresis - Other Names : - Leukocytopheresis, Therapeutic Leukopheresis

#Eligibility Criteria: Inclusion Criteria: * Have the capacity to give informed consent * Eastern Cooperative Oncology Group (ECOG) performance status score =< 2. * Have measurable disease by International Myeloma Working Group (IMWG) criteria based on one or more of the following findings: * Serum M-protein >= 1 g/dL * Urine M-protein >= 200 mg/24 hour * Involved serum free light chain (sFLC) level >= 10 mg/dL with abnormal kappa/lambda ratio * Measurable biopsy-proven plasmacytomas (>= 1 lesion that has a single diameter >= 2 cm) * Bone marrow plasma cells >= 30% * Have a diagnosis of BCMA+ MM (>= 5% BCMA+ by flow cytometry on CD138 co-expressing plasma cells obtained within 45 days of study enrollment); the MM diagnosis must be confirmed by internal pathology review of a fresh biopsy specimen at the Fred Hutchinson Cancer Research Center (FHCRC)/Seattle Cancer Care Alliance (SCCA) * Have relapsed or treatment refractory disease with >= 10% CD138+ malignant plasma cells (IHC) on BM core biopsy, either: * Following autologous stem cell transplant (ASCT) * Or, if a patient has not yet undergone ASCT, the individual must: * Be transplant ineligible, due to age, comorbidity, patient choice, insurance reasons, concerns of rapidly progressive disease, and/or discretion of attending physician and principal investigator and, * Demonstrate disease that persists after > 4 cycles of induction therapy and that is double refractory (persistence/progression) after therapy with both a proteasome inhibitor and immunomodulatory drug (IMiD) administered either in tandem, or in sequence; > 4 cycles of therapy are not required for patients with a diagnosis of plasma cell leukemia * Patients receiving retreatment do not need to meet the > 10% CD138+ malignant plasma cells (immunohistochemistry staining method [IHC]) on BM core biopsy * Male and female patients of reproductive potential must be willing to use an effect contraceptive method before, during, and for at least 4 months after the CAR T cell infusion Exclusion Criteria: * History of another primary malignancy that requires intervention beyond surveillance or that has not been in remission for at least 1 year (the following are exempt from the 1 year limit: non-melanoma skin cancer, curatively treated localized prostate cancer, and cervical carcinoma in situ on biopsy or a squamous intraepithelial lesion on papanicolaou [PAP] smear) * Active hepatitis B, hepatitis C at the time of screening * Patients who are (human immunodeficiency virus [HIV]) seropositive * Subjects with uncontrolled active infection * > 1 hospital admission (lasting 5 days or more) for documented infection in prior 6 months * Presence of acute or chronic graft-versus-host disease (GVHD) requiring active treatment unless limited to skin involvement and managed with topical steroid therapy alone * History of any one of the following cardiovascular conditions within the past 6 months: Class III or IV heart failure as defined by the New York Heart Association (NYHA), cardiac angioplasty or stenting, myocardial infarction, unstable angina, or other clinically significant cardiac disease as determined by the principal investigator (PI) or designee * History of clinically relevant or active central nervous system (CNS) pathology such as epilepsy, seizure, paresis, aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychosis, active central nervous system MM involvement and/or carcinomatous meningitis; subjects with previously treated central nervous systems involvement may participate, provided they are free of disease in the CNS (documented by flow cytometry performed on the cerebrospinal fluid [CSF] within 14 days of enrollment) and have no evidence of new sites of CNS activity * Pregnant or breastfeeding females * Allogeneic HSCT or donor lymphocyte infusion within 90 days of leukapheresis. * Use of any of the following: * Therapeutic doses of corticosteroids (defined as > 20 mg/day prednisone or equivalent) within 7 days prior to leukapheresis; physiologic replacement, topical, and inhaled steroids are permitted * Cytotoxic chemotherapeutic agents within 1 week of leukapheresis; oral chemotherapeutic agents are allowed if at least 3 half-lives have elapsed prior to leukapheresis * Lymphotoxic chemotherapeutic agents within 2 weeks of leukapheresis * Daratumumab (or other anti-CD38 therapy) within 30 days of leukapheresis * Experimental agents within 4 weeks of leukapheresis unless progression is documented on therapy and at least 3 half-lives have elapsed prior to leukapheresis * Absolute neutrophil count (ANC) < 1000/mm^3, or per PI discretion if cytopenia thought to be related to underlying myeloma. * Hemoglobin (Hgb) < 8 mg/dl, or per PI discretion if cytopenia thought to be related to underlying myeloma. * Platelet count < 50,000/mm^3, or per PI discretion if cytopenia thought to be related to underlying myeloma. * Active autoimmune disease requiring immunosuppressive therapy * Major organ dysfunction defined as: * Creatinine clearance < 20 ml/min * Significant hepatic dysfunction (serum glutamic-oxaloacetic transaminase [SGOT] > 5 x upper limit of normal; bilirubin > 3.0 mg/dL) * Forced expiratory volume in 1 second (FEV1) of < 50% predicted or diffusion capacity of the lung for carbon monoxide (DLCO) (corrected) < 40% (patients with clinically significant pulmonary dysfunction, as determined by medical history and physical exam should undergo pulmonary function testing) * Anticipated survival of < 3 months * Contraindication to cyclophosphamide or fludarabine chemotherapy * Patients with known AL subtype amyloidosis * Uncontrolled medical, psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol, as judged by the PI; or unwillingness or inability to follow the procedures required in the protocol Sex : ALL Ages : - Minimum Age : 21 Years - Age Group (Child: birth-17, Adult: 18-64, Older Adult: 65+) : ADULT, OLDER_ADULT Accepts Healthy Volunteers: No

{ "NCT_ID" : "NCT03744676", "Brief_Title" : "A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)", "Official_title" : "A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting", "Conditions" : ["Lymphoma, Non-Hodgkin", "Lymphoma", "Lymphoma, B-Cell", "Lymphoma, Large B-Cell, Diffuse", "Neoplasms", "Neoplasms by Histologic Type", "Lymphoproliferative Disorders", "Lymphatic Diseases", "Immunoproliferative Disorders", "Immune System Disorder"], "Interventions" : ["Biological: lisocabtagene maraleucel"], "Location_Countries" : ["United States"], "Study_Design" : { "Study_Type" : "INTERVENTIONAL", "Phase" : ["PHASE2"], "Primary_Purpose" : "TREATMENT", "Allocation" : "NA", "Interventional Model" : "SINGLE_GROUP", "Masking" : "NONE" } }

#Study Description Brief Summary This is an open-label, multicenter, Phase 2 study to determine the safety, PK, and efficacy of lisocabtagene maraleucel (JCAR017) in subjects who have relapsed from, or are refractory to, two lines of immunochemotherapy for aggressive B-cell non-Hodgkin lymphoma (NHL) in the outpatient setting. Subjects will receive treatment with JCAR017 and will be followed for up to 2 years. Detailed Description This is an open-label, multicenter, Phase 2 study to assess the safety and antitumor activity in adult patients with relapsed or refractory B-cell non-Hodgkin Lymphoma when administered with lisocabtagene maraleucel (JCAR017) in the outpatient setting. Upon the successful product generation of lisocabtagene maraleucel, subjects will enter the treatment phase of the study. Treatment will include lymphodepleting chemotherapy followed by lisocabtagene maraleucel administration. Subjects will then enter the post-treatment follow-up phase of the study and will be followed for approximately 24 months for safety, disease status, health-related quality of life (HRQoL), and survival. Long-term follow-up will continue under a separate long-term follow-up protocol, per health regulatory authority guidelines, currently up to 15 years after the last lisocabtagene maraleucel administration. #Intervention - BIOLOGICAL : lisocabtagene maraleucel - lisocabtagene maraleucel will be administered as single dose intravenous (IV) injection - Other Names : - JCAR017, liso-cel

#Eligibility Criteria: Inclusion Criteria: * Age >= 18 years at the time of consent * Relapsed or refractory B-cell NHL of the following histologies: diffuse large B cell lymphoma (DLBCL) not otherwise specified; includes biopsy-confirmed transformed DLBCL from indolent histologies, high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with DLBCL histology, primary mediastinal B-cell lymphoma(PMBCL), and follicular lymphoma Grade 3B. Subjects must have been treated with an anthracycline and rituximab (or other CD20-targeted agent) and have relapsed or refractory disease after at least 2 systemic lines of therapy for DLBCL or after auto-HSCT. * Positron-emission tomography-positive disease by Lugano Classification * Eastern Cooperative Oncology Group performance status of 0 to 1 * Adequate bone marrow, renal, hepatic, pulmonary, cardiac organ function * Adequate vascular access for leukapheresis procedure * Subjects who have received previous CD19-targeted therapy must have CD19-positive lymphoma confirmed on a biopsy since completing the prior CD19-targeted therapy * Subjects must agree to use appropriate contraception. Exclusion Criteria: * Subjects with central nervous system (CNS)-only involvement by malignancy (note: subjects with secondary CNS involvement are allowed on study) * History of prior allogeneic hematopoietic stem cell transplant * Treatment with alemtuzumab within 6 months of leukapheresis, or treatment with fludarabine or cladribine within 3 months of leukapheresis * History of another primary malignancy that has not been in remission for at least 2 years.The following are examples of exceptions from the 2-year limit: nonmelanoma skin cancer, definitively-treated stage 1 solid tumor with a low risk of recurrence, curatively treated localized prostate cancer, and cervical carcinoma in situ on biopsy or a squamous intraepithelial lesion on a Papanicolau smear. * Active hepatitis B or hepatitis C infection at the time of screening * History of or active human immunodeficiency virus infection at the time of screening * Uncontrolled systemic fungal, bacterial, viral or other infection despite appropriate anti-infection treatment at the time of leukapheresis or lisocabtagene maraleucel administration * Presence of acute or chronic graft-versus-host disease * History of clinically significant cardiac conditions within the past 6 months * History or presence of clinically relevant CNS pathology such as epilepsy/seizure, paresis, aphasia, stroke, cerebral edema, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychosis * Pregnant or nursing women * Subject does not meet protocol-specified washout periods for certain prior treatments * Prior CAR T-cell or other genetically modified T-cell therapy * Progressive vascular tumor invasion, thrombosis, or embolism * Venous thrombosis or embolism not managed on stable regimen of anticoagulation * Uncontrolled medical, psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol; or unwillingness or inability to follow the procedures required in the protocol Sex : ALL Ages : - Minimum Age : 18 Years - Age Group (Child: birth-17, Adult: 18-64, Older Adult: 65+) : ADULT, OLDER_ADULT Accepts Healthy Volunteers: No

{ "NCT_ID" : "NCT01837602", "Brief_Title" : "cMet CAR RNA T Cells Targeting Breast Cancer", "Official_title" : "Clinical Trial of Autologous cMet Redirected T Cells Administered Intratumorally in Patients With Breast Cancer", "Conditions" : ["Metastatic Breast Cancer", "Triple Negative Breast Cancer"], "Interventions" : ["Biological: cMet RNA CAR T cells"], "Location_Countries" : ["United States"], "Study_Design" : { "Study_Type" : "INTERVENTIONAL", "Phase" : ["PHASE1"], "Primary_Purpose" : "TREATMENT", "Allocation" : "NA", "Interventional Model" : "SINGLE_GROUP", "Masking" : "NONE" } }

#Study Description Brief Summary An open-label, clinical trial of autologous cMet redirected T cells administered intratumorally (IT) in patients with breast cancer. Fifteen evaluable patients will be enrolled in stepwise fashion. Step 1 will enroll patients with metastatic breast cancer refractory to at least 1 standard therapy, step 2 will include newly diagnosed patients with operable triple negative breast cancer. Detailed Description This study is designed to determine the safety and feasibility of intratumoral administration of autologous T cells that have had genetic material transferred into the cell to redirect them to target breast cancer cells rather than their usual target. Eligible subjects will have metastatic breast cancer refractory to at least one standard therapy or to newly diagnosed with operable triple negative breast cancer. #Intervention - BIOLOGICAL : cMet RNA CAR T cells

#Eligibility Criteria: Inclusion Criteria: * Step 1 subjects only: metastatic breast cancer patients with an accessible tumor (cutaneous, subcutaneous, or superficial) and/or palpable adenopathy/mass. The targeted tumor is accessible (i.e. is not near a great vessel or the spinal cord) and can be surgically excised or biopsied. * Step 2 subjects only: Newly diagnosed, operable, triple negative breast cancer, i.e. ER/PR-negative, her2/neu-negative, with tumor size between 2 - 3 cm (T2) as measured by either clinical breast exam, mammogram, ultrasound or MRI, with or without ipsilateral axilla node involvement (N0 or N1). * cMet expression in >= 30% tumor cells as demonstrated on immuno-histochemistry analysis of archival slides. The intensity for cMet IHC should be greater than or equal to 1+. Punch biopsy or percutaneous core biopsy may be offered to Cohort 1 patients. To establish eligibility for patients in step 1, archival tumor tissues from any previously biopsied metastatic tumor deposit may be used for IHC staining. The metastatic tumor nodule to be targeted for IT injection may not necessarily be the same as previously biopsied metastatic site. * Age > 18 years * Baseline Eastern Cooperative Oncology Group (ECOG) Clinical Performance Status 0 or 1 * Adequate hematologic function: WBC > 3.0 Plt > 75,000 Hgb > 10 g/dl Adequate renal function defined as serum creatinine < 1.5 times upper limit of normal * Adequate hepatic function defined as: Total bilirubin < 1.5 times upper limit of normal, and ALT and AST < 2.5 times upper limit of normal * Women of child bearing potential must have a negative pregnancy test (blood or urine) and agree to use appropriate contraception from study screen through the duration of the trial. Men must agree to use appropriate contraception from IT injection through the duration of the trial. * Signed and dated written informed consent. Exclusion Criteria: * Step 1 subjects only: Targeted tumor near a great vessel or spinal cord * Step 2 subjects only: Women already undergoing neoadjuvant chemotherapy to treat their primary triple negative breast cancer * Step 1 and 2 subjects:Positive for HIV-1/HIV-2 * Active hepatitis B or hepatitis C infection * The anticipated use of the following within 2 weeks prior to apheresis and prior to planned IT T-cell injection: Immunosuppressive drugs Cytotoxic chemotherapy (See Section 5.7 for complete details) Systemic glucocorticoids (steroid prep due to dye allergies prior to staging scans or use in anti-emetic prophylaxis for patients undergoing chemotherapy is allowed) Hematopoietic growth factors Other experimental therapy Note: Step 1 patients receiving non-investigational targeted therapy (lapatinib, trastuzumab, and/or pertuzumab) are eligible provided these medicines are at a stable dose and the patient began taking them more than 30 days prior to the planned IT T-cell injection. * Anticipated use of anti-coagulants such as coumadin, heparin, or Lovenox within 14 days before the planned IT T-cell injection RETIRED AS OF PROTOCOL VERSION 11 * Pregnant women or nursing mothers * History of alcohol abuse or illicit drug use within 12 months of IT T-cell injection * Clinically significant comorbid disease or other underlying condition, including major autoimmune disorders that would contraindicate study therapy or confuse interpretation of study results * Significant psychiatric disorder and any other reason that in the Investigator's opinion would jeopardize protocol compliance or compromise the patient's ability to give informed consent. * Prior MI ascertained from medical history and review of systems Sex : ALL Ages : - Minimum Age : 18 Years - Age Group (Child: birth-17, Adult: 18-64, Older Adult: 65+) : ADULT, OLDER_ADULT Accepts Healthy Volunteers: No

{ "NCT_ID" : "NCT01475058", "Brief_Title" : "CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant", "Official_title" : "A Phase I/II Study of Cellular Immunotherapy With Donor Central Memory-derived Virus-specific CD8+ T-cells Engineered to Target CD19 for CD19+ Malignancies After Allogeneic Hematopoietic Stem Cell Transplant", "Conditions" : ["Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia", "Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Immunoblastic Large Cell Lymphoma", "Recurrent Mantle Cell Lymphoma", "Refractory Chronic Lymphocytic Leukemia"], "Interventions" : ["Biological: allogeneic cytomegalovirus-specific cytotoxic T lymphocytes"], "Location_Countries" : ["United States"], "Study_Design" : { "Study_Type" : "INTERVENTIONAL", "Phase" : ["PHASE1", "PHASE2"], "Primary_Purpose" : "TREATMENT", "Allocation" : "NA", "Interventional Model" : "SINGLE_GROUP", "Masking" : "NONE" } }

#Study Description Brief Summary This phase I/II trial studies the safety and toxicity of post-transplant treatment with donor T cells engineered to express a chimeric antigen receptor (CAR) targeting CD19 in patients who have had a matched related allogeneic hematopoietic stem cell transplant for a CD19+ B cell malignancy. Detailed Description PRIMARY OBJECTIVES: I. To assess the safety and feasibility of pre-emptive adoptive T cell therapy using ex vivo expanded cytomegalovirus (CMV)- or Epstein-Barr virus (EBV)-specific T cells derived from donor CD62L+ central memory (TCM) cells and genetically modified to express a CD19-specific chimeric antigen receptor (CAR) in patients in complete remission after human leukocyte antigen (HLA)-matched related donor hematopoietic stem cell transplantation (HCT) for CD19+ B cell malignancies at high risk of post-HCT relapse. (Cohort A) II. To assess the safety and feasibility of adoptive T cell therapy using ex vivo expanded CMV- or EBV-specific T cells derived from donor CD62L+ TCM cells and genetically modified to express a CD19-specific CAR in patients with persistent, progressive or relapsed disease after HLA-matched related donor HCT for CD19+ B cell malignancies. (Cohort B) SECONDARY OBJECTIVES: I. To determine the duration of in vivo persistence of adoptively transferred bi-specific CD8+ T cells, and the phenotype of persisting T cells. II. To determine if adoptively transferred bi-specific CD8+ T cells traffic to the bone marrow and function in vivo. III. To determine if adoptively transferred bi-specific CD8+ T cells proliferate in allogeneic HCT recipients that reactivate CMV or EBV. IV. To determine if the adoptive transfer of bi-specific CD8+ T cells eliminates CD19+ tumor cells in the subset of patients with a measurable tumor burden prior to T cell transfer. OUTLINE: At least 30 days after HCT, patients will receive one intravenous (IV) infusion of CMV/CD19 or EBV/CD19 bi-specific CD8+ T cells. After completion of study treatment, patients are followed up periodically for 15 years. #Intervention - BIOLOGICAL : allogeneic cytomegalovirus-specific cytotoxic T lymphocytes - Allogeneic CD19-specific chimeric antigen receptor-modified CD8+ central memory derived virus-specific T cells. Allogeneic CD19CAR-TCM cells given IV - Other Names : - allogeneic CMV-specific CTLs

#Eligibility Criteria: Inclusion Criteria: * Patients with CD19+ B cell malignancy who have persistent, relapsed or progressive disease after hematopoietic stem cell transplant from an human leukocyte antigen (HLA)-matched related donor OR patients with CD19+ B cell malignancy who are planned for or have had a hematopoietic stem cell transplant from an HLA-matched related donor and are at risk of relapse after HCT defined by any one of the disease-specific criteria listed below: * Philadelphia chromosome negative acute lymphoblastic leukemia: * Beyond first complete remission (CR) at the time of pre-transplant evaluation * Required > 1 cycle of induction chemotherapy to achieve CR * First morphologic CR but with evidence of minimal residual disease by flow cytometry, conventional cytogenetics, fluorescence in situ hybridization (FISH) or polymerase chain reaction (PCR) * First CR with poor risk cytogenetics (t(4:11), t(8;14), hypodiploidy, near triploidy or > 5 cytogenetic abnormalities) at diagnosis * Planned for or have had a reduced intensity conditioned or non-myeloablative transplant * Philadelphia positive acute lymphoblastic leukemia * Not in CR at the time of pre-transplant evaluation * In CR with the following features: * Intolerant or unwilling to use a TKI after HCT * Current or previous detection of cytogenetic abnormalities in addition to t(9;22) by conventional karyotyping, FISH or molecular methods * Chronic lymphocytic leukemia, or low grade B cell lymphomas: * Failed or ineligible for prior immunochemotherapy that included a purine analog and anti-CD20 monoclonal antibody AND a lymph node >= 5 cm at the time of pre-transplant evaluation * Mantle cell lymphoma: * Failed or ineligible for autologous transplant AND a lymph node >= 2 cm at the time of pre-transplant evaluation * Diffuse large B cell lymphomas, large B cell transformation of an indolent lymphoma or other aggressive B cell lymphomas * Failed or ineligible for autologous transplant AND not in CR at the time of pre-transplant evaluation * Confirmation of tumor diagnosis and expression of CD19 after review by University of Washington Medical Center (UWMC) or Seattle Cancer Care Alliance (SCCA) pathology services * The patient has signed the informed consent form for this study * DONOR: Genotypic or phenotypic HLA-identical family members * DONOR: Express one or more of the following combinations of viral serostatus and HLA allele: * CMV seropositive and HLA-A*0101 positive * CMV seropositive and HLA-A*0201 positive * CMV seropositive and HLA-B*0702 positive * CMV seropositive and HLA-B*0801 positive * EBV seropositive and HLA-A*0201 positive * EBV seropositive and HLA-B*0801 positive * DONOR: Hematocrit >= 35% at enrollment * DONOR: Age >= 18 years * DONOR: The donor has signed the informed consent form for the study Exclusion Criteria: * Known central nervous system (CNS) tumor (CNS2 or CNS3) that is refractory to intrathecal chemotherapy and/or cranio-spinal radiation; patients with a history of CNS disease that has been effectively treated to CNS1 or lower evidence of disease will be eligible * Human immunodeficiency virus (HIV) seropositive * Significant medical or psychological conditions that would make them unsuitable candidates for T cell therapy * Fertile patients unwilling to use contraception during and for 12 months after protocol enrollment * Pregnant or breast-feeding * DONOR: G-CSF administered within one month prior to the blood draw for T cell collection * DONOR: Unable for any reason to provide a 400 ml blood draw * DONOR: Inadequate peripheral veins for blood collection * DONOR: HIV-1, HIV-2, human T-lymphotropic virus (HTLV)-1 or HTLV-2 seropositive * DONOR: Active hepatitis B or hepatitis C virus infection * DONOR: Positive serologic test for syphilis * DONOR: Aberrant CD45RA isoform expression on all T cells * DONOR: Systolic blood pressure (BP) < 80 or > 200 * DONOR: Heart rate < 50 or > 120, if considered due to cardiac disease * DONOR: Oxygen (O2) saturation < 88% on room air * DONOR: Serum creatinine (Cr) > 3.0 * DONOR: Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 4 x the upper limit of normal * DONOR: Unable to provide informed consent to participate * DONOR: Significant medical conditions (e.g. immunosuppressive therapy) that would make them unsuitable T cell donors * DONOR: Pregnant or nursing Sex : ALL Ages : - Minimum Age : 18 Years - Maximum Age : 75 Years - Age Group (Child: birth-17, Adult: 18-64, Older Adult: 65+) : ADULT, OLDER_ADULT Accepts Healthy Volunteers: No

{ "NCT_ID" : "NCT03173417", "Brief_Title" : "Safety and Efficacy Evaluation of IM19 CAR-T Cells (IM19CAR-T)", "Official_title" : "Safety and Efficacy Evaluation of IM19 CAR-T Cells On CD19+ Refractory or Relapsed B-ALL Patients", "Conditions" : ["Leukemia"], "Interventions" : ["Drug: fludarabine and cyclophosphamide", "Biological: IM19 CAR-T"], "Location_Countries" : ["China"], "Study_Design" : { "Study_Type" : "INTERVENTIONAL", "Phase" : ["PHASE1", "PHASE2"], "Primary_Purpose" : "TREATMENT", "Allocation" : "NA", "Interventional Model" : "SINGLE_GROUP", "Masking" : "NONE" } }

#Study Description Brief Summary Assessment of the Safety and Feasibility of Administering T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor to Patients With CD19+ B-cell leukemia. Detailed Description Assessment of the Safety and Feasibility of Administering T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor to Patients With CD19+ B-cell leukemia and determine the best dosage. #Intervention - BIOLOGICAL : IM19 CAR-T - T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor - Other Names : - IM19 - DRUG : fludarabine and cyclophosphamide - Two days before cell infusion,all patients will be treated with fludarabine and cyclophosphamide for 3 days - Other Names : - FC

#Eligibility Criteria: Inclusion Criteria: * Patients with CD19+ Refractory or Relapsed B-ALL（At least 2 prior combination chemotherapy regimens） * To be aged 3 <= age <= 75 * Blast in blood <= 30% * ECOG score <=2 * Women of childbearing potential must have a urine pregnancy test taken and proven negative prior to the treatment. All patients agree to use reliable methods of contraception during the trial period and until follow-up for the last time. * Voluntary participation in the clinical trials and sign the informed consent. Exclusion Criteria: * Intracranial hypertension or unconsciousness * Respiratory failure * CD19 negative * Disseminated intravascular coagulation * ALT /AST>3 x normal value; Creatinine> 1.5 x normal value; Bilirubin >2.0 x normal value * Hematosepsis or Uncontrolled active infection * Uncontrolled diabetes * Abalienation; * WHO Sscore >3 * Patients in pregnancy or breast-feeding period * Previously treatment with any gene therapy products * Any uncontrolled medical disorders that the researchers consider are not eligible to participate the clinical trial * Any situation that would increase dangerousness of subjects or disturb the outcome of the clinical study according to the researcher's evaluation. Sex : ALL Ages : - Minimum Age : 3 Years - Maximum Age : 75 Years - Age Group (Child: birth-17, Adult: 18-64, Older Adult: 65+) : ADULT, CHILD, OLDER_ADULT Accepts Healthy Volunteers: No

{ "NCT_ID" : "NCT01897415", "Brief_Title" : "Autologous Redirected RNA Meso CAR T Cells for Pancreatic Cancer", "Official_title" : "Phase I Clinical Trial of Autologous Mesothelin Re-directed T Cells in Patients With Chemotherapy Refractory Metastatic Pancreatic Cancer", "Conditions" : ["Subjects With Metastatic Pancreatic Ductal Adenocarcinoma (PDA)"], "Interventions" : ["Biological: Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1"], "Location_Countries" : ["United States"], "Study_Design" : { "Study_Type" : "INTERVENTIONAL", "Phase" : ["PHASE1"], "Primary_Purpose" : "TREATMENT", "Allocation" : "NA", "Interventional Model" : "SINGLE_GROUP", "Masking" : "NONE" } }

#Study Description Brief Summary This is a Phase I safety and feasibility study. Subjects will be enrolled serially. For subject safety, the preceding subject must have completed one cycle of therapy (28 days) before the next subject can be treated. Subjects will be treated with i.v. administration of 1 to 3e8 per meter squared RNA CAR T cells three times weekly (M-W-F) for three weeks. Detailed Description This phase I study is being conducted to establish safety and feasibility of intravenous (IV) RNA mesothelin re-directed autologous T cell administration in patients with chemotherapy-refractory metastatic pancreatic cancer. Subjects will be enrolled serially. For subject safety, the preceding subject must have completed therapy and be 28 days from their last infusion before the next subject can be treated.. Subjects will be treated with IV administration of 1 to 3e8/m2 RNA CAR T cells three times weekly (M-W-F) for three weeks. Main eligibility criteria: Subjects with metastatic pancreatic ductal adenocarcinoma (PDA) who have chemotherapy-refractory disease. Inclusion criteria include patients older than 18 years of age diagnosed with metastatic PDA with ECOG 0-1 performance status and 3 month expected survival. Exclusion criteria include a pericardial effusion, active autoimmune disease requiring immunosuppressive therapy, active anti-coagulation therapy, known HIV or HTLV I/II positivity, prior treatment with murine monoclonal antibodies or history of allergy to murine proteins. #Intervention - BIOLOGICAL : Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1

#Eligibility Criteria: Inclusion Criteria: * Histologically confirmed metastatic pancreatic adenocarcinoma. * Patients greater than or equal to 18 years. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Life expectancy greater than 3 months. * Evidence of metastatic disease and failure of at least 1 prior chemotherapy for metastatic disease. * Subjects must have measureable disease as defined by RECIST 1.1 criteria. * Satisfactory organ and bone marrow function * Blood coagulation parameters: PT such that international normalized ratio (INR) is less than or equal to 1.5 (or an in-range INR, usually between 2 and 3, if a subject is on a stable dose of therapeutic warfarin for management of venous thrombosis including pulmonary thromboembolus) and a PTT less than or equal to 1.2 time the upper limit of normal. * Subjects must have adequate venous peripheral access for apheresis. Patients must also have adequate venous access for subsequent modified CAR T cell administration which can be done through a central venous access (e.g. port for systemic chemotherapy) * Ability to understand and the willingness to provide written informed consent. * Short-term therapy for acute conditions not specifically related to pancreatic cancer is allowed if such therapy does not include immune modulating agents. * Male and Female subjects agree to use approved contraceptive methods (e.g. birth control pills, barrier device, intrauterine device, abstinence) during the study and for 3 months following the last dose of the study cell infusion. * Subject must understand and sign the study-specific informed consent. Exclusion Criteria: * Participated in any other trial in which receipt of an investigational study drug occurred within 28 days (42 days for non-murine monoclonal antibodies) prior to entry into the study. * Received any anticancer medication in the 2 weeks (i.e. 14 days) prior to receiving their first dose of study treatment and no other concurrent chemotherapy or immunotherapy (e.g. monoclonal antibodies) * Active invasive cancer other than pancreatic adenocarcinoma. Patients with active non-invasive cancers (such as non-melanoma skin cancer, superficial cervical and bladder and prostate cancer with PSA level less than 1.0) are not excluded. * Known HIV, HCV, and HBV positive * Active autoimmune disease (including but not limited to: systemic lupus erythromatosis, Sjogrens syndrome, rheumatoid arthritis, psoriasis, multiple sclerosis, inflammatory bowel disease, etc.) requiring immunosuppressive therapy within the past 4 weeks, with exception of thyroid replacement. * Patients with ongoing or active infection. * Planned concurrent treatment with systemic high dose corticosteroids. * Prior gene therapy or therapy with murine monoclonal antibodies or products of murine origin. * Concurrent treatment with any anticancer agent. * History of allergy to murine proteins * History of allergy or hypersensitivity to study product excipients (human serum albumin, DMSO, and Dextran 40) * Any clinically significant pericardial effusion; CHF (NY Heart Association Grade II-IV) or cardiovascular condition that would preclude assessment of mesothelin induced pericarditis. * Subjects on active anti-coagulation therapy. * Pregnant women are excluded from this study because autologous transduced T cells may have the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants, secondary to treatment of the mother with autologous transduced T cells, breastfeeding should be discontinued if the mother is treated. * Feasibility assessment demonstrates less than 20% transfection of target lymphocytes or insufficient expansion of modified CAR T cells to complete 9 infusions. Sex : ALL Ages : - Minimum Age : 18 Years - Age Group (Child: birth-17, Adult: 18-64, Older Adult: 65+) : ADULT, OLDER_ADULT Accepts Healthy Volunteers: No

{ "NCT_ID" : "NCT04650724", "Brief_Title" : "Clinical Study of T Cell Infusion Targeting BCMA Chimeric Antigen Receptor", "Official_title" : "Single Arm, Single Center, Open Label Clinical Trial of BCMA Autologous Chimeric Antigen Receptor T Cell Infusion in Patients With BCMA Positive Recurrent or Refractory Multiple Myeloma", "Conditions" : ["Multiple Myeloma"], "Interventions" : ["Drug: T cell infusion agent targeting BCMA chimeric antigen receptor"], "Location_Countries" : ["China"], "Study_Design" : { "Study_Type" : "INTERVENTIONAL", "Phase" : ["EARLY_PHASE1"], "Primary_Purpose" : "TREATMENT", "Allocation" : "NA", "Interventional Model" : "SINGLE_GROUP", "Masking" : "NONE" } }

#Study Description Brief Summary Chimeric antigen receptor T cells (car-t) is one of the most effective therapies for malignant tumors (especially hematological tumors). Like other immunotherapies, the basic principle is to use the patient's own immune cells to clear cancer cells. Chimeric antigen receptor (car) is the core component of car-t, which endows T cells with the ability to recognize tumor antigens in an independent manner, which enables car modified T cells to recognize a wider range of targets than natural T cell surface receptors (TCR). The basic design of car includes a tumor associated antigen binding region (usually derived from scFv segment of monoclonal antibody antigen binding region), transmembrane region and intracellular signal region. The selection of target antigen is a key determinant for the specificity and effectiveness of car and the safety of genetically modified T cells. BCMA is a specific surface protein of B lymphocytes, which plays an important role in the development, proliferation and differentiation of B cells. BCMA is highly expressed in malignant mm plasma cells and provides a large number of anti apoptotic signals, which makes bcam an ideal target in targeted immunotherapy. At present, a variety of immunotherapy strategies targeting BCMA are being carried out in laboratory and clinical practice, which have achieved encouraging therapeutic effects in multiple myeloma and effectively promoted the development of targeted immunotherapy. #Intervention - DRUG : T cell infusion agent targeting BCMA chimeric antigen receptor - Chimeric antigen receptor T cells (car-t) is one of the most effective therapies for malignant tumors (especially hematological tumors). Like other immunotherapies, the basic principle is to use the patient's own immune cells to clear cancer cells. Chimeric antigen receptor (car) is the core component of car-t, which endows T cells with the ability to recognize tumor antigens in an independent manner, which enables car modified T cells to recognize a wider range of targets than natural T cell surface receptors (TCR). The basic design of car includes a tumor associated antigen binding region (usually derived from scFv segment of monoclonal antibody antigen binding region), transmembrane region and intracellular signal region. The selection of target antigen is a key determinant for the specificity and effectiveness of car and the safety of genetically modified T cells.

#Eligibility Criteria: Inclusion Criteria: * 1. Subjects who voluntarily participated in the study and signed written informed consent; 2. The age of signing informed consent is 14 <= age <= 65 years; 3. Patients with multiple myeloma were diagnosed according to the IMWG diagnostic criteria; 4. The expression of BCMA was confirmed by flow cytometry or immunohistochemistry; 5. The expected survival time was > 12 weeks; 6. The main researchers and attending physicians believe that there is no other feasible and effective alternative treatment, such as hematopoietic stem cell transplantation; 7. Relapsed or refractory multiple myeloma (mm) A. At least one complete regimen including induction, consolidation and maintenance of proteasome inhibitors and / or immunomodulators was performed at least once, and the interval between the two regimens was more than 3 months; B. According to the criteria of IMWG, recurrence was considered; C. Refractory patients (disease progression during standard treatment; efficacy of proteasome inhibitor combined with immunomodulator less than PR; efficacy after autologous stem cell transplantation less than PR; disease progression within 6 months after transplantation; progression and recurrence within 1 year after initial treatment); D. Recurrence occurred after allogeneic SCT treatment; 8. The main organ functions are sound, including: A. Renal function: serum creatinine clearance rate > 40 ml / min / 1.73 m2, adjusted according to age / gender standard; B. Alanine transferase (ALT) was less than 2 times the normal maximum value of the same age; C. Bilirubin < 2.0 mg / dl; D. Echocardiography or multi gated angiography (MUGA) showed left ventricular short axis shortening (LVSF) >= 28%, or left ventricular ejection fraction (LVEF) >= 45%; 9. ECOG physical status (PS) <= 2; 10. The pregnant test results of fertile female subjects within 48 hours before infusion were negative, and they were not in lactation period; all subjects with reproductive potential should take adequate contraceptive measures from the beginning of the study to one year after the end of the study. Exclusion Criteria: * 1. Pregnant or lactating female patients; 2. Participate in another clinical trial within 4 weeks before enrollment (3 months in case of monoclonal antibody clinical trial) or intend to participate in another clinical trial during the whole study period; 3. Other anti BCMA treatments have been used in the past; 4. Uncontrolled active infection; for example, there is a known history of human immunodeficiency virus; active hepatitis B or hepatitis C infection; HBV-DNA detection exceeds normal, etc; 5. There is grade 2 <= age <= 4 acute or systemic chronic GVHD or GVHD under treatment; 6. Cns-3 disease progression, or the presence of central nervous system parenchymal lesions that may increase the central nervous system toxicity; patients with active central nervous system leukemia infiltration; 7. The researchers think that they are not suitable to participate in this clinical trial due to various reasons. Sex : ALL Ages : - Minimum Age : 14 Years - Maximum Age : 65 Years - Age Group (Child: birth-17, Adult: 18-64, Older Adult: 65+) : ADULT, CHILD, OLDER_ADULT Accepts Healthy Volunteers: No

{ "NCT_ID" : "NCT05907603", "Brief_Title" : "Research Development（RD）13-02 Chimeric Antigen Receptor(CAR) -T Cell Injection for Patients With r/r Cluster Of Differentiation 7（CD7）+ T-Acute Lymphoblastic Leukemia(ALL)/T-Lymphoblastic Lymphoma(LBL) /Acute Myelogenous Leukemia(AML)", "Official_title" : "Clinical Study on Efficacy, Safety and Pharmacokinetics of CAR T Cell Injection in Patients With Recurrent or Refractory Cluster Of Differentiation 7(CD7)-Positive Hematologic Malignancies", "Conditions" : ["Neoplasms", "Hematologic Neoplasms", "Hematologic Diseases"], "Interventions" : ["Drug: RD13-02 cell infusion"], "Location_Countries" : ["China"], "Study_Design" : { "Study_Type" : "INTERVENTIONAL", "Phase" : ["EARLY_PHASE1"], "Primary_Purpose" : "TREATMENT", "Allocation" : "NA", "Interventional Model" : "SINGLE_GROUP", "Masking" : "NONE" } }

#Study Description Brief Summary This is a single-arm, open-label, single-center, phase I study. The primary objective is to evaluate the safety of CD7 CAR-T therapy for patients with CD7-positive relapsed or refractory T-ALL/LBL/AML, and to evaluate the pharmacokinetics of CD7 CAR-T in patients. #Intervention - DRUG : RD13-02 cell infusion - CAR-T cells

#Eligibility Criteria: Inclusion Criteria: * Age 3 <= age <= 70 * Diagnosis of r/r T-ALL/LBL/AML. * CD7 positive expression * Bone marrow lymphoblasts >=5% by morphologic evaluation at screening * Creatinine clearance (as estimated by Cockcroft Gault) >= 60 mL/min, Serum alanine aminotransferase(ALT)/aspartate aminotransferase(AST) < 3×upper limit of normal, Total bilirubin < 1.5×upper limit of normal or <=1.5mg/dl * Left ventricular ejection fraction >= 50% . * Baseline oxygen saturation >= 92% on room air. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2. * The estimated survival time is more than 3 months. * Subjects or their legal guardians volunteer to participate in the study and sign the informed consent. Exclusion Criteria: * For AML patients, there are acute promyelocytic leukemia (APL) and Abelson Murine Leukemia Viral Oncogene Homolog(BCR-ABL) positive leukemia (chronic myeloid leukemia with acute(CML)-BC). * Subjects with concomitant genetic syndromes associated with bone marrow failure states. * Subjects with some cardiac conditions will be excluded. * History of traumatic brain injury, consciousness disturbance, epilepsy, cerebrovascular ischemia, and cerebrovascular hemorrhagic disease, which might compromise the ability of the subject to compliance with the obligations under the protocol. * History of malignancy other than non-melanoma skin cancer or carcinoma. * Primary immune deficiency. * Presence of uncontrolled infections. * Subjects with some anticancer therapy before CAR-T infusion will be excluded. * Active uncontrolled acute infections. * Known history of infection with human immunodeficiency virus (HIV); active or latent hepatitis B, hepatitis C and syphilis. * Subjects who are receiving systemic steroid therapy prior to screening. * Subjects with acute graft-versus-host disease (GvHD) * Having received live/attenuated vaccine within 4 weeks prior to screening. * History of allergy to any component of the cell therapy product. * Pregnant or breastfeeding women * Any other issue which, in the opinion of the investigator, would make the subjects ineligible for the study. Sex : ALL Ages : - Minimum Age : 3 Years - Maximum Age : 70 Years - Age Group (Child: birth-17, Adult: 18-64, Older Adult: 65+) : ADULT, CHILD, OLDER_ADULT Accepts Healthy Volunteers: No

{ "NCT_ID" : "NCT06392763", "Brief_Title" : "Care Pathway and Associated Costs of Patients Treated With CAR T-cells Based on SNDS Data", "Official_title" : "Care Pathway and Associated Costs of Patients Treated With CAR T-cells Based on SNDS Data", "Conditions" : ["Diffuse Large B-cell Lymphoma", "Acute Lymphoblastic Leukemia (ALL)"], "Location_Countries" : ["France"], "Study_Design" : { "Study_Type" : "OBSERVATIONAL", } }

#Study Description Brief Summary This retrospective cohort study, based on the French medico-administrative database (SNDS), evaluated the care pathway, the effectiveness of management and the costs associated with patients treated with chimeric antigen receptor (CAR) T cells (CART-cells) (KYMRIAH or YESCARTA): paediatric and young adult patients (up to and including 25 years of age) with acute lymphoblastic leukaemia (ALL); and adult patients (18 years of age or older) with DLBCL.

#Eligibility Criteria: Inclusion criteria: DLBCL population: * Patients with hospitalisation for CAR T-cell administration from 2017 to 2020 AND * Diagnosed with DLBCL (International Classification of Diseases [ICD-10 C833]) when receiving CAR-T AND * Being 18 years or older. ALL population: * Patients with hospitalisation for CAR T-cell administration from 2017 to 2020 AND * Diagnosed with ALL (ICD-10 C910) when receiving CAR-T AND * Being 25 years or younger. Exclusion criteria: DLBCL population: * Patients hospitalised with a diagnosis other than DLBCL during the historical period or during the index stay. ALL population: * Patients hospitalised with a diagnosis other than ALL during the historical period or during the index stay. Sex : ALL Ages : - Minimum Age : 1 Year - Age Group (Child: birth-17, Adult: 18-64, Older Adult: 65+) : ADULT, CHILD, OLDER_ADULT Accepts Healthy Volunteers: No

{ "NCT_ID" : "NCT04316624", "Brief_Title" : "A Study of C-CAR066 in Subjects With r/r Diffuse Large B Cell Lymphoma Who Received CD19 CAR-T Therapy", "Official_title" : "A Study Evaluating Safety and Efficacy of CBM.CD20 CAR-T(C-CAR066) in Subjects With r/r Diffuse Large B Cell Lymphoma Who Received CD19 CAR-T Therapy", "Conditions" : ["Diffuse Large B Cell Lymphoma"], "Interventions" : ["Drug: C-CAR066"], "Location_Countries" : ["China"], "Study_Design" : { "Study_Type" : "INTERVENTIONAL", "Phase" : ["PHASE1"], "Primary_Purpose" : "TREATMENT", "Allocation" : "NA", "Interventional Model" : "SINGLE_GROUP", "Masking" : "NONE" } }

#Study Description Brief Summary This is a single-center, non-randomized and dose-escalation study to evaluate the safety and efficacy of C-CAR066 in treatment of r/r DLBCL who received CD19 CAR-T therapy. Detailed Description This study plans to enroll 10 patients to assess the safety and efficacy of C-CAR066. Subjects who meet the eligibility criteria will receive a single dose of C-CAR066 injection. The study will include the following sequential phases: Screening, Pre-Treatment (Cell Product Preparation, Lymphodepleting Chemotherapy), C-CAR066 infusion and Follow-up Visit. #Intervention - DRUG : C-CAR066 - Autologous 2nd generation CD20-directed CAR-T cells, single infusion intravenously

#Eligibility Criteria: Inclusion Criteria: * The patient volunteered to participate in the study, and signed the Informed Consent * Age 18 <= age <= 75 years, male or female * Patients diagnosed with diffuse large B-cell lymphoma (DLBCL, De novo or transformed) histologically according to the 2016 WHO Classification, at least one measurable lesion(LDi>=1.5 cm) * r/r DLBCL patients who received prior CD19 CAR-T therapy, and positive for CD20 * At least 2 weeks from last treatment (radiation, chemotherapy, mAb, etc) to apheresis * Adequate organ and bone marrow fuction * No contraindications of apheresis * Expected survival time > 3 months * ECOG scores 0 - 1 Exclusion Criteria: * Have a history of allergy to cellular products * Patients with cardiac insufficiency classified as Class III or IV according to the New York Heart Association (NYHA) Heart Function Classification Standard * A history of craniocerebral trauma, consciousness disorder, epilepsy, cerebral ischemia or hemorrhagic cerebrovascular disease * Patients with active CNS involvement * Patients with autoimmune disease, immunodeficiency, or other treatment requiring inhibitors * Severe active infection (except simple urinary tract, bacterial pharyngitis), or currently receiving intravenous antibiotics. However, prophylactic antibiotics, antiviral and antifungal treatments are allowed * Live vaccination within 4 weeks before peripheral blood apheresis * HIV, HBV, HCV and TPPA / RPR infections, and HBV carriers * Have a history of alcoholism, drug addiction and mental illness * Non-sterile subjects had any of the following: a) being pregnant / lactating; or b) having a pregnancy plan during the trial; or c) having fertility without taking effective contraception * Patients with severe fludarabine or cyclophosphamide hypersensitivity * The patient has a history of other primary cancers, except for the following: 1. Non-melanoma such as skin basal cell carcinoma cured by resection 2. Cured carcinoma in situ such as cervical, bladder or breast cancer * The investigators believe that there are other circumstances that are not suitable for the trial Sex : ALL Ages : - Minimum Age : 18 Years - Maximum Age : 75 Years - Age Group (Child: birth-17, Adult: 18-64, Older Adult: 65+) : ADULT, OLDER_ADULT Accepts Healthy Volunteers: No

{ "NCT_ID" : "NCT05812326", "Brief_Title" : "PD-1 Knockout Anti-MUC1 CAR-T Cells in the Treatment of Advanced Breast Cancer", "Official_title" : "Exploratory Clinical Study of PD-1 Knockout Targeting MUC1 CAR-T Cells (AJMUC1) in the Treatment of MUC1-positive Advanced Breast Cancer", "Conditions" : ["Advanced Breast Cancer", "Breast Neoplasm Malignant Female"], "Interventions" : ["Drug: AJMUC1- PD-1 gene knockout anti-MUC1 CAR-T cells"], "Location_Countries" : ["China"], "Study_Design" : { "Study_Type" : "INTERVENTIONAL", "Phase" : ["PHASE1", "PHASE2"], "Primary_Purpose" : "TREATMENT", "Allocation" : "NA", "Interventional Model" : "SEQUENTIAL", "Masking" : "NONE" } }

#Study Description Brief Summary This exploratory clinical study aims to assess the safety and preliminary efficacy of an immunotherapy using PD-1 knockout anti-MUC1 CAR-T cells in the treatment of advanced MUC1-positive breast cancer Detailed Description This is a single-center, open-label, dose-escalation exploratory study investigating the safety,tolerability and preliminary efficacy of AJMUC1, PD-1 knockout CAR-T cells targeting aberrantly glycosylated MUC1, in the treatment of patients with advanced MUC1 positive breast cancer. The primary objective of this study is to evaluate the safety, tolerability, biological activity, and preliminary antitumor efficacy of AJMUC1. The study adopts a '3+3' dose escalation design to identify the maximum tolerated dose (MTD)/ maximum administered dose (MAD). Three doses are set: 3×105 CAR T cells/kg, 1×106 CAR T cells/kg and 3×106 CAR T cells/kg, with a total of 15 patients planned by the data cutoff date. Participants may receive one, two, three or more cycles of AJMUC1 infusion dependent on the adverse effects and potential clinical benefits.. This study is initiated by the investigators and approved by the Human Ethics Committee of Sun Yat-sen Memorial Hospital affiliated with Sun Yat-sen University. All patients have signed informed consent. #Intervention - DRUG : AJMUC1- PD-1 gene knockout anti-MUC1 CAR-T cells - AJMUC1 is a genetically modified T cell therapeutic product targeting the aberrantly glycosylated MUC1 protein. CAR targeting MUC1 is introduced into autologous T cells by lentiviral vector, so that T cells expressing the receptor can recognize and kill MUC1 positive tumor cells. Preclinical studies have shown that binding of scFv targeting MUC1 to the MUC1 epitope on the surface of the target cell can induce the costimulatory CD28 and CD3ζ costimulatory domains to activate downstream signaling pathways and promote T cell activation and expansion. Activated CAR-T cells secrete a series of inflammatory cytokines and chemokines, leading to apoptosis and necrosis of target tumor cells. Following introduction of a CAR structure, the PD-1 gene of CAR-T cells is knocked out using CRISPR/Cas9, so that the CAR-T cell does not express PD-1, resulting in improved tumor killing efficiency of AJMUC due to the release of inhibition in the signaling pathway PD-1/PD-L1 in the tumor microenvironment. - Other Names : - Therapeutic T cells

#Eligibility Criteria: Inclusion Criteria: * Patient age: 18 <= age <= 70 years (including the boundary value); * Pathologically diagnosed with recurrent/metastatic breast cancer (except for intracranial metastasis), who have received at least one standard treatment regimen in the past, the disease is in a stable or progressive state, and refuses to undergo subsequent chemotherapy; * Abnormal glycosylated MUC1 expression confirmed by immunohistochemistry in tumor tissue or puncture tissue within 12 months; * Expected survival period >= 4 months; * ECOG score<=2 points; * The subjects voluntarily joined the study, signed the informed consent form, had good compliance, and cooperated with the follow-up; * Able to cooperate with tumor puncture; * At least one measurable lesion that meets the RECIST v1.1 criteria; * Female patients of childbearing age must not be breastfeeding, and serum or urine HCG test is negative within 72 hours before study enrollment. All subjects must use medically approved contraception during the study period and within 3 months after the end of the study. measures (eg, IUDs, birth control pills) for contraception; * Organ function and bone marrow reserve are in good condition and the following requirements must be met: (1) The absolute value of neutrophils is >=1.5×109/L; (2) Platelet count >=75×109/L; (3) Hemoglobin >=9g/dl; (4) Bilirubin value < 1.5 times the upper limit of normal (except for obstruction of the bile duct caused by tumor compression); (5) Creatinine value < 1.5 times the upper limit of normal or creatinine clearance rate >= 60ml/min; (6) ALT or AST < 2.5 times the upper limit of normal (with liver involvement < 5 times the upper limit of normal); (7) Stable coagulation function: INR<=1.5, PTT<1.2 times the upper limit of normal (except for tumor-related anticoagulation therapy). Exclusion Criteria: * Have used immunosuppressive drugs or hormones within 1 week prior to enrollment; * Patients with moderate or more moderate pleural and ascites who need catheter drainage to relieve symptoms; * Human immunodeficiency virus (HIV) positive; * Active hepatitis B or C infection; * Pregnant or lactating women; * Past or concurrent history of other malignant tumors. Excluded: Patients with basal or squamous cell carcinoma of the skin and carcinoma in situ of the cervix who have been cured at any time prior to the study; * Those with central transfer; * Serious, uncontrollable concomitant diseases that may affect protocol compliance or interfere with the interpretation of results, or have any serious medical conditions that may affect the subject's safety (such as uncontrollable heart disease, high blood pressure, active or uncontrollable disease) infection, etc.); * Active autoimmune diseases (including but not limited to, systemic lupus erythematosus, Sjögren syndrome, rheumatoid arthritis, psoriasis, multiple sclerosis, inflammatory bowel disease, etc.); * Those with a history of organ transplantation; * Subjects whose last medication was less than 2 weeks before enrollment, or subjects who participated in other relevant clinical studies at the same time; * Those who have received gene therapy in the past; * Vaccination with live vaccine within 4 weeks prior to study; * History of myocardial infarction and severe arrhythmia within half a year; uncontrolled hypertension, coronary heart disease, stroke, liver cirrhosis, nephritis and other serious complications; * Those who have a history of psychotropic substance abuse and cannot quit or who have a history of mental disorders; * Hypersensitivity constitution, allergic to human serum albumin; * Hemorrhagic and thrombotic tendency: patients with clinically significant bleeding symptoms or clear bleeding tendency within 3 months before the study, such as gastrointestinal bleeding, hemorrhagic gastric ulcer, abnormal coagulation function (PT>16s, APTT>43s) , TT>21s, FIB<2g/L), hereditary or acquired bleeding and thrombosis tendency to (such as hemophilia, coagulation disorder, thrombocytopenia, hypersplenism, etc.), are receiving thrombolytic or anticoagulation therapy, arterial/venous thrombotic events occurred within the previous 6 months, such as cerebrovascular disease (including cerebral hemorrhage, cerebral infarction), deep vein thrombosis and pulmonary embolism; * Other severe, acute, or chronic medical or psychiatric conditions that may increase the risks associated with participation in the study or may interfere with the interpretation of the study results, in the opinion of the investigator. Sex : ALL Ages : - Minimum Age : 18 Years - Maximum Age : 70 Years - Age Group (Child: birth-17, Adult: 18-64, Older Adult: 65+) : ADULT, OLDER_ADULT Accepts Healthy Volunteers: No

{ "NCT_ID" : "NCT04788472", "Brief_Title" : "Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph+ B-ALL", "Official_title" : "Clinical Trial for the Efficacy and Safety of Sequential CD19 and CD22 CAR-T Therapy for Adult Patients with Newly Diagnosed Ph Chromosome Positive B-cell Acute Lymphoblastic Leukemia", "Conditions" : ["B-Cell Acute Lymphoblastic Leukemia, Adult"], "Interventions" : ["Drug: CAR-T cells targeting CD19 and CD22"], "Location_Countries" : ["China"], "Study_Design" : { "Study_Type" : "INTERVENTIONAL", "Phase" : ["PHASE2"], "Primary_Purpose" : "TREATMENT", "Allocation" : "NA", "Interventional Model" : "SINGLE_GROUP", "Masking" : "NONE" } }

#Study Description Brief Summary Clinical Trial for the Efficacy and Safety of Sequential CD19 and CD22 CAR-T Therapy for Adult Patients With Newly Diagnosed Ph Chromosome Positive B-cell Acute Lymphoblastic Leukemia Detailed Description This study was designed as a prospective, open-label, single-center study. It aims to evaluate the efficacy and safety of CD19 CAR-T cells in combination with dasatinib for the treatment of newly diagnosed Ph-positive B-cell acute lymphoblastic leukemia in adult. #Intervention - DRUG : CAR-T cells targeting CD19 and CD22 - Each subject receives sequential CD19 and CD22 CAR-T cells by intravenous infusion

#Eligibility Criteria: Inclusion Criteria: * Age >= 18 years; * Subjects with a diagnosis of B-cell acute lymphoblastic leukemia according to the 2016 edition of the WHO classification criteria for acute leukemia; * Subjects whose chromosomal and fusion gene analysis showed positivity for the Ph chromosome, BCR/ABL1 fusion gene; * Leukemia cells were CD19 and CD22 positive; * Patients with newly diagnosed B-ALL were not treated with standard chemotherapy regimens; * Serum total bilirubin <= 51 mol/L, serum ALT and AST both <= 3 times the upper limit of the normal range, blood creatinine <= 176.8 mol/L; * Echocardiography showed a left ventricular ejection fraction (LVEF) >=50%; * Subjects had no active pulmonary infection and oxygen saturation >=92% without oxygen; * The prognosis for survival is more than 3 months; * ECOG score 0 <= age <= 2; * Subjects volunteered to participate in this trial and signed an informed consent form. Exclusion Criteria: Subjects with any of the following exclusion criteria were not eligible for enrollment in this trial: * Those with a history of epilepsy or other central nervous system disorders; * Those with a history of prolonged QT period or severe cardiac disease; * Women who are pregnant or breastfeeding (the safety of this therapy for the unborn child is not known); * Those with uncontrolled active infection; * Active hepatitis B or hepatitis C virus infection; * Those who have previously used any gene therapy product; * Those with insufficient amplification (<5-fold) in response to CD3/CD28 co-stimulatory signals; * Creatinine > 2.5 mg/dl or ALT / AST > 3 times the upper limit of the normal range or bilirubin > 2.0 mg/dl; * Those who suffer from other uncontrolled medical conditions that, in the opinion of the investigator, make them unsuitable for enrollment; * HIV-infected persons; * Any condition that, in the opinion of the investigator, may increase the risk to the subject or interfere with the results of the test. Sex : ALL Ages : - Minimum Age : 18 Years - Age Group (Child: birth-17, Adult: 18-64, Older Adult: 65+) : ADULT, OLDER_ADULT Accepts Healthy Volunteers: No

{ "NCT_ID" : "NCT04888468", "Brief_Title" : "Phase I Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents", "Official_title" : "A Phase I Clinical Study of Anti-CD19 CAR-T Therapy (pCAR-19B) in the Treatment of CD19-positive Relapsed/Refractory B-ALL", "Conditions" : ["Acute Lymphoblastic Leukemia", "Relapsed Pediatric ALL", "Refractory Acute Lymphoblastic Leukemia"], "Interventions" : ["Biological: pCAR-19B cells"], "Location_Countries" : ["China"], "Study_Design" : { "Study_Type" : "INTERVENTIONAL", "Phase" : ["PHASE1"], "Primary_Purpose" : "TREATMENT", "Allocation" : "NA", "Interventional Model" : "SINGLE_GROUP", "Masking" : "NONE" } }

#Study Description Brief Summary This is a phase I clinical study to evaluate the safety and tolerability of pCAR-19B in patients with relapsed or refractory B-ALL, and to obtain the maximum tolerated dose of pCAR-19B and phase II Recommended dose. Detailed Description This is a single-center, single-arm, open-label study. The study plans to set up 3 dose groups, adopting a dose-escalating 3+3 design, and plan to recruit about 9-18 subjects with relapsed or refractory B-ALL.pCAR-19B will be infused to the subject by intravenous infusion. #Intervention - BIOLOGICAL : pCAR-19B cells - Drug: pCAR-19B cells； Administration method: intravenous infusion； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.

#Eligibility Criteria: Inclusion Criteria: * Diagnosed with B-ALL，and meet one of the following conditions: 1. First-line or multiple-line salvage chemotherapy did not achieve complete remission； 2. Early relapse after complete remission (<12 months), or late relapse after complete remission (>=12 months) and complete remission has not been achieved after 1 course of treatment； 3. Relapse after autologous or allogeneic hematopoietic stem cell transplantation; * Ph+ALL patients should also receive at least two TKI treatments； * For allogeneic hematopoietic stem cell transplant subjects, the following conditions must be met： 1. Allo-HSCT takes >=6 months before pCAR-19B infusion； 2. No GVHD of grade 2 or above occurred within 2 weeks before PBMC collection; * Express CD19; * 3~21 years, no gender limit; * The expected survival time is more than 12 weeks; * KPS>60; * No serious mental disorders; * The function of important organs is basically normal: 1. Heart function: echocardiography indicates that the cardiac ejection fraction is >=50%, and the electrocardiogram has no obvious abnormalities; 2. Renal function: serum creatinine<=2.0×ULN; 3. Liver function: ALT and AST <=5×ULN; 4. Total bilirubin and alkaline phosphatase<=3×ULN ; 5. Blood oxygen saturation>92%. * Have standards for apheresis or venous blood collection, and no other cell collection contraindications; * The patient himself or his guardian agrees to participate in the clinical trial and signs the ICF, indicating that he understands the purpose and procedures of the clinical trial and is willing to participate in the research. Exclusion Criteria: * With central nervous system disease at the time of screening; * Have received CAR-T therapy or other genetically modified cell therapy; * Participated in other clinical studies within 1 month before screening; * Have received the following anti-tumor treatments before screening: received chemotherapy, targeted therapy or other experimental drug treatments within 14 days or at least 5 half-lives (whichever is shorter); * Have received a live attenuated vaccine within 4 weeks before screening; * Cerebrovascular accident or seizure occurred within 6 months before signing the ICF; * Suffered from any of the following heart diseases: 1. NYHA stage III or IV congestive heart failure; 2. Myocardial infarction or CABG occurred <=6 months before enrollment; 3. Clinically significant ventricular arrhythmia, or history of unexplained syncope (except for cases caused by vasovagal or dehydration); 4. History of severe non-ischemic cardiomyopathy. * Uncontrollable infection in the 2 weeks before screening； * Active autoimmune diseases； * Patients with malignant tumors other than acute lymphoblastic leukemia within 5 years before screening, except for fully treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, local prostate cancer after radical resection, and duct in situ after radical resection cancer； * HBsAg or HBcAb positive and HBV DNA is greater than the normal range; HCV antibody is positive and HCV RNA greater than the normal range; HIV antibody positive; syphilis positive; CMV DNA positive; * Women who are pregnant or breastfeeding, and male or female subjects who plan to have children within 1 year after receiving pCAR-19B cell reinfusion; * Other situations considered by the researcher to be unsuitable to participate in the study. Sex : ALL Ages : - Minimum Age : 3 Years - Maximum Age : 21 Years - Age Group (Child: birth-17, Adult: 18-64, Older Adult: 65+) : ADULT, CHILD Accepts Healthy Volunteers: No

{ "NCT_ID" : "NCT02631044", "Brief_Title" : "Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)", "Official_title" : "A Phase 1, Multicenter, Open-Label Study of JCAR017, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL)", "Conditions" : ["Non-Hodgkin Lymphoma", "Diffuse Large B Cell Lymphoma", "Follicular Lymphoma", "Mantle-cell Lymphoma", "Primary Mediastinal B-cell Lymphoma"], "Interventions" : ["Biological: JCAR017 (lisocabtagene maraleucel) 2-dose schedule", "Biological: JCAR017 (lisocabtagene maraleucel) single-dose schedule"], "Location_Countries" : ["United States"], "Study_Design" : { "Study_Type" : "INTERVENTIONAL", "Phase" : ["PHASE1"], "Primary_Purpose" : "TREATMENT", "Allocation" : "NON_RANDOMIZED", "Interventional Model" : "PARALLEL", "Masking" : "NONE" } }

#Study Description Brief Summary This open-label Phase 1 study will evaluate the safety, PK, and antitumor activity of modified T cells (JCAR017) administered to adult patients with relapsed or refractory B-cell NHL. The dose and schedule of JCAR017 will be evaluated and modified, as needed, for safety and antitumor activity. We will also determine how long the modified T cells stay in the patient's body and how well JCAR017 works in treating patients with non-Hodgkin's lymphoma whose disease has come back or has not responded to treatment. Detailed Description This is an open-label, multicenter Phase 1 study to determine the safety, pharmacokinetics (PK), and antitumor activity of JCAR017 in adult patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma (PMBCL), follicular lymphoma Grade 3B, and mantle cell lymphoma (MCL). This study will evaluate and refine the dose and schedule of JCAR017 to optimize safety and antitumor activity. A dose-confirmation group or groups will further evaluate the safety and efficacy of JCAR017 at the recommended regimen(s). Upon successful generation of JCAR017 product, participants will receive treatment with one or more cycles of JCAR017 therapy. Each cycle will include lymphodepleting chemotherapy followed by one or two doses of JCAR017 administered by intravenous (IV) injection. The follow-up period for each participant is approximately 24 months after the final JCAR017 infusion. Long-term follow-up for survival, toxicity, and viral vector safety will continue under a separate long-term follow-up protocol per health regulatory authority guidelines, currently up to 15 years after the last JCAR017 infusion. #Intervention - BIOLOGICAL : JCAR017 (lisocabtagene maraleucel) single-dose schedule - Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCAR017. During JCAR017 production, participants may receive low-dose chemotherapy for disease control. Upon successful generation of JCAR017 product, participants will receive treatment with JCAR017 therapy. Treatment will include lymphodepleting chemotherapy followed by one dose of JCAR017 administered by intravenous (IV) injection. - BIOLOGICAL : JCAR017 (lisocabtagene maraleucel) 2-dose schedule - Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCAR017. During JCAR017 production, participants may receive low-dose chemotherapy for disease control. Upon product availability, participants will receive study treatment consisting of lymphodepleting chemotherapy followed by two IV doses of JCAR017.

#Eligibility Criteria: Inclusion Criteria: * Age >=18 years * Relapsed or refractory B-cell NHL, including 1. DLBCL cohort (no longer enrolling): DLBCL, not otherwise specified (NOS; includes transformed DLBCL from indolent histology [tDLBCL]), high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with DLBCL histology (Swerdlow 2016), primary mediastinal B-cell lymphoma (PMBCL), and follicular lymphoma Grade 3B. Subjects must have been treated with an anthracycline and rituximab (or other CD20-targeted agent) and have relapsed or refractory disease after at least 2 lines of systemic therapy or after auto-HSCT. 2. MCL cohort: MCL (diagnosis must be confirmed with cyclin D1 expression or evidence of t(11;14) by cytogenetics, fluorescent in situ hybridization [FISH], or PCR) with relapsed or refractory disease after at least 2 prior lines of systemic MCL therapy. Subjects must have been treated with an alkylating agent, Bruton's tyrosine kinase inhibitor (BTKi), and rituximab (or other CD20-targeted agent). * PET-positive disease by Lugano classification * Archived tumor biopsy tissue available from the last relapse and corresponding pathology report available or, if at least one tumor-involved site is deemed accessible at time of screening, willing to undergo pre-treatment biopsy (excisional when possible) for disease confirmation. If a subject has never had a complete response, a sample from the most recent biopsy is acceptable. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Adequate bone marrow, renal, hepatic, pulmonary, and cardiac function * Adequate vascular access for leukapheresis procedure * Participants who have received previous CD19-targeted therapy must have CD19-positive lymphoma confirmed on a biopsy since completing the prior CD19-targeted therapy. * Participants must agree to use appropriate contraception. Exclusion Criteria: * Active central nervous system (CNS)-only involvement by malignancy (note: participants with secondary CNS involvement are allowed on study) * History of other primary malignancy not in remission for at least 2 years (The following are exempt from the 2-year limit: nonmelanoma skin cancer, definitively treated stage 1 solid tumor with low risk for recurrence, curatively treated localized prostate cancer, and cervical carcinoma in situ on biopsy or a squamous intraepithelial lesion on Pap smear) * Treatment with alemtuzumab within 6 months of leukapheresis or fludarabine or cladribine within 3 months of leukapheresis * Active hepatitis B, hepatitis C, or Subjects with a history of or active human immunodeficiency virus (HIV) infectionare excluded. Subjects with active hepatitis B, or active hepatitis C are also excluded. Subjects with a negative PCR assay for viral load for hepatitis B or C are permitted. Subjects positive for hepatitis B surface antigen and/or anti-hepatitis B core antibody with negative viral load are eligible and should be considered for prophylactic antiviral therapy * Uncontrolled systemic fungal, bacterial, viral, or other infection * Presence of graft-vs-host disease (GVHD) * History of cardiovascular disease * History or presence of clinically relevant CNS pathology such as epilepsy, seizure, paresis, aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychosis * Pregnant or nursing women * Use of the following: * Therapeutic doses of corticosteroids (defined as >20 mg/day prednisone or equivalent) within 7 days of leukapheresis or 72 hours prior to JCAR017 administration. Physiologic replacement, topical, and inhaled steroids are permitted. * Low dose chemotherapy (e.g., vincristine, rituximab, cyclophosphamide <=300 mg/m2) given after leukapheresis to maintain disease control must be stopped >=7 days prior to lymphodepleting chemotherapy. * Cytotoxic chemotherapeutic agents that are not considered lymphotoxic (see below) within 1 week of leukapheresis. Oral chemotherapeutic agents, including lenalidomide and ibrutinib, are allowed if at least 3 half-lives have elapsed prior to leukapheresis. * Lymphotoxic chemotherapeutic agents (e.g., cyclophosphamide, ifosfamide, bendamustine) within 2 weeks of leukapheresis. * Experimental agents within 4 weeks of leukapheresis unless no response or disease progression is documented on the experimental therapy and at least 3 half-lives have elapsed prior to leukapheresis * Immunosuppressive therapies within 4 weeks of leukapheresis and JCAR017 administration (e.g., calcineurin inhibitors, methotrexate or other chemotherapeutics, mycophenolyate, rapamycin, thalidomide, immunosuppressive antibodies such as anti-TNF, anti IL6, or anti-IL6R) * Donor lymphocyte infusions (DLI) within 6 weeks of JCAR017 administration * Radiation within 6 weeks of leukapheresis. Subjects must have progressive disease in irradiated lesions or have additional non-irradiated, PET-positive lesions to be eligible. Radiation to a single lesion, if additional non-irradiated PET-positive lesions are present, is allowed up to 2 weeks prior to leukapheresis. * Allo-HSCT within 90 days of leukapheresis * Prior CAR T-cell or other genetically-modified T-cell therapy, with the exception of prior JCAR017 treatment in this protocol for subjects receiving retreatment * Progressive vascular tumor invasion, thrombosis, or embolism * Venous thrombosis or embolism not managed on a stable regimen of anticoagulation Sex : ALL Ages : - Minimum Age : 18 Years - Age Group (Child: birth-17, Adult: 18-64, Older Adult: 65+) : ADULT, OLDER_ADULT Accepts Healthy Volunteers: No

{ "NCT_ID" : "NCT02975687", "Brief_Title" : "CD19 CAR T Cells in Patients With Resistant or Refractory CD19+ Acute Lymphoblastic Leukemia", "Official_title" : "CD19 CAR T Cells in Patients With Resistant or Refractory CD19+ Acute Lymphoblastic Leukemia", "Conditions" : ["Acute Lymphoblastic Leukemia, Adult B-Cell", "Acute Lymphoblastic Leukaemia Recurrent"], "Interventions" : ["Biological: CD19 CAR T cells"], "Location_Countries" : ["China"], "Study_Design" : { "Study_Type" : "INTERVENTIONAL", "Phase" : ["PHASE1"], "Primary_Purpose" : "TREATMENT", "Allocation" : "NA", "Interventional Model" : "SINGLE_GROUP", "Masking" : "NONE" } }

#Study Description Brief Summary In this single-center, open-label, no control, prospective clinical trial, a total of 20 resistant or refractory CD19+ B cell acute lymphoblastic leukemia (ALL) patients will be enrolled. CD19 CAR T cells will be administered by i.v. injection as a using a 'split dose' (total dose of 5x10\^6/kg-5x10\^7/kg) approach to dosing:10% on day 0, 30% on day 1 and 60% on day 2. The purpose of current study is to determine the clinical efficacy and safety of CD19 CAR T cells in patients with chemotherapy resistant or refractory CD19+ ALL. Detailed Description In this single-center, open-label, nonrandomized, no control, prospective clinical trial, a total of 20 resistant or refractory CD19+ B cell acute lymphoblastic leukemia (ALL) patients will be enrolled. Patients will be diagnosed according to morphologic, immunologic, cytogenetic and molecular(MICM) criteria, including bone marrow morphology, immunophenotype, cytogenetic and molecular examination. CD19 CAR T cells transduced with a lentiviral vector to express anti-CD19 scFv TCRζ:4-1BB,administered by i.v. injection as a using a 'split dose' (total dose of 5x10\^6/kg-5x10\^7/kg) approach to dosing:10% on day 0, 30% on day 1 and 60% on day 2. This protocol will be given to subjects with unmet medical needs for which there are no effective therapies known at this time. Side effects of CD19 CAR T cells therapy will be monitored. The purpose of current study is to determine the clinical efficacy and safety of CD19 CAR T cells therapy in patients with chemotherapy resistant or refractory CD19+ ALL. #Intervention - BIOLOGICAL : CD19 CAR T cells - CD19 CAR T cells was transduced with a lentiviral vector to express anti-CD19 scFv TCRζ:4-1BB.

#Eligibility Criteria: Inclusion Criteria: * Patients aged 18 <= age <= 70 with relapsed or refractory CD19 positive ALL(ie, >=20% blasts CD19-positive) due to receive either salvage 1 or salvage 2 therapy. Ph+ ALL patients must have failed treatment with at least 1 second generation tyrosine kinase inhibitor. * Bone marrow involvement with>=20% lymphoblasts. * Eastern Cooperative Oncology Group (ECOG) Performance status 0 <= age <= 2. * Adequate end organ function as defined by: Total bilirubin <= 1.5 x upper limit of normal（ULN）; serum glutamic-oxaloacetic transaminase(SGOT) and serum glutamic pyruvic transaminase(SGPT) <= 2.5 x ULN; Creatinine <= 1.5 x ULN or any serum creatinine level associated with a measured or calculated creatinine clearance of >= 40ml/min. * Patients should sign informed consent form. Exclusion Criteria: * Isolated extramedullary relapse. * Active central nervous system leukemia. * Prior chemotherapy within <=2 weeks before enrollment with the following exceptions: steroids, hydroxyurea, oral mercaptopurine, methotrexate, vincristine, thioguanine, and tyrosine kinase inhibitors are permitted within 2 weeks of enrollment as maintenance or to reduce the peripheral blood blast count. Patients must have recovered from acute toxicity of all previous therapy prior to enrollment. * Prior allogeneic hematopoietic stem cell transplant (HSCT) <= 4 months before enrollment. Patients must have completed immunosuppression therapy prior to enrollment. At enrollment, patients must not have > grade 2 acute GVHD, or either moderate or severe limited chronic GVHD, or extensive GVHD of any severity. * Peripheral lymphoblasts > 10,000/μl (treatment with hydroxyurea and/or steroids is permitted within 2 weeks of enrollment to reduce the WBC count). * Known systemic vasculitides, primary or secondary immunodeficiency(such as HIV infection or severe inflammatory disease). * Major surgery within <= 4 weeks before enrollment. * Impaired cardiac function:Ejection fraction < 45 % on MUGA scan. QTc interval > 450 msec on baseline ECG (using the QTcB formula). If QTcB interval>450 msec and electrolytes are not within normal ranges, electrolytes should be corrected and then the patient re-screened for QTc. Myocardial infarction within 6 months prior to starting study; other clinically significant heart disease (e.g. unstable angina, congestive heart failure or uncontrolled hypertension, uncontrolled arrhythmias). * Administration of live vaccine <= 4 weeks before enrollment. * Other concurrent severe and/or uncontrolled medical conditions: Patients with another primary malignant disease, except those that do not currently require treatment; acute or chronic liver, pancreatic or severe renal disease; another severe and/or life-threatening medical disease. * Evidence of uncontrolled current serious active infection. * Patients who are: (a) pregnant, (b) breast feeding, (c) of childbearing potential without a negative pregnancy test prior to baseline and (d) male or female of childbearing potential unwilling to use contraceptive precautions throughout the trial (post-menopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential). * Who is known human deficiency virus (HIV) positive. * Use of any other investigational agent in the last 30 days. Sex : ALL Ages : - Minimum Age : 18 Years - Maximum Age : 70 Years - Age Group (Child: birth-17, Adult: 18-64, Older Adult: 65+) : ADULT, OLDER_ADULT Accepts Healthy Volunteers: No

{ "NCT_ID" : "NCT02658929", "Brief_Title" : "Study of bb2121 in Multiple Myeloma", "Official_title" : "CRB-401 A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma", "Conditions" : ["Multiple Myeloma"], "Interventions" : ["Biological: bb2121"], "Location_Countries" : ["United States"], "Study_Design" : { "Study_Type" : "INTERVENTIONAL", "Phase" : ["PHASE1"], "Primary_Purpose" : "TREATMENT", "Allocation" : "NA", "Interventional Model" : "SINGLE_GROUP", "Masking" : "NONE" } }

#Study Description Brief Summary Study CRB-401 is a 2-part, non-randomized, open label, multi-site Phase 1 study of bb2121 in adults with relapsed/refractory multiple myeloma (MM). Detailed Description This is a 2-part, non-randomized, open label, multi-site Phase 1 study. the study design consists of 2 parts: Part A (Dose Escalation), in which the RP2D is determined, and Part B (Expansion Cohorts), in which subjects are treated with the determined RP2D. Following consent, enrolled subjects will undergo a leukapheresis procedure to collect autologous mononuclear cells for manufacture of investigational drug product (bb2121). Following manufacture of the drug product, subjects will receive lymphodepleting therapy with fludarabine and cyclophosphamide prior to bb2121 infusion. All subjects who have received bb2121 infusion will be followed for up to 60 months on CRB-401. All subjects who complete the study, as well as those who withdraw from the study after receiving bb2121 for reasons other than death or meeting the early termination criteria, will be asked to continue to undergo long-term follow-up in a companion study for up to 15 years after their last bb2121 infusion, with a focus on long-term safety and efficacy. #Intervention - BIOLOGICAL : bb2121 - bb2121

#Eligibility Criteria: Inclusion Criteria: * 18 years at the time of signing informed consent * Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 * Subjects must have measurable disease including at least one of the criteria below: Serum M-protein greater or equal to 0.5 g/dL Urine M-protein greater or equal to 200 mg/24 h Serum free light chain (FLC) assay: involved FLC level greater or equal to 10 mg/dL (100 mg/L) provided serum FLC ratio is abnormal -Women of child-bearing potential (WCBP) must have a negative serum pregnancy test prior to treatment and refrain from tissue donation including egg donation or any other tissue/blood/organ donations, for at least 1 year following bb2121 infusion. All sexually active WCBP and all sexually active male subjects must agree to use effective methods of birth control throughout the study. All sexually active males subjects must refrain from tissue donation including egg donation or any other tissue/blood/organ donations, for at least 1 year following bb2121 infusion. Part A: Diagnosis of MM with relapsed or refractory disease and have had at least 3 different prior lines of therapy including proteasome inhibitor (e.g., bortezomib or carfilzomib) and immunomodulatory therapy (IMiD; e.g., lenalidomide or pomalidomide), or have 'double refractory' disease to a proteasome inhibitor and IMiD, defined as progression on or within 60 days of treatment with these agents * Part B: Diagnosis of MM with relapsed or refractory disease with previous exposure to PI (e.g., bortezomib or carfilzomib), IMiDs (e.g., lenalidomide or pomalidomide), and daratumumab, and refractory (based on IMWG criteria) to their last line of therapy Exclusion Criteria: * Subjects with known central nervous system disease * Inadequate hepatic function * Inadequate renal function * Inadequate bone marrow function * Presence of active infection within 72 hours * Significant co-morbid condition or disease which in the judgment of the Investigator would place the subject at undue risk or interfere with the study; examples include, but are not limited to, cirrhotic liver disease, sepsis, recent significant traumatic injury, and other conditions * Subjects with second malignancies in addition to myeloma if the second malignancy has required therapy in the last 3 years or is not in complete remission * Subjects with a history of class III or IV congestive heart failure or non-ischemic cardiomyopathy, unstable angina, myocardial infarction, or ventricular arrhythmia requiring medication or mechanical control within the previous 6 months * Known human immunodeficiency virus (HIV) positivity * Subjects who have plasma cell leukemia or clinically significant amyloidosis * Pregnant or lactating women Sex : ALL Ages : - Minimum Age : 18 Years - Age Group (Child: birth-17, Adult: 18-64, Older Adult: 65+) : ADULT, OLDER_ADULT Accepts Healthy Volunteers: No

{ "NCT_ID" : "NCT03097770", "Brief_Title" : "Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20", "Official_title" : "Clinical Study of CD19/CD20 tanCAR T Cells in Relapsed and/or Chemotherapy Refractory B-cell Leukemias and Lymphomas", "Conditions" : ["Hematopoietic/Lymphoid Cancer", "Adult Acute Lymphoblastic Leukemia in Remission", "B-cell Adult Acute Lymphoblastic Leukemia", "B-cell Chronic Lymphocytic Leukemia", "Prolymphocytic Leukemia", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Stage III Adult Diffuse Large Cell Lymphoma", "Stage III Chronic Lymphocytic Leukemia", "Stage III Grade 1 Follicular Lymphoma", "Stage III Grade 2 Follicular Lymphoma", "Stage III Grade 3 Follicular Lymphoma", "Stage III Mantle Cell Lymphoma", "Stage IV Adult Diffuse Large Cell Lymphoma", "Stage IV Chronic Lymphocytic Leukemia", "Stage IV Grade 1 Follicular Lymphoma", "Stage IV Grade 2 Follicular Lymphoma", "Stage IV Grade 3 Follicular Lymphoma", "Stage IV Mantle Cell Lymphoma"], "Interventions" : ["Biological: anti-CD19/20-CAR vector-transduced T cells"], "Location_Countries" : ["China"], "Study_Design" : { "Study_Type" : "INTERVENTIONAL", "Phase" : ["PHASE1", "PHASE2"], "Primary_Purpose" : "TREATMENT", "Allocation" : "NA", "Interventional Model" : "SINGLE_GROUP", "Masking" : "NONE" } }

#Study Description Brief Summary RATIONALE: Placing a tumor antigen chimeric receptor that has been created in the laboratory into patient autologous or donor-derived T cells may make the body build immune response to kill cancer cells. PURPOSE: This clinical trial is studying genetically engineered lymphocyte therapy in treating patients with B-cell leukemia or lymphoma that is relapsed (after stem cell transplantation or intensive chemotherapy) or refractory to chemotherapy. Detailed Description PRIMARY OBJECTIVES: To assess the efficacy of TanCAR19/20 T cells in relapsed or refractory NHL, defined as overall response rate (ORR). SECONDARY OBJECTIVES: I. To evaluate the safety and tolerability of TanCAR19/20 T cells. II. To evaluate time to response (TTR), duration of overall response (DOR), progression free survival (PFS) and overall survival (OS). III. To determine in vivo expansion and persistence of TanCAR19/20 T cells. OUTLINE: Patients are assigned to 1 group according to order of enrollment. Patients receive anti-CD19/20-CAR (coupled with CD137 and CD3 zeta signalling domains)vector-transduced autologous T cells on day1 in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed intensively for 6 months, every 3 months for 2 years, and annually thereafter for 3 years. #Intervention - BIOLOGICAL : anti-CD19/20-CAR vector-transduced T cells - genetically engineered lymphocyte therapy - Other Names : - genetically engineered lymphocyte therapy

#Eligibility Criteria: Inclusion Criteria Patients eligible for inclusion in this study have to meet all of the following criteria: * Age >=18 and <=70 years. * Performance status (ECOG) between 0 and 2. * Histologically confirmed CD20+ and/or CD19+ B-cell non-Hodgkin lymphoma (NHL), including the following types defined by WHO 2008: * DLBCL not otherwise specified, DLBCL associated with chronic inflammation, and Epstein-Barr virus (EBV)+ DLBCL in the elderly. * Primary mediastinal (thymic) large B-cell lymphoma (PMBCL). The mediastinal mass had to have an axial diameter <5 cm or extranodal lesion size <3 cm. Patients with large lesions (>=5 cm) were enrolled in our other clinical trial (NCT0334662). * Transformed FL (tFL) . * FL. * Some indolent lymphomas including MCL and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). * Refractory disease or relapsed after treatment with >=2 lines of chemotherapy including rituximab and anthracycline and either having failed autologous HSCT or being ineligible for or not consenting to autologous HSCT. We defined chemotherapy-refractory disease as meeting one or more of the following criteria: * No response to first-line therapy (primary refractory disease). * No response to second-line or later therapy. * PD as the best response to the most recent therapy regimen. * Stable disease (SD) as the best response after at least 2 cycles of the most recent line of therapy with a SD duration of no longer than 6 months from the last dose of therapy. Failure following autologous HSCT was defined as follows: * PD or relapsed disease <=12 months after ASCT (requires biopsy-proven recurrence in relapsed subjects). * No response or relapse after salvage therapy is given post-ASCT. * PD or relapse >=3 months after treatment with a targeted CD19 therapy, including CD19-CAR T cells or anti-CD19/anti-CD3. * Successful leukapheresis assessment and pre-culture of T cells. * Life expectancy > 3 months. * Adequate organ function: * Creatinine < 1.6 mg/dL (140 µmol/L) or creatinine clearance >=60 mL/min. * ALT/AST < 3× upper limit of the normal range. * Bilirubin <2.0 mg/dL unless the subject had Gilbert's Syndrome (<3.0 mg/dL). * A minimum level of pulmonary reserve defined as <= Grade 1 dyspnoea and pulse oxygenation > 91% with room air. No clinically significant pleural effusion. * Cardiac ejection fraction >=50%, no evidence of pericardial effusion as determined by an echocardiogram (ECHO), and no clinically significant electrocardiogram (ECG) findings. * An adequate bone marrow reserve defined as: * Absolute neutrophil count (ANC)>1,000/mm3. * Absolute lymphocyte count (ALC)>=300/mm3. * Platelet count >= 50,000/mm3. * Haemoglobin > 7.0 mg/dL. * Measurable or assessable disease according to the 'IWG Response Criteria for Malignant Lymphoma' (Cheson 2007). Patients in CR with no evidence of disease were not eligible. * Informed consent/assent requiring that all patients have the ability to understand and the willingness to provide written informed consent. Exclusion Criteria: Patients eligible for this study must not meet any of the following criteria: * Patients with definite involvement of gastrointestinal tract. Endoscopy should be performed to conform gastrointestinal involvement for patients suspected. However, patients with central nervous system (CNS) involvement were cautiously enrolled in this clinical study. * CD19 CAR T cell treatment failure or recurrence, detection of a clear HAMA effect, or negative tumour puncture detection of CD19 and CD20. * Pregnant or lactating women. * Uncontrolled active bacterial or viral infection. (active hepatitis B or hepatitis C infection, HIV infection) or treponema pallidum infection. * Class III/IV cardiovascular disability according to the New York Heart Association Classification and a cardiac ejection fraction >=50%. * History of allogeneic stem cell transplantation. * Any autoimmune disease or primary immunodeficiency. * Requirement for urgent therapy due to tumour mass effects such as respiratory obstruction or blood vessel compression. * Current or expected need for systemic corticosteroid therapy. * Any organ failure. * The patients with the second tumour requiring for therapy or intervention. * Subjects considered unlikely to complete all protocol-required study visits or procedures, including follow-up visits, or comply with the study requirements for participation according to the investigator's judgement. Sex : ALL Ages : - Minimum Age : 16 Years - Maximum Age : 70 Years - Age Group (Child: birth-17, Adult: 18-64, Older Adult: 65+) : ADULT, CHILD, OLDER_ADULT Accepts Healthy Volunteers: No

{ "NCT_ID" : "NCT04833504", "Brief_Title" : "Clinical Follow-up Study of CD19 CAR-T Expressing IL7 and CCL19 for Relapsed or Refractory B Cell Lymphoma", "Official_title" : "Clinical Follow-up Study of CD19 CAR-T Expressing IL7 and CCL19 for Relapsed or Refractory B Cell Lymphoma", "Conditions" : ["Diffuse Large B-cell Lymphoma", "Mantle Cell Lymphoma", "Transformed Follicular Lymphoma", "Primary Mediastinal Large B-cell Lymphoma"], "Location_Countries" : ["China"], "Study_Design" : { "Study_Type" : "OBSERVATIONAL", } }

#Study Description Brief Summary This study is designed to monitor all patients exposed to CD19 CAR-T expressing IL7 and CCL19 for 5 years following infusion, to assess their long-term efficacy, including the CAR-vector persistence, the normal immunity rebuilding and the risk of delayed adverse events (AEs). Detailed Description Patients are enrolled following completion from the early clinical study of CD19-7X19 CAR-T treatment ( NCT03258047) and will be followed for 5 years post treatment from the last treatment. They will be monitored for safety and efficacy with the primary treatment protocols for the protocol defined duration. This long-term following up study allow an interim analysis to evaluate the outcomes of the study when it arrives in 2 years Collection of such long term effects of CAR-T cell therapy will help to further define the risk-benefit profile of CAR-T Therapies. #Intervention - BIOLOGICAL : CD19 CAR-T Expressing IL7 and CCL19 - A fourth generation CD19 targeting CAR-T expressing IL7 and CCL19

#Eligibility Criteria: Inclusion Criteria: * All patients who have received the CD19-IL7/CCL19 CAR-T therapy in the earlier enrolled clinical trail and met including and excluding criteria criteria (NCT0325847) Patients who have provided informed consent for the long term follow up study prior to their study participation . Exclusion Criteria: * There are no specific exclusion criteria for this study. Sex : ALL Ages : - Minimum Age : 18 Years - Maximum Age : 75 Years - Age Group (Child: birth-17, Adult: 18-64, Older Adult: 65+) : ADULT, OLDER_ADULT Accepts Healthy Volunteers: No

{ "NCT_ID" : "NCT05390671", "Brief_Title" : "CAR-T Cell Therapy in Patients With Hematological Malignancies", "Official_title" : "Retrospective Analysis of the Use of CAR-T Cell Therapy in Patients With Hematological Malignancies in Spain", "Conditions" : ["CART Therapy"], "Location_Countries" : ["Spain"], "Study_Design" : { "Study_Type" : "OBSERVATIONAL", } }

#Study Description Brief Summary The prognosis of relapsed or refractory lymphoblastic leukaemia (ALL) and diffuse large B-cell lymphoma (DLBCL) is poor with conventional treatment with complete response rates around 25-30% with a median progression-free survival (PFS) of around 2 months and 7 months, respectively, despite the use of allogeneic and autologous haematopoietic stem cell transplantation. The recent introduction of CAR-T (Chimeric Antigen Receptor T-cells) therapy as a therapeutic option has been a breakthrough in the management of these entities. Detailed Description Information on baseline patient characteristics, haematological disease, comorbidities and CAR-T therapy procedure (lymphodepletion schedule, infused product) will be collected. Early post-infusion toxicity and recurrence data will be collected. The grading of adverse effects will follow the EBMT and ASTCT guidelines. Finally, data will be collected to analyse survival and, in case of death, cause of death).

#Eligibility Criteria: Inclusion Criteria: * Adult patients >18 y/o * Patients receiving CAR-T cell therapy in Spain, since 2018. Exclusion Criteria: T * Patients receiving CART therapy as part of a clinical trial. Sex : ALL Ages : - Age Group (Child: birth-17, Adult: 18-64, Older Adult: 65+) : ADULT, CHILD, OLDER_ADULT Accepts Healthy Volunteers: No

{ "NCT_ID" : "NCT03952923", "Brief_Title" : "CD19-CAR-T in B-cell Malignancies Patients", "Official_title" : "CD19-CAR-T for Patients With B Cell Malignancies", "Conditions" : ["B-cell Malignancy"], "Interventions" : ["Biological: CD19-CAR-T cells"], "Location_Countries" : ["China"], "Study_Design" : { "Study_Type" : "INTERVENTIONAL", "Phase" : ["PHASE1"], "Primary_Purpose" : "TREATMENT", "Allocation" : "NA", "Interventional Model" : "SINGLE_GROUP", "Masking" : "NONE" } }

#Study Description Brief Summary This is a single center, single arm, open-lable phase I study to determine the safety and efficacy of CD19-CAR-T cells in patients with refractory and relapsed B-cell malignancies. Detailed Description This Phase I study is designed as a pilot trial evaluating the safety and of CD19-CAR-T cell therapy in subjects with refractory and relapsed B cell malignancies. Subjects will receive cytoreductive chemotherapy with cyclophosphamide and fludarabine on days -5, -4 and -3 followed by infusion of CD19-CAR-T cells. Safety and efficacy of CD19-CAR-T cells therapy will be monitored. The purpose of current study is to determine the clinical efficacy and safety of CD19-CAR-T cells therapy in patients with refractory and relapsed B-cell malignancies. #Intervention - BIOLOGICAL : CD19-CAR-T cells - CD19-CAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of CAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest for 2 days before infusion.

#Eligibility Criteria: Inclusion Criteria: * Relapsed and refractory CD19 positive B-cell acute malignancies with: * Relapsed after competed remission, could not get competed remission after at more than 1 course of chemotherapy (including MRD>=0.1%); * MRD>=0.1% after allogeneic hematopoietic stem cell transplantation(HSCT), or recurrence after complete remission or MRD >= 0.1% after HSCT; * Refractory: at least two courses of chemotherapy did not achieve complete remission or MRD >= 0.1%; * Patients must have evaluable evidence of disease, including minimal residual disease (MRD); * Ph + patients who meet the following criteria can register:Failure to tolerate TKI or TKI treatment failure, or failure to transplant; * Ages 1 <= age <= 70, including boundary values; * ECOG score 0 <= age <= 3 points; * Women of childbearing age (15 <= age <= 49 years) must receive a pregnancy test within 7 days prior to initiation of treatment and the results are negative; male and female patients with fertility must use an effective contraceptive to ensure 3 months after discontinuation of treatment during the study period not pregnant inside. Exclusion Criteria: * patients with organ failure: * Heart: NYHA heart function grade IV; * Liver: Grade C that achieves Child-Turcotte liver function grading; * Kidney: kidney failure and uremia; * Lung: symptoms of respiratory failure; * Brain: a person with a disability; * Active infections that are difficult to control; * Human immunodeficiency virus (HIV) positive; * Liver and kidney function: total bilirubin > 5 × ULN, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) > 5 × ULN, serum creatinine clearance rate 60mL / min; * GVHD >= 2 or anti-GVHD treatment; * Received allogeneic cell therapy within 4 weeks, such as donor lymphocyte infusion; * Subject received anti-tumor treatment (chemotherapy, mAb, or hormone) for less than 1 week; * Central nervous system white blood that is symptomatic or uncontrolled by systemic chemotherapy and intrathecal chemotherapy (a large number of tumor cells in CSF, white blood cell count >15WBCs/mL); * intracranial hypertension or unconsciousness; respiratory failure; diffuse vascular internal coagulation; * pregnant or lactating women; * The patient does not agree to use effective contraception during the treatment period and for the next 3 months; * Patients who participate in other clinical studies at the same time; * The investigator believes that there are other factors that are not suitable for inclusion or influence the subject's participation or completion of the study. Sex : ALL Ages : - Minimum Age : 1 Year - Maximum Age : 70 Years - Age Group (Child: birth-17, Adult: 18-64, Older Adult: 65+) : ADULT, CHILD, OLDER_ADULT Accepts Healthy Volunteers: No

{ "NCT_ID" : "NCT03884751", "Brief_Title" : "Chimeric Antigen Receptor T Cells Targeting Glypican-3", "Official_title" : "A Phase I Clinical Study of Chimeric Antigen Receptor T Cells Targeting Glypican-3 (CAR-GPC3 T Cells) in Patients With Advanced Hepatocellular Carcinoma", "Conditions" : ["Hepatocellular Carcinoma"], "Interventions" : ["Biological: CAR-GPC3 T Cells"], "Location_Countries" : ["China"], "Study_Design" : { "Study_Type" : "INTERVENTIONAL", "Phase" : ["PHASE1"], "Primary_Purpose" : "TREATMENT", "Allocation" : "NA", "Interventional Model" : "SINGLE_GROUP", "Masking" : "NONE" } }

#Study Description Brief Summary A Phase I Clinical Study of Chimeric Antigen Receptor T Cells Targeting Glypican-3 (CAR-GPC3 T Cells) in Patients with Advanced Hepatocellular Carcinoma Detailed Description This is a phase I open-label, single-arm, multicenter clinical trial designed to observe and evaluate the safety, cell metabolokinetics, and efficacy of CAR-GPC3 T cells infused intravenously at single escalating doses in patients with advanced hepatocellular carcinoma. Primary objectives: - To evaluate the safety and tolerability of CAR-GPC3 T cells infused intravenously at escalating doses in patients with advanced hepatocellular carcinoma. Secondary objectives： * To evaluate the metabolic kinetics of single infusion of CAR-GPC3 T cells * To evaluate the overall safety and tolerability of infusion of CAR-GPC3 T cells * To observe the efficacy of CAR-GPC3 T cells in the treatment of advanced hepatocellular carcinoma #Intervention - BIOLOGICAL : CAR-GPC3 T Cells - CAR-GPC3 T Cells injection - Other Names : - Chimeric Antigen Receptor T Cells Targeting Glypican-3

#Eligibility Criteria: Inclusion Criteria: * Aged 18 <= age <= 70, male or female; * Patients with advanced hepatocellular carcinoma (HCC) diagnosed by histopathology or cytology who are not suitable for surgery or local treatment (including ablation, intervention, and radiotherapy), have developed progressive disease or intolerability after standard systemic therapies (including but not limited to systemic chemotherapy, molecular targeted therapy) and have no effective treatment at the time of enrollment; * According to RECIST 1.1, patients have at least one evaluable target lesion, defined as: the longest diameter of non-lymph node lesion >= 10 mm, or the shortest diameter of lymph node lesion >= 15 mm); hepatic lesions require arterial phase contrast enhancement; * In tumor tissue samples GPC3 is detected positive by immunohistochemistry (IHC); * According to Barcelona Clinic Liver Cancer staging(BCLC), the patients are classified into Grade C or Grade B unsuitable for local treatment/progressive disease after local treatment; * Expected survival is > 12 weeks; * Cirrhosis status Child-Pugh score: Grade A; * Eastern Cooperative Oncology Group(ECOG) Performance Status score: 0 to 1 point; * Without active hepatitis B and/or Hepatitis C; * Have venous accesses for pheresis; * Acceptable routine blood test showing no contraindication to the lymphodepletion pretreatment; * Adequate liver, renal, cardiovascular, respiratory function; * Subjects of childbearing age must undergo a serum pregnancy test within 14 days before the initiation of the study and the result must be negative. In addition, they should be willing to use a reliable method of contraception during the trial (within 24 months (M24) after cell infusion); male subjects whose spouses are women of childbearing age should undergo sterilization surgery or agree to use a reliable method of contraception during the trial; * Understand and sign informed consent. Exclusion Criteria: * Pregnant or breast-feeding women; * HCV-RNA(Hepatitis C Virus RNA ), HIV antibodies or Syphilis Serological tests are positive; * HBV（Hepatitis B） and HCV(Hepatitis C virus ) infection exist simultaneously; * Any uncontrollable active infection * Patients who had received systemic steroids or other immunosuppressive agents * Previous or present hepatic encephalopathy; * Current clinically significant ascites; * >=50% of the liver is replaced by tumor or portal vein main tumor thrombus, or tumor thrombus invasion of mesenteric vein / inferior vena cava; * Metastases to the central nervous system and clinically significant central nervous system diseases; * Patients with existing heart disease in need of treatment or hypertension that be poorly controlled * Patients with known active autoimmune diseases which require to be treated with immunosuppressive agents including biological agents; * Patients with a history of organ transplantation or waiting for organ transplantation (including liver transplantation); * Patients with local treatments such as surgical treatment, interventional therapy, radiotherapy, ablation or systemic chemotherapy were performed for the studied disease within 2 weeks prior to apheresis;Or received immunotherapy (PD-1/ PD-L1 monoclonal antibody, see Section 15) or any Chinese herbal or proprietary medicine for the control of liver cancer within 1 week prior to apheresis;Or received sorafenib, regofenib, ramvastinib and other tyrosine kinase inhibitor targeted drugs within 1 week prior to apheresis;Targeted therapy with anti-angiogenic monoclonal antibodies such as bevacizumab or its analogue 4 weeks prior to apheresis; * Patiens with previous treatment with targeted GPC3, TCR-T or CAR-T; * Patients who previously received anti-PD-1/ PD-L1 monoclonal antibody therapy within 4 weeks prior to apheresis; * Patients who had uncured malignant tumors in the past 5 years or at the same time, excluding in situ cervical cancer and skin basal cell carcinoma; * Other serious illnesses that may limit subjects to participate in the trial (such as poorly controlled diabetes mellitus, severe cardiac insufficiency , myocardial infarction or unstable arrhythmia or unstable angina pectoris within the last 6 months, lung embolism, chronic obstructive pulmonary diseases, interstitial pulmonary diseases,gastric ulcer, a history of gastrointestinal bleeding or a clear tendency to gastrointestinal bleeding; * According to the investigators' evaluation, patients are unable or unwilling to comply with the requirements of the study protocol. Sex : ALL Ages : - Minimum Age : 18 Years - Maximum Age : 70 Years - Age Group (Child: birth-17, Adult: 18-64, Older Adult: 65+) : ADULT, OLDER_ADULT Accepts Healthy Volunteers: No

{ "NCT_ID" : "NCT04409314", "Brief_Title" : "Hypoxia-Specific Imaging to Predict Outcomes of Chimeric Antigen Receptor T-cell Therapy", "Official_title" : "Pilot Study of Hypoxia-Specific Imaging to Predict Outcomes of Chimeric Antigen Receptor T-Cell Therapy", "Conditions" : ["Recurrent Aggressive Non-Hodgkin Lymphoma", "Recurrent Diffuse Large B-Cell Lymphoma", "Recurrent High Grade B-Cell Lymphoma", "Recurrent Malignant Neoplasm", "Recurrent Plasma Cell Myeloma", "Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma", "Refractory Aggressive Non-Hodgkin Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma", "Refractory High Grade B-Cell Lymphoma", "Refractory Malignant Neoplasm", "Refractory Plasma Cell Myeloma", "Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma"], "Interventions" : ["Procedure: Positron Emission Tomography", "Drug: Fluorine F 18-fluoroazomycin Arabinoside"], "Location_Countries" : ["United States"], "Study_Design" : { "Study_Type" : "OBSERVATIONAL", } }

#Study Description Brief Summary This study evaluates whether tumors present in patients with cancer who are planned to get CAR T-cells have low amounts of oxygen (hypoxia). PET scans may be used to check the amounts of oxygen within areas of cancer with a special radioactive tracer called FAZA that specifically looks for areas of low oxygen. This study is being done to help researchers determine how the amount of oxygen within areas of cancer affect how well CAR T-cells kill cancer cells. Detailed Description PRIMARY OBJECTIVE: I. To evaluate the incidence of intratumoral hypoxia in patients with relapsed or refractory (R/R) malignancies before treatment with chimeric antigen receptor (CAR) T-cell therapy. SECONDARY OBJECTIVE: I. To evaluate the association between intratumoral hypoxia and clinical responses to CAR T-cell therapy. EXPLORATORY OBJECTIVES: I. To correlate intratumoral hypoxia with markers of CAR T-cell activity and toxicity. 2. To correlate pre-therapy fluorine F 18-fluoroazomycin arabinoside (18F-FAZA) uptake with pre-therapy 18Ffluorodeoxyglucose (FDG) positron emission tomography (PET) uptake (if available). OUTLINE: Prior to CAR T-cell therapy, patients receive 18F-FAZA intravenously (IV). Beginning 2 hours after injection, patients undergo a single PET scan. Patients are followed for up to 6 months after CAR T-cell therapy. #Intervention - DRUG : Fluorine F 18-fluoroazomycin Arabinoside - Given IV - Other Names : - 18F-FAZA, 18F-Fluoroazomycin Arabinoside, FAZA F-18, Fluoroazomycin Arabinoside F-18 - PROCEDURE : Positron Emission Tomography - Undergo PET scan - Other Names : - Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging

#Eligibility Criteria: Inclusion Criteria: * Histologically confirmed diagnosis of: * Aggressive lymphoma, including: Diffuse large B-cell lymphoma (DLBCL) (including transformed disease), high-grade B-cell lymphoma, or primary mediastinal B-cell lymphoma * Multiple myeloma (MM), with imaging within 6 months of enrollment demonstrating >= 1 plasmacytoma measuring >= 5 cm along any axis * Other malignancy with radiographically measurable disease * R/R disease with planned receipt of CAR T-cell therapy at University of California, San Francisco (UCSF), either through an Food and Drug Administration-approved CAR construct or through a separate interventional clinical trial * Ability to provide informed consent prior to study entry Exclusion Criteria: * Any serious and/or unstable pre-existing medical, psychiatric, or other condition that could interfere with participant's safety, provision of informed consent, or compliance with study procedures * Pregnancy or active lactation Sex : ALL Ages : - Minimum Age : 18 Years - Age Group (Child: birth-17, Adult: 18-64, Older Adult: 65+) : ADULT, OLDER_ADULT Accepts Healthy Volunteers: No

{ "NCT_ID" : "NCT04036019", "Brief_Title" : "A Study of C-CAR066 in Subjects With r/r B Cell Lymphoma Who Received CD19 CAR-T Therapy", "Official_title" : "A Study Evaluating Safety and Efficacy of CBM.CD20 CAR-T(C-CAR066) in Subjects With r/r B Cell Lymphoma Who Received CD19 CAR-T Therapy", "Conditions" : ["B Cell Lymphoma"], "Interventions" : ["Biological: CD20-directed CAR-T cells with CliniMACS Prodigy® system"], "Location_Countries" : ["China"], "Study_Design" : { "Study_Type" : "INTERVENTIONAL", "Phase" : ["PHASE1"], "Primary_Purpose" : "TREATMENT", "Allocation" : "NA", "Interventional Model" : "SINGLE_GROUP", "Masking" : "NONE" } }

#Study Description Brief Summary This is a single-center, non-randomized clinical study to evaluate the safety and efficacy of C-CAR066 in treatment of r/r B cell lymphoma who received CD19 CAR-T therapy. Detailed Description This study plans to enroll 10 patients to assess the safety and efficacy of C-CAR066. Subjects who meet the eligibility criteria will receive a single dose of C-CAR066 injection. The study will include the following sequential phases: Screening, Pre- Treatment (Cell Product Preparation, Lymphodepleting Chemotherapy), C-CAR066 infusion and Follow-up Visit. #Intervention - BIOLOGICAL : CD20-directed CAR-T cells with CliniMACS Prodigy® system - Autologous 2nd generation CD20-directed CAR-T cells, single infusion intravenously - Other Names : - C-CAR066

#Eligibility Criteria: Inclusion Criteria: * The patient volunteered to participate in the study, and signed the Informed Consent * Age 18 <= age <= 70 years, male or female * Patients with CD20+ DLBCL (including PMBCL and tFL), FL and MCL, at least one measurable lesion (LDi>= 1.5 cm) * r/r lymphoma patients who received prior CD19 CAR-T therapy * At least one week from last treatment (radiation, chemotherapy, mAb, etc) to apheresis * No immunosuppressive therapy was used within 1 week before C-CAR066 infusion * No mAb treatment within 2 weeks before C-CAR066 infusion * Adequate organ and bone marrow function * No contraindications of apheresis * Expected survival time > 3 months * ECOG scores 0 <= age <= 1 Exclusion Criteria: * Have a history of allergy to cellular products * Patients with cardiac insufficiency classified as Class III or IV according to the New York Heart Association (NYHA) Heart Function Classification Standard * A history of craniocerebral trauma, consciousness disorder, epilepsy, cerebral ischemia or hemorrhagic cerebrovascular disease * Patients with active CNS involvement * Patients with autoimmune disease, immunodeficiency, or other treatment requiring immunosuppressor * Severe active infection (except simple urinary tract, bacterial pharyngitis), or currently receiving intravenous antibiotics. However, prophylactic antibiotics, antiviral and antifungal treatments are allowed * Live vaccination within 4 weeks before apheresis * HIV, HBV, HCV and TPPA / RPR infections, and HBV carriers * Have a history of alcoholism, drug addiction and mental illness * Non-sterile subjects had any of the following: a) being pregnant / lactating; or b) having a pregnancy plan during the trial; or c) having fertility without taking effective contraception * Patients with severe fludarabine or cyclophosphamide hypersensitivity * The patient has a history of other primary cancers, except for the following: 1. Non-melanoma such as skin basal cell carcinoma cured by resection 2. Cured carcinoma in situ such as cervical, bladder or breast cancer * The investigators believe that there are other circumstances that are not suitable for the trial Sex : ALL Ages : - Minimum Age : 18 Years - Maximum Age : 70 Years - Age Group (Child: birth-17, Adult: 18-64, Older Adult: 65+) : ADULT, OLDER_ADULT Accepts Healthy Volunteers: No

{ "NCT_ID" : "NCT03825718", "Brief_Title" : "A Study of GC007F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL", "Official_title" : "A Study of GC007F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL", "Conditions" : ["B-cell Acute Lymphoblastic Leukemia"], "Interventions" : ["Biological: GC007F"], "Location_Countries" : ["China"], "Study_Design" : { "Study_Type" : "INTERVENTIONAL", "Phase" : ["EARLY_PHASE1"], "Primary_Purpose" : "TREATMENT", "Allocation" : "NA", "Interventional Model" : "SINGLE_GROUP", "Masking" : "NONE" } }

#Study Description Brief Summary The study is an early, open, single-centered trial. Detailed Description The aim of this study is to evaluate the safety and tolerance of GC007F CAR-T cell immunotherapy in relapsed or refractory B-ALL. The study will include 20 subjects to receive GC007F therapy. #Intervention - BIOLOGICAL : GC007F - GC007F is the CAR-T cell immunotherapy targeted CD19. The subjects will receive GC007F as one dose. The dosage ranges from 6×10\^4 to 2×10\^6 CAR+T/Kg.

#Eligibility Criteria: Inclusion Criteria: * Relapsed or refractory paediatric B-cell ALL 1) 2nd or greater bone marrow (BM) relapse or 2) Relapse after remission for the first time in 12 months or 3) The interval between relapse after allogeneic hematopoietic stem cell transplantation and CAR-T cells transfusion>=100 days or 4) Primary refractory as defined by not achieving a CR after 2 cycles of a standard chemotherapy regimen or chemorefractory as defined by not achieving a CR after 1 cycle of standard chemotherapy for relapsed leukaemia or 5) Patients with Philadelphia chromosome positive ALL were eligible if they were intolerant to or had failed two lines of tyrosine kinase inhibitor (TKI) therapy, or if TKI therapy was contraindicated or 6) Ineligible for allogeneic SCT because of: i. Comorbid disease ii. Other contraindications to allogeneic SCT conditioning regimen iii. Lack of suitable donor iv. Prior SCT v. Declined allogeneic SCT as a therapeutic option after documented discussion, including expected outcomes, about the role of SCT with a BM transplantation physician not part of the study team * For relapsed patients, CD19 tumour expression demonstrated in bone marrow or peripheral blood by flow cytometry within 3 months of study entry * Aged 2 <= age <= 70 years * Eastern cooperative oncology group (ECOG) performance status of 0 to 2 * Life expectancy>=12 weeks * Adequate organ function defined as:1) Creatinine clearance (as estimated by Cockcroft Gault) >60 mL/min. 2) Serum ALT/AST<2.5 ULN. 3) Total bilirubin<1.5 mg/dl, except in subjects with Gilbert's syndrome. 4) Cardiac ejection fraction>=45%, no evidence of pericardial effusion as determined by an ECHO, and no clinically significant ECG findings. 5) No clinically significant pleural effusion. 6) Baseline oxygen saturation >92% on room air. 7) pulmonary function: ventilation function is normal or is restricted mildly. * Females of reproductive age must be in non-lactation period. Females of childbearing potential must have a negative serum or urine pregnancy test. All subjects must use medical-approved-contraception (such as intrauterine device and contraceptive drugs) during the period of trial and in 6 months after cell transfusion therapy. * The subject agree to and sign informed consent form, willing and able to comply with the planned visit, research, treatment planning, laboratory and other test procedures. Exclusion Criteria: * Isolated extra-medullary disease relapse; * Patients with Burkitt's lymphoma/leukaemia; * Central nervous system leukemia involved CNS3; * Concomitant malignancy other than non-melanoma skin cancer or adequately-treated cervical carcinoma in situ or prostate cancer (PSA score<1.0) or adequately-treated low grade bladder cancer or surgery-cured ductal carcinoma in situ or diagnosis of other malignancy exceeds 5 years without relapse or treatment during the 5 years; * Concomitant genetic diseases except Down syndrome; * Any result of the following virology tests is positive: HIV; HCV; HBsAg; or HBCAb positive with HBV DNA copies positive(>= 5×10^2 copies/ml); RPR+TPPA postive; * Live vaccine <=4 weeks prior to apheresis; * Prior CD19 targeted therapy with the exception of subjects who received GC007F in this study and are eligible for re-treatment; Prior chimeric antigen receptor therapy or other genetically modified T cell therapy; * Presence of grade 2 to 4 graft-versus-host disease (GVHD) after allo-HSCT; * The following medications were excluded: 1) Steroids: Therapeutic systemic doses of steroids must be stopped >72 hours prior to tisagenlecleucel infusion. However, the following physiological replacement doses of steroids are allowed: <12 mg/m^2/day hydrocortisone or equivalent; 2) Allogeneic cellular therapy: Any donor lymphocyte infusions must be completed >6 weeks prior to cell infusion; 3) GVHD therapies: Any systemic drug used for GVHD must be stopped >4 weeks prior to infusion to confirm that GVHD recurrence is not observed; * Prior treatments of CNS diseases must be stoped >3 days prior to infusion (e.g., intrathecal injection of methotrexate) 1) Radiotherapy of non-CNS nidus must be completed >2 weeks prior to infusion; 2) CNS stereotactic radiotherapy must be completed >8 weeks prior to infusion; * >=2 grade toxicities related to previous therapy are not relieved, with the exception of adverse events without safety risk (e.g., alopecia); * Known life-threatening allergy, hypersensitivity or intolerance to GC007F cells and adjuvant, including DMSO (see investigator's brochure); * Patients with active autoimmune disease (e.g., systemic lupus erythematosus, sjogren syndrome, rheumatoid arthritis, psoriasis, multiple sclerosis, inflammatory bowel disease) receive immunosuppressive therapy in 4 weeks before inclusion. thyroid hormone replacement therapy is an exception; * For patients that underwent major surgical operation before CAR-T treatment, or anticipated to undergo a major surgical operation during the study process, they need to be fully recovered and clinically stable before inclusion. * Participate in other clinical trial and received study drugs <28 days prior to inclusion; * Concomitant disease that may or severe medical condition that may affect patients' safety, including active viral or bacterial infection, uncontrollable systemic fungal infection, uncontrollable cardiac disease, hypertension, abuse of psychoactive drugs, et al. * Any other condition that may increase subjects' risk or interfere with trial's results. Sex : ALL Ages : - Minimum Age : 2 Years - Maximum Age : 70 Years - Age Group (Child: birth-17, Adult: 18-64, Older Adult: 65+) : ADULT, CHILD, OLDER_ADULT Accepts Healthy Volunteers: No

{ "NCT_ID" : "NCT03076437", "Brief_Title" : "Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies", "Official_title" : "Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies", "Conditions" : ["Acute Lymphocytic Leukemia", "Chronic Lymphocytic Leukemia", "Lymphoma"], "Interventions" : ["Combination Product: Drugs and Anti-CD19-CAR transduced T cells"], "Location_Countries" : ["China"], "Study_Design" : { "Study_Type" : "INTERVENTIONAL", "Phase" : ["PHASE1", "PHASE2"], "Primary_Purpose" : "TREATMENT", "Allocation" : "NA", "Interventional Model" : "SINGLE_GROUP", "Masking" : "NONE" } }

#Study Description Brief Summary Autologous T cells engineered to express an anti-CD19 chimeric antigen receptor (CAR) will be infused back to patients with B cell malignancies, including lymphoma and leukemia. The patients will be monitored after infusion of anti-CD19 CAR-transduced T cells for adverse events, persistence of anti-CD19 CAR-transduced T cells and treatment efficacy. Objectives: To evaluate the safety and the efficacy of anti-CD19 CAR-transduced T cell therapy for patients with B cell malignancies. Eligibility: Patients between 1 and 80 years of age, who have relapsed or refractory CD19-expressing B-cell malignancies (leukemia or lymphoma) that have not responded to standard treatments. Patients with a history of allogeneic stem cell transplant who meet all eligibility criteria are eligible to participate. Patients must have adequate organ functions. Design: Peripheral blood from patients will be collected for isolation of peripheral blood mononuclear cells (PBMCs), which will be transduced with a lentiviral or retroviral vector encoding anti-CD19 CAR containing a CD28 or 4-1BB and a CD3 zeta as costimulatory domains. Patients will receive a lymphodepleting preconditioning regimen to prepare their immune system to accept modified T cells. Patients will receive an infusion of their own modified T cells. They will remain in the hospital to be monitored for adverse events until they have recovered from the treatment. Patients will have frequent follow-up visits to monitor the persistence of modified T cells and efficacy of the treatment. Detailed Description Despite progress has been made to date in the treatment of patients with B cell malignancies, including leukemia and lymphoma, many patients with relapsed or refractory diseases do not respond to the standard treatments. It has been shown that anti-CD19 CAR-transduced T cells may be an effective approach to treat the relapsed or refractory diseases. The procedure involves collecting PBMCs from the patients and modifying the T cells to attack the malignant B cells. In this trial, autologous T cells engineered to express an anti-CD19 chimeric antigen receptor (CAR) containing the signaling domains of CD28 or 4-1BB and CD3-zeta will be infused back to patients with B cell malignancies, including lymphoma and leukemia. The patients will be pretreated with a lymphodepleting preconditioning regimen before the infusion of anti-CD19 CAR T cells, and will be monitored for adverse events, persistence of anti-CD19 CAR-transduced T cells and the treatment efficacy. OBJECTIVES: Primary objectives: To determine the safety and feasibility of the administration of anti-CD19 CAR transduced T cells in patients with CD19+ B-cell malignancies. Secondary objectives: To determine if the treatment regimen can result in clinical regression of B-cell malignancies in the patients as described above. To determine the in vivo persistency of the anti-CD19 CAR-transduced T cells. #Intervention - COMBINATION_PRODUCT : Drugs and Anti-CD19-CAR transduced T cells - Drug: Fludarabine On days -4 through -2, Fludarabine 30mg/m2 IV will be infused over 30 minutes. Drug: Cyclophosphamide On days -4 through -2, Cyclophosphamide 300mg/m2 IV will be infused over 60 minutes followed by fludarabine. Biological: Anti-CD19-CAR transduced T cells Modified cells will be infused IV over 30 minutes (1-3 days after the last dose of fludarabine).

#Eligibility Criteria: Inclusion Criteria: * Patients must have a CD19+ B cell malignancy，including relapsed or refractory B cell leukemia and B cell lymphoma； * Patients with CD19+ B cell malignancies are not able to receive standard treatments and willing to participate in the trial; * Patients must have a measurable or evaluable disease at the time of enrollment, which may include any evidence of disease including minimal residual disease detected by flow cytometry, cytogenetics, or polymerase chain reaction (PCR) analysis； * patients are not eligible for autologous or allogeneic stem-cell transplantation (SCT) or relapsed after autologous or allogeneic stem-cell transplantation； * Patients with history of allogeneic stem cell transplantation are eligible, providing 6 months had elapsed from SCT, they have no evidence of active graft-versus-host disease and no longer taking immunosuppressive agents during the treatment. * Willing to sign a durable power of attorney； * Able to understand and sign the Informed Consent Document； * Performance status：ECOG 0 <= age <= 2； * Life expectancy：More than 3 months； * Patients of both genders must be willing to practice birth control for four months after receiving a lymphodepleting preconditioning regimen； * Female participants of reproductive potential must have a negative serum or urine pregnancy test performed within 48 hours before infusion, because of the potentially dangerous effects on the fetus； * There is no obvious dysfunctions in heart , liver and kidney, and the functions of vital organs are normal； * Serology： (1) Seronegative for HIV antibody； (2) Seronegative for hepatitis B virus (HBV) and hepatitis C virus (HCV). * More than three weeks must have elapsed since any prior systemic therapy at the time of randomization, and patients' toxicities must have recovered to a grade 1 or less (except for alopecia or vitiligo)； * Normal cardiac ejection fraction and no evidence of pericardial effusion as determined by an echocardiogram； * More than 30 days must have elapsed since Monoclonal antibody therapy administered prior to apheresis. Exclusion Criteria: * Patients that require urgent therapy due to tumor mass effects such as bowel obstruction or blood vessel compression； * Patients that have active hemolytic anemia； * Patients with detectable cerebrospinal fluid malignant cells or brain metastases or with a history of cerebrospinal fluid malignant cells or brain metastases, or any residual intracranial implants； * Women of child-bearing potential who are pregnant or breastfeeding； * Active systemic infections, coagulation disorders or other major medical illnesses of the cardiovascular, respiratory or immune system； * Any form of primary immunodeficiency (such as Severe Combined Immunodeficiency Disease)； * Concurrent opportunistic infections； * Concurrent Systemic steroid therapy； * History of severe immediate hypersensitivity reaction to any of the agents used in this study； * Patients with central nervous system (CNS) metastases or symptomatic CNS involvement (including cranial neuropathies or mass lesions)； * CNS-3 disease or traumatic spinal tap with POSITIVE Steinherz/Bleyer algorithm with cerebral spinal fluid involvement with malignancy will make any patient not eligible for this protocol； * Patients with cardiac atrial or cardiac ventricular lymphoma involvement； * Other anti-neoplastic investigational agents currently or within 30 days prior to start of the treatment； * Previous treatment with any gene therapy products. Sex : ALL Ages : - Minimum Age : 1 Year - Maximum Age : 80 Years - Age Group (Child: birth-17, Adult: 18-64, Older Adult: 65+) : ADULT, CHILD, OLDER_ADULT Accepts Healthy Volunteers: No

{ "NCT_ID" : "NCT02650999", "Brief_Title" : "Pembrolizumab in Patients Failing to Respond to or Relapsing After CAR T Cell Therapy for Relapsed or Refractory Lymphomas", "Official_title" : "Phase I/II Study of Pembrolizumab in Patients Failing to Respond to or Relapsing After Anti-CD19 Chimeric Antigen Receptor Modified T Cell Therapy for Relapsed or Refractory CD19+ Lymphomas", "Conditions" : ["CD19+ Diffuse Large B-cell Lymphomas", "Follicular Lymphomas", "Mantle Cell Lymphomas"], "Interventions" : ["Drug: Pembrolizumab"], "Location_Countries" : ["United States"], "Study_Design" : { "Study_Type" : "INTERVENTIONAL", "Phase" : ["PHASE1", "PHASE2"], "Primary_Purpose" : "TREATMENT", "Allocation" : "NA", "Interventional Model" : "SINGLE_GROUP", "Masking" : "NONE" } }

#Study Description Brief Summary Single center, phase I/II trial of pembrolizumab after CTL019 for CD19+ lymphomas. Patients will have CD19+ diffuse large B-cell, follicular, or mantle cell lymphomas relapsed/refractory after CTL019. 12 total patients will be enrolled. Safety of pembrolizumab (primary endpoint) will be determined using a Bayesian monitoring rule for treatment-related adverse events causing drug discontinuation. Secondary efficacy endpoints include overall response rate and progression-free survival. #Intervention - DRUG : Pembrolizumab - 200mg intravenously (IV)

#Eligibility Criteria: Inclusion Criteria: * Histologically confirmed follicular lymphoma grade 1 <= age <= 3A, diffuse large B cell lymphoma, and mantle cell lymphoma by World Health Organization 2009 classification * Relapsed/refractory lymphoma after CTL019 - Be willing and able to provide written informed consent/assent for the trial. * Age >= 18 years on day of signing informed consent. * Have baseline imaging within 6 weeks of enrollment (CT, MR or PET/CT imaging) and have measurable disease on physical examination or imaging studies. -- Not pregnant or breastfeeding * Any lesion 1.5 cm in long axis dimension is considered measurable. * Performance status of 0 <= age <= 2 on the ECOG Performance Scale * Demonstrate adequate organ function. * Absolute neutrophil count (ANC) >=1,000 /mcL * Platelets>=50,000 / mcL * Hemoglobin >=8 g/dL without transfusion or EPO dependency (within 7 days of assessment) * Serum creatinine OR Measured or calculated a creatinine clearance (aCreatinine clearance should be estimated per institutional standard) (GFR can also be used in place of creatinine or CrCl) <=1.5 X upper limit of normal (ULN) OR >=60 mL/min for subject with creatinine levels > 1.5 X institutional ULN * Serum total bilirubin <= 1.5 X ULN OR Direct bilirubin <= ULN for subjects with total bilirubin levels > 1.5 ULN. * AST (SGOT) and ALT (SGPT) <= 2.5 X ULN OR <= 5 X ULN for subjects with liver metastases * International Normalized Ratio (INR) or Prothrombin Time (PT) <=1.5 X ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants * Activated Partial Thromboplastin Time (aPTT) <=1.5 X ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants. Exclusion Criteria: * Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment. An exception will be made for patients who have received CTL019/CTL119 on experimental protocol; these patients will be eligible to enroll once progression of disease or failure to respond is documented by clinical or radiologic assessment. * Patient has received intervening therapy for lymphoma after CTL019/CTL119 infusion. * Has active cytokine release syndrome from CTL019/CTL119 infusion. * Has a known history of active TB (Bacillus Tuberculosis). * Hypersensitivity to pembrolizumab or any of its excipients. * Has had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study Day 1 or who has not recovered (i.e., <= Grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier. Toxicities that are disease related will not exclude patients. * Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1 or who has not recovered (i.e., <= Grade 1 or at baseline) from adverse events due to a previously administered agent. * Note: Subjects with <= Grade 2 neuropathy are an exception to this criterion and may qualify for the study. * Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention in the opinion of the Principal Investigator prior to starting therapy. * Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer. * Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to trial treatment. * Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. * Has known history of, or any evidence of active, non-infectious pneumonitis. * Has an active infection requiring systemic therapy. * Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator. * Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial. * Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment. * Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent. * Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies). * Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA [qualitative] is detected). * Has received a live vaccine within 30 days of planned start of study therapy. Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines, and are not allowed. * Has a history of (non-infectious pneumonitis that required steroids or has current pneumonitis. Sex : ALL Ages : - Minimum Age : 18 Years - Age Group (Child: birth-17, Adult: 18-64, Older Adult: 65+) : ADULT, OLDER_ADULT Accepts Healthy Volunteers: No

{ "NCT_ID" : "NCT02746952", "Brief_Title" : "Dose Escalation Study of UCART19 in Adult Patients With Relapsed / Refractory B-cell Acute Lymphoblastic Leukaemia", "Official_title" : "Phase I, Open Label, Dose-escalation Study Followed by a Safety Expansion Part to Evaluate the Safety, Expansion and Persistence of a Single Dose of UCART19 (Allogeneic Engineered T-cells Expressing Anti-CD19 Chimeric Antigen Receptor), Administered Intravenously in Patients With Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukaemia (B-ALL)", "Conditions" : ["B-cell Acute Lymphoblastic Leukemia"], "Interventions" : ["Biological: UCART19"], "Location_Countries" : ["France", "Japan", "United States", "United Kingdom"], "Study_Design" : { "Study_Type" : "INTERVENTIONAL", "Phase" : ["PHASE1"], "Primary_Purpose" : "TREATMENT", "Allocation" : "NA", "Interventional Model" : "SINGLE_GROUP", "Masking" : "NONE" } }

#Study Description Brief Summary The study is in two parts: a dose escalation then a safety dose expansion. The purpose of the dose escalation part is to evaluate the safety and tolerability of ascending doses of UCART19 (dose-escalation part) given as a single infusion in patients with relapsed / refractory (R/R) B-cell acute lymphoblastic leukaemia (B-ALL), to determine the maximum tolerated dose (MTD), the recommended dose and the lymphodepletion regimen. The purpose of the safety dose expansion is to assess the safety and tolerability of the RD for UCART19. #Intervention - BIOLOGICAL : UCART19 - Other Names : - S68587

#Eligibility Criteria: Inclusion Criteria: * Male or female participant * Age >= 16 years * Patient with relapsed or refractory CD19 positive B-acute lymphoblastic leukaemia (B-ALL) who have exhausted alternative treatment options * Estimated life expectancy >= 12 weeks (according to investigator's judgement) * Eastern Cooperative Oncology Group (ECOG) performance status < 2 Exclusion Criteria: * Previous treatment with gene or gene-modified cell therapy medicine products or adoptive T cell therapy * Use of previous anti-leukemic therapy (including approved therapies and other investigational products) within 5 half-lives prior to UCART19 administration * CD19 negative B-cell leukaemia * Burkitt cell or mixed lineage acute leukaemia Sex : ALL Ages : - Minimum Age : 16 Years - Maximum Age : 69 Years - Age Group (Child: birth-17, Adult: 18-64, Older Adult: 65+) : ADULT, CHILD, OLDER_ADULT Accepts Healthy Volunteers: No

{ "NCT_ID" : "NCT05180838", "Brief_Title" : "Remote Temperature Data for Early Detection of Febrile Neutropenia", "Official_title" : "Remote Data Capture of Elevated Temperature Data for Early Detection of Febrile Neutropenia in Patients With Hematologic Malignancies", "Conditions" : ["Hematologic Malignancy"], "Interventions" : ["Device: BioSticker"], "Location_Countries" : ["United States"], "Study_Design" : { "Study_Type" : "OBSERVATIONAL", } }

#Study Description Brief Summary BioSticker data is remotely tracked and displayed in a report termed the BioReport for retrospective data analysis. Typically, the biosensor collects data on an interval of \~1 minute and this data is collated and reported remotely back to the BioReport every 6 hours. More importantly, for future applications of the BioSticker for early detection of FN, there are ongoing efforts to implement real time reporting and alarms using remote monitoring services that could alert the patient that they need to seek medical care. There are no known deleterious effects from the BioSticker and it is now being widely used and tested in diverse applications including detection and contact tracing of COVID and others. Detailed Description The BioIntelliSense BioSticker potentially offers a solution to these challenges through early and reliable detection of elevated temperature and perhaps other relevant physiologic changes. The BioSticker is an FDA approved medical device which can be worn on the upper left chest for remote data capture and can provide for up 30 days of continuous vital sign monitoring (see https://biointellisense.com as well as attached documents on BioSticker instructions for a full description and use instructions). The BioSticker detects the following: * Respiratory rate, heart rate at rest and skin temperature * Body position, activity levels, sleep status * High-resolution gait analysis and fall detection * Symptomatic events BioSticker data is remotely tracked and displayed in a report termed the BioReport for retrospective data analysis. Typically, the biosensor collects data on an interval of \~1 minute and this data is collated and reported remotely back to the BioReport every 6 hours. More importantly, for future applications of the BioSticker for early detection of FN, there are ongoing efforts to implement real time reporting and alarms using remote monitoring services that could alert the patient that they need to seek medical care. There are no known deleterious effects from the BioSticker and it is now being widely used and tested in diverse applications including detection and contact tracing of COVID and others. #Intervention - DEVICE : BioSticker - The BioSticker is an FDA approved medical device which can be worn on the upper left chest for remote data capture and can provide for up 30 days of continuous vital sign monitoring

#Eligibility Criteria: Inclusion Criteria: * Ages 18 <= age <= 80 years (inclusive) * Provision to sign and date the consent form. * Diagnosed with a hematologic malignancy and undergoing cytotoxic chemotherapy, stem cell transplants or CAR T-cell treatments at the Blood Disorders and Cell Therapies Center at UCHealth (BDCTC) * Will have longitudinal care provided by the BDCTC for >1 additional month * Receive chemotherapy or other therapies known to cause reductions in WBC <1000 on a routine basis * Scheduled to be discharged home and self-monitor for FN and other complications * Patient is willing to tell TSA or any security representative that you are wearing a 'medical device' * Patient has agreed to not submerge the device underwater including while swimming or bathing * Patient is willing to complete a self-check temperature log comply and be available for the duration of the study * Patient has access to a thermometer Exclusion Criteria: * Patient that wears a defibrillator, pacemaker, or other implantable device * Patient has broken skin including wounds, sores, or abrasions in the area that the BioSticker would be applied * Patient has had a severe reaction to silicone adhesives * Patient has any clinically significant medical or psychiatric disease or condition that, in the Investigator's opinion, may interfere with protocol adherence or a subject's ability to give informed consent. Sex : ALL Ages : - Minimum Age : 18 Years - Maximum Age : 80 Years - Age Group (Child: birth-17, Adult: 18-64, Older Adult: 65+) : ADULT, OLDER_ADULT Accepts Healthy Volunteers: No

{ "NCT_ID" : "NCT04231747", "Brief_Title" : "A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma", "Official_title" : "A Phase 1, Multicenter, Open-label Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma", "Conditions" : ["Lymphoma Non-Hodgkin", "Agressive Lymphoma", "Diffuse-large B-cell Lymphoma (DLBCL)"], "Interventions" : ["Biological: CC-97540"], "Location_Countries" : ["United States", "Canada"], "Study_Design" : { "Study_Type" : "INTERVENTIONAL", "Phase" : ["PHASE1"], "Primary_Purpose" : "TREATMENT", "Allocation" : "NA", "Interventional Model" : "SINGLE_GROUP", "Masking" : "NONE" } }

#Study Description Brief Summary This is a Phase 1, first-in-human, open-label, multicenter study of CC-97540, CD19-targeted NEX-T chimeric antigen receptor (CAR) T cells, in subjects with relapsed or refractory B-cell non-Hodgkin lymphoma. The study will consist of 2 parts: dose-escalation (Part A) and dose-expansion (Part B). The dose-escalation part (Part A) of the study is to evaluate the safety and tolerability of increasing dose levels of CC-97540 to establish a recommended Phase 2 dose (RP2D); and the dose-expansion part (Part B) of the study is to further evaluate the safety, pharmacokinetics/pharmacodynamics, and efficacy of CC-97540 at the RP2D. #Intervention - BIOLOGICAL : CC-97540 - Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) to produce CC 97540. During CC 97540 production, subjects may receive bridging chemotherapy for disease control. Upon successful generation of CC 97540 product, subjects will receive treatment with CC 97540 therapy. Each cycle will include lymphodepleting chemotherapy followed by one dose of CC 97540 administered by intravenous (IV) injection.

#Eligibility Criteria: Inclusion Criteria: Subjects must satisfy the following criteria to be enrolled in the study: * Age >= 18 years at the time of informed consent. * Signed written informed consent obtained prior to any study procedure. * Willing and able to adhere to the study visit schedule and other protocol requirements. * Relapsed and/or refractory aggressive B-cell NHL as defined: 1. Histologically confirmed DLBCL not otherwise specified, high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with DLBCL histology (HGBCL), transformed DLBCL from follicular (tFL) or marginal zone lymphoma (tMZL), primary mediastinal B-cell lymphoma (PMBCL), or FL grade 3b (FL3B) (Note: Subjects with Richter's transformation (transformed DLBCL from CLL) are ineligible) AND 2. Have relapsed and/or refractory disease after at least 2 lines of systemic therapy which must include at least one anthracycline and rituximab (or other anti-CD20 monoclonal antibody). Note: Lines of therapy will exclude those given for prior indolent lymphoma. It is not required for subjects to have had anthracycline for their DLBCL if received for indolent disease AND/OR 3. Have relapsed and/or refractory DLBCL failed to ASCT treatment. Note: ASCT failure is defined as either failure to achieve an objective response (PR or better), or disease progression after ASCT(Note: Subjects who were not candidates to receive ASCT treatment (due to age or other factors) are eligible; the reason for not receiving ASCT must be documented in the electronic case report form (eCRF). * Positron emission tomography (PET)-positive disease as per the Lugano Classification (at screening or following bridging therapy, whichever is later). * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Adequate organ function as detailed in the protocol. * Adequate vascular access for leukapheresis. * Willing and able to undergo tumor biopsies (in subjects with accessible disease). * Agree to not donate blood, organs, sperm or semen, and egg cells for usage in other individuals as detailed in the protocol. * Female and male subjects agree to use effective contraception as detailed in the protocol. Exclusion Criteria: The presence of any of the following will exclude a subject from enrollment: * Uncontrolled medical, psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol, as judged by the Investigator; or unwillingness or inability to follow the procedures required in the protocol. * Any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study. * Any condition that confounds the ability to interpret data from the study. * Central nervous system (CNS)-only involvement by malignancy (note: subjects with pathologically-confirmed secondary CNS involvement are allowed).) * Prior CAR T- cell or genetically-modified T- cell therapy, or prior CD19- targeted therapy (including, but not limited to, anti-CD19 mAbs or bispecific antibodies).) * Treatment with the following therapies or procedure within the specified period: 1. Therapeutic doses of corticosteroids (defined as > 20 mg/day prednisone or equivalent) within 14 days before leukapheresis administration. Physiologic replacement, topical, and inhaled steroids are permitted. 2. Cytotoxic chemotherapeutic agents (eg, doxorubicin, vincristine, gemcitabine, oxaliplatin, carboplatin, etoposide) within 7 days of leukapheresis, with the exception of alkylating agents. 3. Intrathecal therapy (eg, dexamethasone, methotrexate, cytosine arabinoside, cytarabine) within 7 days of leukapheresis. 4. Oral chemotherapeutic agents, including lenalidomide and ibrutinib, are allowed if at least 5 half-lives have elapsed prior to leukapheresis. 5. Alkylating agents (eg, cyclophosphamide, ifosfamide, bendamustine) within 4 weeks of leukapheresis. 6. Any experimental therapy within 8 weeks (for biologics) or 5 half-lives (for small molecules) before leukapheresis 7. Immunosuppressive therapies within 4 weeks of leukapheresis (eg, calcineurin inhibitors, methotrexate or other chemotherapeutics, mycophenolate, rapamycin, immunosuppressive antibodies such as anti-TNF, anti-IL6, or anti-IL6R) 8. Monoclonal antibodies (including rituximab, polatuzumab, etc.) within 7 days. 9. Donor lymphocyte infusions within 6 weeks of leukapheresis 10. Radiation within 6 weeks of leukapheresis. Subjects must have progressive disease in irradiated lesions or have additional non-irradiated, PET-positive lesions to be eligible. Radiation to a single lesion, if additional non-irradiated PET-positive lesions are present, is allowed up to 14 days prior to leukapheresis. 11. Autologous stem-cell transplant (SCT) (ie, Day 0 receipt of hematopoietic stem cells) within 3 months of leukapheresis 12. Washout of prior therapy (eg, bridging therapy for disease control) * Active autoimmune disease requiring immunosuppressive therapy. * Allogenic SCT (ie, Day 0 receipt of hematopoietic stem cells) within 6 months of leukapheresis or presence of ongoing symptoms or treatment for chronic graft-versus host disease (GVHD).) * Hypersensitivity to fludarabine and/or cyclophosphamide. * Prior history of malignancies, other than studied NHL, unless the subject has been free of the disease for >= 2 years except for the following non-invasive malignancies: 1. Basal or squamous cell carcinoma of the skin 2. Carcinoma in situ of the cervix or the breast 3. Incidental histologic finding of prostate cancer (T1a or T1b using the TNM (tumor, nodes, metastasis) clinical staging system) or prostate cancer that is curative 4. Other completely resected stage 1 solid tumor with low risk for recurrence * Active hepatitis B, hepatitis C, or any human immunodeficiency virus (HIV) infection at the time of screening. * Uncontrolled or active systemic fungal, bacterial, viral or other infection despite appropriate anti-infection treatment at the time of leukapheresis or pre-treatment evaluation. * History of any one of the following cardiovascular conditions within the 6 months prior to screening: Class III or IV heart failure as defined by the New York Heart Association, myocardial infarction, unstable angina, angioplasty or stenting, or other clinically significant cardiac disease. * History or presence of clinically significant CNS pathology such as seizure disorder, aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, or cerebellar disease. Presence of clinically active psychosis. * History of >= Grade 2 hemorrhage within 30 days of screening. * Pregnant or nursing (lactating) women. * Previous SARS-CoV-2 infection within 10 days for mild or asymptomatic infections or 20 days for severe/critical illness prior to leukapheresis or initiation of LD chemotherapy. -Acute symptoms must have resolved and based on investigator assessment in consultation with the Sponsor Medical Monitor, there are no sequelae that would place the subject at a higher risk of receiving study treatment. * Previous SARS-CoV-2 vaccine within 14 days prior to leukapheresis or initiation of LD chemotherapy. Sex : ALL Ages : - Minimum Age : 18 Years - Age Group (Child: birth-17, Adult: 18-64, Older Adult: 65+) : ADULT, OLDER_ADULT Accepts Healthy Volunteers: No

{ "NCT_ID" : "NCT04279470", "Brief_Title" : "Chimeric Antigen Receptor T-cell and Cellular Therapies for the Treatment of cAncer or BLood Diseases: Evaluation of Reporting of Adverse Events", "Official_title" : "Chimeric Antigen Receptor T-cell and Cellular Therapies for the Treatment of cAncer or BLood Diseases: Evaluation of Reporting of Adverse Events", "Conditions" : ["Adverse Drug Reactions", "Cancer"], "Interventions" : ["Drug: CAR T-cell and Cellular Therapies"], "Location_Countries" : ["France"], "Study_Design" : { "Study_Type" : "OBSERVATIONAL", } }

#Study Description Brief Summary CAR-T cells and cellular therapies may lead to various adverse reactions. This study investigates reports of different toxicities for cellular therapies in the World Health Organization's (WHO) global database of individual safety case reports (VigiBase). Detailed Description CAR-T cells and cellular therapies are responsible of a wide range of side effects.The investigators use VigiBase, the World Health Organization (WHO) database of individual safety case reports, to identify cases of adverse drug reactions following treatment with cellular therapies #Intervention - DRUG : CAR T-cell and Cellular Therapies - Chimeric Antigen Receptor T-cell and Cellular Therapies for the treatment of a cancer either solid or hematologic malignancy

#Eligibility Criteria: Inclusion Criteria: * Case reported in the World Health Organization (WHO) database of individual safety case reports to 01/01/2020 * Adverse events reported were including any MedDRA terms * Patients treated with cellular therapies reported in the WHO database. Exclusion Criteria: * Chronology not compatible between the drug and the toxicity Sex : ALL Ages : - Maximum Age : 100 Years - Age Group (Child: birth-17, Adult: 18-64, Older Adult: 65+) : ADULT, CHILD, OLDER_ADULT Accepts Healthy Volunteers: No

{ "NCT_ID" : "NCT05716113", "Brief_Title" : "CD7 CAR-T for Patients With r/r CD7+ T-ALL/T-LBL", "Official_title" : "A Study for Safety, Efficacy and Cellular Pharmacokinetics of CD7 CAR-T Cell for Patients With Relapsed or Refractory CD7 Positive T-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma", "Conditions" : ["Neoplasms", "Hematologic Neoplasms", "Neoplasms by Site", "Hematologic Diseases"], "Interventions" : ["Drug: RD13-02 cell infusion"], "Location_Countries" : ["China"], "Study_Design" : { "Study_Type" : "INTERVENTIONAL", "Phase" : ["EARLY_PHASE1"], "Primary_Purpose" : "TREATMENT", "Allocation" : "NA", "Interventional Model" : "SINGLE_GROUP", "Masking" : "NONE" } }

#Study Description Brief Summary This is a single-arm, open-label, single-center, phase I study. The primary objective is to evaluate the safety of CD7 CAR-T therapy for patients with CD7-positive relapsed or refractory T-ALL/LBL, and to evaluate the pharmacokinetics of CD7 CAR-T in patients. #Intervention - DRUG : RD13-02 cell infusion - CAR-T cells

#Eligibility Criteria: Inclusion Criteria: * Age 3 <= age <= 70 * Diagnosis of r/r T-ALL/LBL. * CD7 positive expression * Bone marrow lymphoblasts >=5% by morphologic evaluation at screening * Creatinine clearance (as estimated by Cockcroft Gault) >= 60 mL/min, Serum alanine aminotransferase(ALT)/aspartate aminotransferase(AST) < 3×upper limit of normal, Total bilirubin < 1.5×upper limit of normal or <=1.5mg/dl * Left ventricular ejection fraction >= 50% . * Baseline oxygen saturation >= 92% on room air. * ECOG performance status of 0 to 2. * The estimated survival time is more than 3 months. * Subjects or their legal guardians volunteer to participate in the study and sign the informed consent. Exclusion Criteria: * Sujects with concomitant genetic syndromes associated with bone marrow failure states. * Sujects with some cardiac conditions will be excluded. * History of traumatic brain injury, consciousness disturbance, epilepsy, cerebrovascular ischemia, and cerebrovascular hemorrhagic disease, which might compromise the ability of the subject to compliance with the obligations under the protocol. * History of malignancy other than non-melanoma skin cancer or carcinoma. * Primary immune deficiency. * Presence of uncontrolled infections. * Sujects with some anticancer therapy before CAR-T infusion will be excluded. * Active uncontrolled acute infections. * Known history of infection with human immunodeficiency virus (HIV); active or latent hepatitis B, hepatitis C and syphilis. * Subjects who are receiving systemic steroid therapy prior to screening. * Subjects with acute graft-versus-host disease (GvHD) * Having received live/attenuated vaccine within 4 weeks prior to screening. * History of allergy to any component of the cell therapy product. * Pregnant or breastfeeding women * Any other issue which, in the opinion of the investigator, would make the sujects ineligible for the study. Sex : ALL Ages : - Minimum Age : 3 Years - Maximum Age : 70 Years - Age Group (Child: birth-17, Adult: 18-64, Older Adult: 65+) : ADULT, CHILD, OLDER_ADULT Accepts Healthy Volunteers: No

{ "NCT_ID" : "NCT02395250", "Brief_Title" : "Anti-GPC3 CAR T for Treating Patients With Advanced HCC", "Official_title" : "Autologous T Cells Redirected to GPC3 for Treating Patients With Advanced HCC", "Conditions" : ["Hepatocellular Carcinoma"], "Interventions" : ["Biological: anti-GPC3 CAR T"], "Location_Countries" : ["China"], "Study_Design" : { "Study_Type" : "INTERVENTIONAL", "Phase" : ["PHASE1"], "Primary_Purpose" : "TREATMENT", "Allocation" : "NA", "Interventional Model" : "SINGLE_GROUP", "Masking" : "NONE" } }

#Study Description Brief Summary The purpose of this study is to determine whether autologous T cells bearing chimeric antigen receptor that can specifically recognize glypican-3 (GPC3) is safe and effective for patients with relapsed or refractory hepatocellular carcinoma (HCC). #Intervention - BIOLOGICAL : anti-GPC3 CAR T - Other Names : - CAR T cells redirected to Glypican-3 in cancer cells

#Eligibility Criteria: Inclusion criteria: * Age of 18 <= age <= 70 years; * Pathologically confirmed advanced hepatocellular carcinoma (HCC); * >=1 measurable target lesion per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1); * Tumor tissue positive for GPC3 expression per immunohistochemical staining (IHC) assay; * Estimated survival > 12 weeks; * Child-Pugh grade A; * ECOG performance score of 0 <= age <= 1; * HBV-DNA < 200 IU/mL if positive for HBsAg or HBcAb. Patients positive for HBsAg shall receive anti-viral treatment per 'The guideline of prevention and treatment for chronic hepatitis B: a 2015 update'; * Have adequate venous access for apheresis or venous blood collection; * White blood cells >= 2.5 x 109/L, platelet >= 60×109/L, haemoglobin >= 9.0 g/dL, lymphocyte >= 0.4×109/L * Serum albumin >= 30 g/dL, serum lipase and amylase<=1.5 upper limit of normal (ULN), serum creatinine <= 1.5 ULN and endogenous creatinine clearance >= 40mL/min, ALT and AST <= 5 ULN, Serum total bilirubin <= 2.5 ULN, Prothrombin Time is less than 4s longer than normal; * Negative serum pregnancy test within 14 days before CAR T infusion, and with willingness to use reliable contraceptive methods to avoid pregnancy until 12 months after CAR T infusions for females of childbearing age; Having undergone sterilization procedure or with willingness to use reliable contraceptive methods to avoid pregnancy for males with female partner of childbearing age during the study; * Able to understand and sign the informed consent form Exclusion criteria: If the patient meets any of the exclusion criteria, the patient must be excluded from the study. * Pregnant or lactating female patients; * Positive serum tests for HCV, HIV, or syphilis; * Presence of HBV/HCV coinfection; * Presence of any uncontrollable active infection, such as, but not limited to, active tuberculosis * History of systemic administration of steroids (not including inhaled steroids), or other immunosuppressant drugs within 2 weeks before apheresis; * History of allergy to immunotherapy and related drugs, or β-lactam antibiotics, or history of other severe allergy; * History or current presence of hepatic encephalopathy; * Presence of ascites with clinical significance that is defined as positive focused physical examination for ascites, or ascites that requires treatment intervention (not including any ascites shown on image examinations without the need for clinical intervention); * >= 50% of normal liver occupied with HCC tumor tissue, or presence of tumor thrombus in the portal vein, or mesenteric vein, or inferior vena based on image analysis; * Presence of HCC metastatic lesion in the central nervous system, or presence of other diseases of central nervous system with clinical significance; * Presence of heart disease that requires treatment intervention, or poorly controlled hypertension (systolic pressure > 160 mmHg, or diastolic pressure > 100 mmHg); * Presence of active auto-immune disease that requires immunosuppressant treatment; * History of organ transplantation or currently on the waiting list for organ transplantation, including, but not limited to, liver transplantation; * Anti-HCC therapies including, but not limited to, surgical resection, interventional therapy, radiation therapy, chemotherapy, and immunotherapy, within 2 weeks before apheresis; * History of receiving anti-PD-1 or anti-PD-L1 monoclonal antibodies, or other immunotherapy; * History of other malignancies in the past 5 years, or presence of other active malignancies (not including cervical cancer in situ and basal cell carcinomas); * Presence of other serious diseases or conditions, including uncontrolled diabetes (HbA1c > 7% with treatment); severe cardiac dysfunction with LVEF < 45%; myocardial infarction, unstable angina, or unstable arrhythmia in the past 6 months pulmonary embolism; chronic obstructive pulmonary disease; interstitial lung disease; forced expiratory volume in 1 second (FEV1) < 60%, gastric ulcer; history of gastrointestinal bleeding, or confirmed tendency for gastrointestinal bleeding; * Determined by the investigator to be lack of compliance for the study. Sex : ALL Ages : - Minimum Age : 18 Years - Maximum Age : 70 Years - Age Group (Child: birth-17, Adult: 18-64, Older Adult: 65+) : ADULT, OLDER_ADULT Accepts Healthy Volunteers: No

{ "NCT_ID" : "NCT04432506", "Brief_Title" : "Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma", "Official_title" : "Pilot Study of Anakinra to Mitigate CAR-T Toxicity in Subjects With Relapsed or Refractory Large B-Cell Lymphoma", "Conditions" : ["Hematopoietic and Lymphoid Cell Neoplasm", "Recurrent Diffuse Large B-Cell Lymphoma", "Recurrent High Grade B-Cell Lymphoma", "Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma", "Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma", "Refractory High Grade B-Cell Lymphoma", "Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma", "Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma"], "Interventions" : ["Biological: Axicabtagene Ciloleucel", "Drug: Fludarabine", "Drug: Cyclophosphamide", "Biological: Anakinra"], "Location_Countries" : ["United States"], "Study_Design" : { "Study_Type" : "INTERVENTIONAL", "Phase" : ["PHASE2"], "Primary_Purpose" : "TREATMENT", "Allocation" : "NA", "Interventional Model" : "SINGLE_GROUP", "Masking" : "NONE" } }

#Study Description Brief Summary This phase II trial studies the side effects and best dose of anakinra and to see how well it works in reducing side effects (toxicity) associated with a CAR-T cell treatment called axicabtagene ciloleucel in patients with large B-cell lymphoma that has come back (relapsed) or has not responded to treatment (refractory). Anakinra is a drug typically used to treat rheumatoid arthritis but may also help in reducing CAR-T cell therapy toxicity. Giving anakinra in combination with axicabtagene ciloleucel may help control relapsed or refractory large B-cell lymphoma. Detailed Description PRIMARY OBJECTIVE: I. To assess safety and tolerability of anakinra in reducing incidence of cytokine release syndrome (CRS) within 30 days after infusion of chimeric antigen receptor (CAR) T cells in subjects with relapsed or refractory large B-cell lymphoma. SECONDARY OBJECTIVES: I. To determine incidence of all grades and duration of both CRS and immune-cell associated neurotoxicity syndrome (ICANS). II. To determine the complete response rate (CRR), overall response rate (ORR), progression-free survival (PFS) and overall survival (OS). EXPLORATORY OBJECTIVES: I. To determine the effects of anakinra on the cytokine and chemokine profile in peripheral blood after CAR-T therapy. II. To determine the effects of anakinra on the expansion and persistence of CAR T cells. III. To correlate baseline characteristics with toxicity, response and survival after anakinra combined with CAR-T therapy. OUTLINE: This is a dose-escalation study of anakinra. Patients receive cyclophosphamide intravenously (IV) over 60 minutes and fludarabine IV over 30 minutes on days -5 to -3 in the absence of disease progression or unacceptable toxicity. Patients then receive axicabtagene ciloleucel IV over 30 minutes or less on day 0 and anakinra subcutaneously (SC) on days 0-6 in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up at 2 and 4 weeks, and then at 2, 3, 6, 9, 12, 18, and 24 months. #Intervention - BIOLOGICAL : Anakinra - Given SC - Other Names : - Kinaret, Kineret, rIL-1ra, rIL1RN - BIOLOGICAL : Axicabtagene Ciloleucel - Given IV - Other Names : - KTE C19, KTE-C19, KTE-C19 CAR, Yescarta - DRUG : Cyclophosphamide - Given IV - Other Names : - (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719 - DRUG : Fludarabine - Given IV - Other Names : - Fluradosa

#Eligibility Criteria: Inclusion Criteria: * Relapsed or refractory diffuse large B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma (PMBCL), transformed follicular lymphoma (tFL), or high-grade B-cell lymphoma (HGBCL), at least 2 prior lines of systemic therapy * Planned to receive standard of care therapy with axicabtagene ciloleucel * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Measurable disease of >= 1.5 cm * At least two weeks or 5 half-lives, whichever is shorter, must have elapsed since any prior systemic therapy at the time the subject is planned for axicabtagene ciloleucel (axi-cel) therapy, except for systemic immune checkpoint inhibitory / immune stimulatory therapy. At least 3 half-lives must have elapsed from any prior systemic immune checkpoint inhibitory / immune stimulatory therapy at the time the subject is planned for leukapheresis (e.g. ipilimumab, nivolumab, pembrolizumab, atezolizumab, OX40 agonists, 4 <= age <= 1BB agonists, etc) * Toxicities due to prior therapy must be stable and recovered to =< grade 1 (except for clinically non-significant toxicities such as alopecia) * Absolute neutrophil count of >= 1.0 x 10^9/L * Platelet count of >= 60 x 10^9/L * Creatinine clearance (as estimated by Cockcroft Gault) >= 45 mL/minute (min) * Serum alanine transaminase (ALT) / aspartate transaminase (AST) =< 2.5 upper limit of normal (ULN) * Total bilirubin =< 1.5 mg/dL, except in subjects with Gilbert's syndrome * Cardiac ejection fraction >= 50% with no evidence of pericardial effusion * Baseline oxygen saturation > 92% on room air * No evidence, suspicion, and/or history of lymphoma involving the central nervous system (CNS) * Females of childbearing potential must have a negative serum or urine pregnancy test (females who have undergone surgical sterilization or who have been postmenopausal for at least 2 years are not considered to be of childbearing potential) Exclusion Criteria: * History of malignancy other than nonmelanoma skin cancer or carcinoma in situ (e.g. cervix, bladder, breast) unless disease free for at least 3 years * History of Richter's transformation of chronic lymphocytic leukemia (CLL) * Autologous stem cell transplantation within 6 weeks of planned axi-cel infusion * History of allogeneic stem cell transplantation * Prior CD19 targeted therapy * Prior chimeric antigen receptor therapy or other genetically modified T cell therapy * Presence of fungal, bacterial, viral, or other infection that is uncontrolled or requiring IV antimicrobials for management. Simple urinary tract infection (UTI) and uncomplicated bacterial pharyngitis are permitted if responding to active treatment and after consultation with the principal investigator * Known history of infection with human immunodeficiency virus (HIV) or hepatitis B (hepatitis B virus surface antigen [HBsAg] positive) or hepatitis C virus (anti-HCV positive). A history of hepatitis B or hepatitis C is permitted if the viral load is undetectable per quantitative polymerase chain reaction (PCR) and/or nucleic acid testing * Known history of tuberculosis. A negative Quantiferon or purified protein derivative (PPD) up to 2 months before start of anakinra is enough if no specific risk factors * Presence of any indwelling line or drain (e.g., percutaneous nephrostomy tube, indwelling foley catheter, biliary drain, or pleural/peritoneal/pericardial catheter). Dedicated central venous access catheters such as a Port-a-Cath or Hickman catheter are permitted * Subjects with detectable cerebrospinal fluid malignant cells, or brain metastases, or with a history of CNS lymphoma, cerebrospinal fluid malignant cells or brain metastases * History or presence of CNS disorder such as seizure disorder, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease with CNS involvement * Subjects with cardiac atrial or cardiac ventricular lymphoma involvement * History of myocardial infarction, cardiac angioplasty or stenting, unstable angina, or other clinically significant cardiac disease within 12 months of enrollment * Requirement for urgent therapy due to tumor mass effects such as bowel obstruction or blood vessel compression * Primary immunodeficiency * History of autoimmune disease (e.g. Crohn's, rheumatoid arthritis, systemic lupus) resulting in end organ injury or requiring systemic immunosuppression/systemic disease modifying agents within the last 2 years * History of symptomatic deep vein thrombosis or pulmonary embolism within 6 months of enrollment * Any medical condition likely to interfere with assessment of safety or efficacy of study treatment * History of severe immediate hypersensitivity reaction to any of the agents used in this study, including E coli-derived proteins * Live vaccine =< 6 weeks prior to planned start of conditioning regimen * Women of child-bearing potential who are pregnant or breastfeeding because of the potentially dangerous effects of the preparative chemotherapy on the fetus or infant * Subjects of both genders who are not willing to practice birth control from the time of consent through 6 months after the completion of anakinra injections * In the investigator's judgment, the subject is unlikely to complete all protocol-required study visits or procedures, including follow-up visits, or comply with the study requirements for participation Trial Treatments Sex : ALL Ages : - Minimum Age : 18 Years - Age Group (Child: birth-17, Adult: 18-64, Older Adult: 65+) : ADULT, OLDER_ADULT Accepts Healthy Volunteers: No

{ "NCT_ID" : "NCT05918809", "Brief_Title" : "Real-world Resource Use and Costs of CAR-T Therapies in Diffuse Large B-cell Lymphoma (DLBCL): Inpatient and Outpatient Settings", "Official_title" : "Real-world Resource Use and Costs of CAR-T Therapies in Diffuse Large B-cell Lymphoma (DLBCL): Inpatient and Outpatient Settings", "Conditions" : ["Diffuse Large B-cell Lymphoma"], "Location_Countries" : ["United States"], "Study_Design" : { "Study_Type" : "OBSERVATIONAL", } }

#Study Description Brief Summary A retrospective, non-interventional cohort study was used to address the study objectives. This study aimed to provide a better understanding of real-world healthcare resource utilization (HRU) and healthcare reimbursement costs associated with chimeric antigen receptor modified T cell (CAR-T) therapy among patients with DLBCL.

#Eligibility Criteria: Inclusion Criteria: CAR-T cohort: * Patients had at least one International Classification of Diseases, Tenth Revision (ICD-10) diagnosis code for DLBCL. * Patients received CAR-T therapy following DLBCL diagnosis. The administration date of CAR-T therapy was defined as the index date. Patients who received both CAR-T therapy and allo-HSCT were classified based on the first treatment that the patient received. * Patients were at least 18 years as of the index date. * Patients had at least three months of continuous eligibility in the Medicare Part A and Part B data before the index date. Since 2020 Part D data is not available in the current data cut; eligibility requirement in the Part D data was not required. * Patients were further classified into CAR-T IP and CAR-T OP cohorts depending on where the administration occurred. Allo-HSCT cohort: * Patients had at least one ICD-10 diagnosis code for DLBCL. * Patients received allo-HSCT following DLBCL diagnosis. The date of allo-HSCT procedure was defined as the index date. Patients who received both CAR-T therapy and allo-HSCT were classified based on the first treatment the patient received. * Patients were at least 18 years as of the index date. * Patients had at least three months of continuous eligibility in the Medicare Part A and Part B data before the index date. Since 2020 Part D data is not available in the current data cut; eligibility requirement in the Part D data was not required. Exclusion criteria: * Patients had a medical claim associated with a clinical trial (ICD-9 CM code V70.7; ICD-10 CM code Z00.6) during one month before and after the index date. Sex : ALL Ages : - Minimum Age : 18 Years - Age Group (Child: birth-17, Adult: 18-64, Older Adult: 65+) : ADULT, OLDER_ADULT Accepts Healthy Volunteers: No

{ "NCT_ID" : "NCT04768608", "Brief_Title" : "PD1 Integrated Anti-PSMA CART in Treating Patients With Castrate-Resistant Prostate Cancer", "Official_title" : "Clinical Trial for the Safety and Efficacy of Non-viral PD1 Integrated Anti-PSMA Chimeric Antigen Receptor T Cells in the Treatment of Refractory Castrate-Resistant Prostate Cancer", "Conditions" : ["Castrate-Resistant Prostate Cancer"], "Interventions" : ["Drug: PD1-PSMA-CART cells"], "Location_Countries" : ["China"], "Study_Design" : { "Study_Type" : "INTERVENTIONAL", "Phase" : ["PHASE1"], "Primary_Purpose" : "TREATMENT", "Allocation" : "NA", "Interventional Model" : "SEQUENTIAL", "Masking" : "NONE" } }

#Study Description Brief Summary PD1-PSMA-CART in Treating Patients With Castrate-Resistant Prostate Cancer Detailed Description Clinical trial for the safety and efficacy of Non-viral programmed cell death protein-1(PD1) integrated anti-prostate-specific-membrane-antigen(PSMA) chimeric antigen receptor T(CART) cells in the treatment of Refractory Castrate-Resistant Prostate Cancer(CRPC) #Intervention - DRUG : PD1-PSMA-CART cells - PD1-PSMA-CART cells will be given IV at split doses - Other Names : - Non-viral PD1 integrated anti-PSMA chimeric antigen receptor T cell

#Eligibility Criteria: Inclusion Criteria: * Fully understand and voluntarily sign informed consent. * Aged 18 <= age <= 75 old. * Expected survival > 6 months. * CRPC patients:Serum testosterone reached castration level (<50ng/dl or<1.7nmol/L) and: prostate specific antigen (PSA) increased more than 50% at intervals of one week or three consecutive times, with PSA>2 ng/ml; or imaging scans revealed two or more new lesions or enlargement of soft tissue lesions that met the criteria for evaluating solid tumor response. * CRPC patients received abiraterone or chemotherapy for 3 months or more, and were ineffective or progressive (PSA continued to rise for 3 months, or bone scan/whole-body imaging showed local recurrence or new metastasis). * Immunohistochemical staining of repetitive biopsy tissues showed the expression of PSMA in tumor cells was more than 50%. * Eastern Cooperative Oncology Group (ECOG) score <=2. * Virological examination was negative. * Hematological indexes: hemoglobin > 100 g/L, platelet count > 100×10^9/L, absolute neutrophil count > 1.5×10^9/L. Exclusion Criteria: * Prior treatment with any CART therapy targeting any target. * Prior treatment with any PSMA targeting therapy. * Need steroid therapy, except physiological replacement therapy. * Prior treatment with any immunotherapy, including tumor vaccine therapy, radium-223, checkpoint inhibitors and others. * Subjects with severe mental disorders. * Subjects with other malignant tumors. * Subjects with severe cardiovascular diseases: a, New York Heart Association (NYHA) stage III or IV congestive heart failure; b, history of myocardial infarction or coronary artery bypass grafting (CABG) within 6 months; c, clinical significance of ventricular arrhythmia, or history of unexplained syncope, non-vasovagal or dehydration; d, history of severe non-ischemic cardiomyopathy; e, the left ventricular ejection fraction (left ventricular ejection fraction< 55%) was decreased by echocardiography or multiple gated acquisition scan (within 8 weeks before peripheral blood mononuclear cell (PBMC) collection), and abnormal interventricular septal thickness and atrioventricular size associated with myocardial amyloidosis. * Patients with ongoing or active infection. * Organ function: a, Alanine aminotransferase or Aspartate aminotransferase >2.5*Upper limit of normal (ULN); Creatine kinase>1.5*ULN; Creatine kinase isoenzyme >1.5*ULN; Troponin T >1.5*ULN; b, Total bilirubin >1.5*ULN; c, Partial prothrombin time or activated partial thromboplastin time or international standardized ratio > 1.5*ULN without anticoagulant treatment. * History of participation in other clinical studies within 3 months or treatment with any gene therapy product. * Intolerant or allergic to cyclophosphamide or fludarabine. * Subjects not appropriate to participate in this clinical study judged by investigators. Sex : MALE Ages : - Minimum Age : 18 Years - Maximum Age : 75 Years - Age Group (Child: birth-17, Adult: 18-64, Older Adult: 65+) : ADULT, OLDER_ADULT Accepts Healthy Volunteers: No

{ "NCT_ID" : "NCT02159716", "Brief_Title" : "CART-meso in Mesothelin Expressing Cancers", "Official_title" : "Phase I Study of Chimeric Antigen Receptor Modified T Cells in Patients With Mesothelin Expressing Cancers", "Conditions" : ["Metastatic Pancreatic (Ductal) Adenocarcinoma", "Epithelial Ovarian Cancer", "Malignant Epithelial Pleural Mesothelioma"], "Interventions" : ["Biological: CART-meso"], "Location_Countries" : ["United States"], "Study_Design" : { "Study_Type" : "INTERVENTIONAL", "Phase" : ["PHASE1"], "Primary_Purpose" : "TREATMENT", "Allocation" : "NON_RANDOMIZED", "Interventional Model" : "PARALLEL", "Masking" : "NONE" } }

#Study Description Brief Summary Phase I study to establish safety and feasibility of intravenously administered lentiviral transduced CART-meso cells administered with and without cyclophosphamide in a 3+3 dose escalation design in patients with metastatic pancreatic cancer, serous epithelial ovarian cancer, or pleural mesothelioma. Dose: 1-3xE7 /mE2 (Cohort 1 and 2) and 1-3xE8 /mE2 (Cohort 3 and 4 ) CAR+ T cells by intravenous route. In the event of 2 DLTs at each dose level, we will dose deescalate by 10-fold. #Intervention - BIOLOGICAL : CART-meso - CART-meso are autologous T cells lentivirally transduced with chimeric anti-mesothelin immunoreceptor SS1 fused to the 4-1BB and CD3ζ signaling domains.

#Eligibility Criteria: Inclusion Criteria: * Histologically confirmed cancer (one of the following): * Metastatic pancreatic adenocarcinoma. * Persistent or recurrent serous epithelial ovarian cancer or primary peritoneal carcinoma * Malignant pleural mesothelioma (histologically confirmed epithelial) * Failure of at least one prior standard of care chemotherapy for advanced stage disease. * Subjects must have measureable disease as defined by RECIST 1.1 criteria or modified RECIST criteria. * Patients > 18 years. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Life expectancy > 3 months. * Satisfactory organ and bone marrow function as defined by the following (of note, the minimal blood counts should be in the absence of transfusion or cytokine support): i. Absolute neutrophil count > 1,000/μl ii. Platelets >75,000/μl iii. Hemoglobin > 9 g/dL iv. Bilirubin < 2.0x the institutional normal upper limit unless secondary to bile duct obstruction by tumor v. Creatinine < 1.5x the institutional normal upper limit vi. Albumin >=2 vii. Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) < 5x the institutional normal upper limit viii. Cardiac ejection fraction of >55% as measured by resting echocardiogram, with no significant pericardial effusion. * Blood coagulation parameters: PT such that international normalized ratio (INR) is <= 1.5 and a PTT < 1.2 time the upper limit of normal unless the patient is therapeutically anti-coagulated for history of cancer-related thrombosis and has stable coagulation parameters. * Ability to understand and the willingness to provide written informed consent. * Male and Female subjects of reproductive potential agree to use approved contraceptive methods (e.g. birth control pills, barrier device, intrauterine device, abstinence) and abstain from other methods of conception during the study and for 6 months following the study cell infusion or proof of sterility. Exclusion Criteria * Sarcomatoid MPM histology which is known in the literature to not express mesothelin; biphasic MPM is also excluded. * Participated in any other trial in which receipt of an investigational study drug occurred within 28 days prior to enrollment and anticipated treatment with another investigational product while on study. This refers to non-commercially approved investigational drugs different than those used in this protocol. * Anticipated need for systemic chemotherapy within 2 weeks before apheresis and infusion of CART-meso cells. * Active invasive cancer other than the one of the three cancers in this study. Patients with active non-invasive cancers (such as non-melanoma skin cancer, superficial cervical and bladder and prostate cancer with PSA level < 1.0) are not excluded.CART-meso in mesothelin expressing cancers * HIV, HCV, or HBV infections * Active autoimmune disease (including but not limited to: systemic lupus erythromatosis, Sjogren's syndrome, rheumatoid arthritis, psoriasis, multiple sclerosis, inflammatory bowel disease, etc.) requiring immunosuppressive therapy within the past 4 weeks, with exception of thyroid replacement. * Patients with ongoing or active infection. * Planned concurrent treatment with systemic high dose corticosteroids. Patients may be on a stable low dose of steroids (<10mg equivalent of prednisone) for chronic respiratory conditions. * Patients requiring supplemental oxygen therapy. * Prior therapy with gene modified cells. * Previous experimental therapy with SS1 moiety, murine or chimeric antibodies (human and humanized antibodies are allowed). * History of allergy to murine proteins * History of allergy or hypersensitivity to study product excipients (human serum albumin, DMSO, and Dextran 40) * Any clinically significant pericardial effusion; CHF (NY Heart Association Grade II-IV) or cardiovascular condition that would preclude assessment of mesothelin induced pericarditis or that may worsen as a result of toxicities expected for this study. This determination will be made by a cardiologist. * Any clinically significant pleural or peritoneal effusion that cannot be drained with standard approaches. An indwelling drainage device placed prior to enrollment is acceptable. * Pregnant or breastfeeding women. Female study participants of reproductive potential must have a negative urine pregnancy test of enrollment. A serum pregnancy test will be performed within 2 weeks before infusion. Sex : ALL Ages : - Minimum Age : 18 Years - Age Group (Child: birth-17, Adult: 18-64, Older Adult: 65+) : ADULT, OLDER_ADULT Accepts Healthy Volunteers: No

{ "NCT_ID" : "NCT05902845", "Brief_Title" : "RD13-02 CAR-T Cell Injection for Patients With r/r CD7+ T-ALL/T-LBL", "Official_title" : "Efficacy, Safety and Cytopharmacokinetics of RD13-02 Cell Injection in the Treatment of Patients With Recurrent or Refractory CD7-positive Hematologic Malignancies", "Conditions" : ["Neoplasms", "Hematologic Neoplasms", "Hematologic Diseases"], "Interventions" : ["Drug: RD13-02 cell infusion"], "Location_Countries" : ["China"], "Study_Design" : { "Study_Type" : "INTERVENTIONAL", "Phase" : ["EARLY_PHASE1"], "Primary_Purpose" : "TREATMENT", "Allocation" : "NA", "Interventional Model" : "SINGLE_GROUP", "Masking" : "NONE" } }

#Study Description Brief Summary This is a single-arm, open-label, single-center, phase I study. The primary objective is to evaluate the safety of CD7 CAR-T therapy for patients with CD7-positive relapsed or refractory T-ALL/LBL, and to evaluate the pharmacokinetics of CD7 CAR-T in patients. #Intervention - DRUG : RD13-02 cell infusion - CAR-T cells

#Eligibility Criteria: Inclusion Criteria: * Age 3 <= age <= 70 * Diagnosis of r/r T-ALL/LBL. * CD7 positive expression * Bone marrow lymphoblasts >=5% by morphologic evaluation at screening * Creatinine clearance (as estimated by Cockcroft Gault) >= 60 mL/min, Serum alanine aminotransferase(ALT)/aspartate aminotransferase(AST) < 3×upper limit of normal, Total bilirubin < 1.5×upper limit of normal or <=1.5mg/dl * Left ventricular ejection fraction >= 50% . * Baseline oxygen saturation >= 92% on room air. * ECOG performance status of 0 to 2. * The estimated survival time is more than 3 months. * Subjects or their legal guardians volunteer to participate in the study and sign the informed consent. Exclusion Criteria: * Sujects with concomitant genetic syndromes associated with bone marrow failure states. * Sujects with some cardiac conditions will be excluded. * History of traumatic brain injury, consciousness disturbance, epilepsy, cerebrovascular ischemia, and cerebrovascular hemorrhagic disease, which might compromise the ability of the subject to compliance with the obligations under the protocol. * History of malignancy other than non-melanoma skin cancer or carcinoma. * Primary immune deficiency. * Presence of uncontrolled infections. * Sujects with some anticancer therapy before CAR-T infusion will be excluded. * Active uncontrolled acute infections. * Known history of infection with human immunodeficiency virus (HIV); active or latent hepatitis B, hepatitis C and syphilis. * Subjects who are receiving systemic steroid therapy prior to screening. * Subjects with acute graft-versus-host disease (GvHD) * Having received live/attenuated vaccine within 4 weeks prior to screening. * History of allergy to any component of the cell therapy product. * Pregnant or breastfeeding women * Any other issue which, in the opinion of the investigator, would make the sujects ineligible for the study. Sex : ALL Ages : - Minimum Age : 3 Years - Maximum Age : 70 Years - Age Group (Child: birth-17, Adult: 18-64, Older Adult: 65+) : ADULT, CHILD, OLDER_ADULT Accepts Healthy Volunteers: No

{ "NCT_ID" : "NCT04394650", "Brief_Title" : "A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma", "Official_title" : "A Phase I, Multi Center, Open Label Study of CC-98633, BCMA Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed and/or Refractory Multiple Myeloma", "Conditions" : ["Multiple Myeloma"], "Interventions" : ["Biological: CC-98633"], "Location_Countries" : ["United States"], "Study_Design" : { "Study_Type" : "INTERVENTIONAL", "Phase" : ["PHASE1"], "Primary_Purpose" : "TREATMENT", "Allocation" : "NA", "Interventional Model" : "SINGLE_GROUP", "Masking" : "NONE" } }

#Study Description Brief Summary This is a Phase 1, multicenter, open-label study of CC-98633, BCMA-Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in participants with relapsed and/or refractory multiple myeloma. The study will consist of 2 parts: dose-escalation (Part A) and dose-expansion (Part B). The dose-escalation part (Part A) of the study is to evaluate the safety and tolerability of increasing dose levels of CC-98633 to establish a recommended Phase 2 dose RP2D(s); and the dose-expansion part (Part B) of the study is to further evaluate the safety, pharmacokinetics/pharmacodynamics, and efficacy of CC-98633 at the RP2D(s). #Intervention - BIOLOGICAL : CC-98633 - Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) to produce CC-98633. During CC-98633 production, subjects may receive bridging chemotherapy for disease control. Upon successful generation of CC-98633 product, subjects will receive treatment with CC-98633 therapy. Study treatment will include lymphodepleting chemotherapy followed by one dose of CC-98633 administered by intravenous (IV) injection.

#Eligibility Criteria: Inclusion Criteria: * Age >= 18 years. * Signed written informed consent prior to any study procedure. * Relapsed and/or refractory multiple myeloma (MM). 1. Subjects must have documented progressive disease as per International Myeloma Working Group (IMWG) criteria during or within 12 months of completing treatment with the last anti-myeloma treatment regimen before study entry. Also, subjects with confirmed progressive disease within 6 months prior to start of Screening and who are refractory (or non-responsive) to their most recent anti-myeloma treatment regimen afterwards will be also eligible. 2. Part A and Part B Cohort A: Subjects must have confirmed at least 3 prior antimyeloma treatment regimens. 3. Part B Cohort B only: Subjects must have received at least 1 but no greater than 3 prior antimyeloma treatment regimens, including a proteasome inhibitor and immunomodulatory agent. 4. Subjects must have previously received all of the following therapies: i) Autologous stem cell transplant ii) A regimen that included an immunomodulatory agent (eg, thalidomide, lenalidomide, pomalidomide) and a proteasome inhibitor (eg, bortezomib, carfilzomib, ixazomib), either alone or combination iii) Anti-CD38 (eg, daratumumab), either alone or combination Subjects in Cohort B do not require prior anti-CD38 antibody therapy. * Measurable disease * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Adequate organ function Exclusion Criteria: * Known active or history of central nervous system (CNS) involvement of MM * Active or history of plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes) syndrome, or clinically significant amyloidosis * Prior treatment with CAR T-cell or another genetically modified T-cell therapy * Part A and Part B Cohort A only: Prior treatment with investigational therapy directed at BCMA * Uncontrolled or active infection * Active autoimmune disease requiring immunosuppressive therapy * History or presence of clinically significant CNS pathology such as seizure disorder, aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychosis Sex : ALL Ages : - Minimum Age : 18 Years - Age Group (Child: birth-17, Adult: 18-64, Older Adult: 65+) : ADULT, OLDER_ADULT Accepts Healthy Volunteers: No

{ "NCT_ID" : "NCT04260932", "Brief_Title" : "CD19/CD20 Dual-CAR-T in B-cell Lymphoma Patients", "Official_title" : "CD19/CD20 Dual-CAR-T for Patients With B-cell Lymphoma", "Conditions" : ["B-cell Lymphoma"], "Interventions" : ["Biological: CD19/CD20 Dual-CAR-T cells"], "Location_Countries" : ["China"], "Study_Design" : { "Study_Type" : "INTERVENTIONAL", "Phase" : ["PHASE1"], "Primary_Purpose" : "TREATMENT", "Allocation" : "NA", "Interventional Model" : "SINGLE_GROUP", "Masking" : "NONE" } }

#Study Description Brief Summary This is a single center, single arm, open-label, phase I study to evaluate the safety and efficacy of CD19/CD20 Dual-CAR-T cells in patients with refractory and relapsed B-cell lymphoma. Detailed Description This Phase I study is designed as a pilot trial evaluating the safety and efficacy of CD19/CD20 Dual-CAR-T cell therapy in subjects with refractory and relapsed B cell lymphoma. Subjects will receive cytoreductive chemotherapy with cyclophosphamide and fludarabine on days -5, -4 and -3 followed by infusion of CD19/CD20 Dual-CAR-T cells. Safety and efficacy of CD19/CD20 Dual-CAR-T cells therapy will be monitored. The purpose of current study is to determine the clinical efficacy and safety of CD19/CD20 Dual-CAR-T cells therapy in patients with refractory and relapsed B-cell lymphoma. #Intervention - BIOLOGICAL : CD19/CD20 Dual-CAR-T cells - CD19/CD20 Dual-CAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of CAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest at least for 2 days before infusion. CD19/CD20 Dual-CAR-T cells will be intravenously infused with a escalated dose of 1-6×106 cells/kg.

#Eligibility Criteria: Inclusion Criteria: * Relapsed and refractory B-cell lymphoma with: Relapsed or refractory disease after >=2 lines of chemotherapy including rituximab and anthracycline and either having failed after autologous or allogeneic hematopoietic stem cell transplantation (ASCT); * Patients must have evaluable evidence of disease, including minimal residual disease (MRD); * Double positive expression of CD19 / CD20 in B cells; * Ages 1 <= age <= 80, including boundary values; * ECOG score 0 <= age <= 3 points; * Women of childbearing age (15 <= age <= 49 years) must receive a pregnancy test within 7 days prior to initiation of treatment and the results are negative; male and female patients with fertility must use an effective contraceptive to ensure 3 months after discontinuation of treatment during the study period not pregnant inside; * Patients who voluntarily sign informed consent and are willing to comply with treatment plans. Exclusion Criteria: * patients with organ failure: * Heart: NYHA heart function grade IV; * Liver: Grade C that achieves Child-Turcotte liver function grading; * Kidney: kidney failure and uremia; * Lung: symptoms of respiratory failure; * Brain: a person with a disability; * Active infections that are difficult to control; * Human immunodeficiency virus (HIV) positive; * Liver and kidney function: total bilirubin > 5 × ULN, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) > 5 × ULN, serum creatinine clearance rate 60mL / min; * GVHD >= 2 or anti-GVHD treatment; * intracranial hypertension or unconsciousness; respiratory failure; diffuse vascular internal coagulation; * pregnant or lactating women; * The patient does not agree to use effective contraception during the treatment period and for the next 3 months; * Patients who participate in other clinical studies at the same time; * The investigator believes that there are other factors that are not suitable for inclusion or influence the subject's participation or completion of the study. Sex : ALL Ages : - Minimum Age : 1 Year - Maximum Age : 80 Years - Age Group (Child: birth-17, Adult: 18-64, Older Adult: 65+) : ADULT, CHILD, OLDER_ADULT Accepts Healthy Volunteers: No

{ "NCT_ID" : "NCT03980288", "Brief_Title" : "4th Generation Chimeric Antigen Receptor T Cells Targeting Glypican-3", "Official_title" : "A Phase I Clinical Study of 4th Generation Chimeric Antigen Receptor T Cells Targeting Glypican-3 ( CAR-GPC3 T Cells) in Patients With Advanced Hepatocellular Carcinoma", "Conditions" : ["Advanced Hepatocellular Carcinoma"], "Interventions" : ["Drug: CAR-GPC3 T Cells"], "Location_Countries" : ["China"], "Study_Design" : { "Study_Type" : "INTERVENTIONAL", "Phase" : ["PHASE1"], "Primary_Purpose" : "TREATMENT", "Allocation" : "NA", "Interventional Model" : "SINGLE_GROUP", "Masking" : "NONE" } }

#Study Description Brief Summary A Phase I Clinical Study of 4th generation Chimeric Antigen Receptor T Cells Targeting Glypican-3 ( CAR-GPC3 T Cells) in Patients with Advanced Hepatocellular Carcinoma Detailed Description This is a phase I open-label, single and multiple infusion, dose escalation/cohort expansion study to evaluate the safety, cell pharmacokinetics, and preliminary efficacy of CAR-GPC3 T cells, infused intravenously in subjects who have been diagnosed with GPC3 positive advanced hepatocellular carcinoma and refractory or intolerant to current standard systemic treatment. Primary objectives: •To evaluate the safety and tolerability of CAR-GPC3 T cells infused intravenously at escalating doses in patients with advanced hepatocellular carcinoma. Secondary objectives: * To evaluate the cellular pharmacokinetics of CAR-GPC3 T cells * To evaluate the overall safety and tolerability of infusion of CAR-GPC3 T cells * To investigate the preliminary efficacy of CAR-GPC3 T cells in the treatment of advanced hepatocellular carcinoma #Intervention - DRUG : CAR-GPC3 T Cells - Pretreatment with fludarabine and cyclophosphamide CAR-GPC3 T Cells infusion

#Eligibility Criteria: Inclusion Criteria: * Aged 18 <= age <= 75, male or female; * Patients with advanced hepatocellular carcinoma (HCC) diagnosed by histopathology or cytology who are not suitable for surgery or local treatment, have developed progressive disease or intolerability after standard systemic therapies (including but not limited to systemic chemotherapy, molecular targeted therapy); * According to BCLC, the patients are classified into Grade C or Grade B unsuitable for local treatment/progressive disease after local treatment; * In tumor tissue samples GPC3 is detected positive by immunohistochemistry (IHC); * According to RECIST 1.1, patients have at least one evaluable target lesion, defined as: the longest diameter of non-lymph node lesion >= 10 mm, or the shortest diameter of lymph node lesion >= 15 mm); hepatic lesions require arterial phase contrast enhancement; * Expected survival is > 12 weeks; * Cirrhosis status Child-Pugh score:<=7; * ECOG Performance Status score: 0 to 1 point; * If the patient is HBsAg positive or HBcAb positive, HBV-DNA should be <200 IU/ml. HBsAg positive patients must receive antiviral treatment according to the 2015 China Edition of Guideline for Chronic Hepatitis B Prevention and Treatment; * Subjects should have adequate organ functions before screening and pre-treatment (at baseline); * Have venous accesses for pheresis; * Subjects of childbearing age must undergo a serum pregnancy test within 14 days before the initiation of the study and the result must be negative. In addition, they should be willing to use a reliable method of contraception during the trial (within 52 weeks after cell infusion); male subjects whose spouses are women of childbearing age should undergo sterilization surgery or agree to use a reliable method of contraception during the trial; * Understand and sign informed consent. Exclusion Criteria: * Pregnant or breast-feeding women; * HCV-RNA, HIV antibodies or Syphilis Serological tests are positive; * Any uncontrollable active infection, including but not limited to active tuberculosis; * Subjects have clinically significant thyroid dysfunction determined by investigator (serum thyroid hormone assays TT4, TT3, FT3, FT4, and serum thyroid stimulating hormone TSH) which is not suitable for entering into the study; * Previous or present hepatic encephalopathy; * Current clinically significant ascites, which is defined as ascites that are physically positive or require intervention (e.g., puncture or medication) for control (those whose imaging result shows ascites requiring no intervention may be included); * Imaging results:>=50% of the liver is replaced by tumor or portal vein main tumor thrombus, or tumor thrombus invasion of mesenteric vein / inferior vena cava; * Patients with known active autoimmune diseases which require to be treated with immunosuppressive agents including biological agents; * The side effects caused by the previous treatment of the subjects did not return to CTCAE <=1; except hair loss and other tolerable events determined by investigator; * Patients who had received systemic steroids or other immunosuppressive agents within 2 weeks before collection of mononuclear cells, except those who had recently used or are currently using inhaled steroids; * Allergic to immunotherapy and related drugs; * Subjects have untreated or symptomatic brain metastases; * Subjects have central or extensively metastases in lung; * Subjects with unstable or active ulcers and gastrointestinal bleeding currently; * Patients with a history of organ transplantation or waiting for organ transplantation (including liver transplantation); * Subjects who have undergone antitumor therapy within 2 weeks prior to apheresis; * Previously received any chimeric antigen receptor-modified T-cells (CAR-T) , TCR T immunotherapy; * Subjects who have undergone PD-1/PD-L1 therapy within 3 months prior to screening; * Subjects who have undergone major surgery or significant trauma within 4 weeks prior to apheresis, or who are expected to undergo major surgery during the study; * There are no other serious diseases that may limit subjects' participation in this trial; * Prior to pretreatment and infusion,the subject has a central nervous system disease sign or an abnormal neurological test result with clinical significance; * Prior to pretreatment, subjects developed, including but not limited to, new arrhythmias that could not be controlled with drugs, hypotension requiring pressor agent, bacterial, fungal or viral infections that required intravenous antibiotics. Creatinine clearance rate <50mL/min; The investigator judges that the subject is not suitable for continuing the trial. Subjects who use antibiotics to prevent infection can continue the trials if judged by the investigator; * According to the investigators' evaluation, patients are unable or unwilling to comply with the requirements of the study protocol. Sex : ALL Ages : - Minimum Age : 18 Years - Maximum Age : 75 Years - Age Group (Child: birth-17, Adult: 18-64, Older Adult: 65+) : ADULT, OLDER_ADULT Accepts Healthy Volunteers: No

{ "NCT_ID" : "NCT03851146", "Brief_Title" : "A Study of Anti-Lewis Y Chimeric Antigen Receptor-T Cells (LeY-CAR-T) in Patients With Solid Tumours", "Official_title" : "A Phase I Investigation of the Safety, Tolerability and Immunological Effects of T Lymphocytes Transduced With an Anti-Lewis Y (LeY) Chimeric Antigen Receptor Gene (LeY-CAR-T) in Patients With LeY Antigen Expressing Advanced Solid Tumours", "Conditions" : ["Advanced Cancer"], "Interventions" : ["Biological: LeY CAR T cells"], "Location_Countries" : ["Australia"], "Study_Design" : { "Study_Type" : "INTERVENTIONAL", "Phase" : ["PHASE1"], "Primary_Purpose" : "TREATMENT", "Allocation" : "NA", "Interventional Model" : "SEQUENTIAL", "Masking" : "NONE" } }

#Study Description Brief Summary This clinical trial is an open-label, single-centre, phase I study designed to investigate the safety and tolerability of a single infusion of autologous peripheral blood T-lymphocytes transduced with the anti-LeY-scFv-CD28-ζ vector (LeY CAR T-cells) The primary aim of the trial is to evaluate the safety and tolerability of LeY CAR T cells in patients with Lewis Y antigen-expressing, advanced solid tumours. The secondary aim of the trial is to assess the anti-tumour activity of LeY CAR T cells in patients with LeY antigen-expressing, advanced solid tumours. Patients aged 18 years or older with advanced solid tumours have consented to pre-screening that allows their tumours to be assessed for LeY expression by immunohistochemistry. Patients whose tumours test positive for LeY were then able to proceed to eligibility screening and, if found to fulfil the eligibility criteria, were registered in the study. The study involves an initial dose escalation phase followed by an expansion phase. Detailed Description To autologous peripheral blood T-lymphocytes transduced with the anti-LeY-scFv-CD28-ζ vector in patients with LeY expressing advanced solid tumours. evaluate the safety and tolerability of an intravenous infusion of autologous peripheral blood T-lymphocytes transduced with the anti-LeY-scFv-CD28-ζ vector in patients with LeY expressing advanced solid tumours. Aims: To evaluate the safety and tolerability of an intravenous infusion of autologous peripheral blood T-lymphocytes transduced with the anti-LeY-scFv-CD28-ζ vector in patients with LeY expressing advanced solid tumours. Primary Objectives To determine the maximum tolerated dose and rate of dose limiting toxicities of a single intravenous infusion of autologous peripheral blood T-lymphocytes transduced with the anti-LeY-scFv-CD28-ζ vector in patients with LeY expressing advanced solid tumours (LeY CAR T cells). Secondary Objectives i. To assess the anti-tumour activity of the LeY CAR T cells in terms of overall response, duration of response, progression free survival and overall survival. ii. To assess persistence in peripheral blood of the LeY CAR T cells. The study will recruit an anticipated number of 12 patients in the dose escalation phase consisting of 4 dose levels, each with dose level cohorts of 3 patients. Following completion of the dose-escalation phase, additional patients with Le Y expressing solid tumours will be recruited to the study. These patients will be administered the maximum number of cells safely delivered in the dose escalation phase of the study. A subset comprising 5 patients in the expansion cohort will be administered Indium-111 labelled T-cells and imaged by SPECT to determine the biodistribution of reinfused T cells. If the proposed number of T cells is unable to be obtained due to technical production reasons, the available number will be infused. It is anticipated that up to 30 patients will be treated on this protocol. #Intervention - BIOLOGICAL : LeY CAR T cells - Autologous peripheral blood T-lymphocytes transduced with the anti-LeY-scFv-CD28-ζ vector (LeY CAR T cells)

#Eligibility Criteria: Inclusion Criteria: All of the following must apply at the time of enrollment: * Patients with an advanced solid tumour (defined as incurable locally advanced or metastatic disease and excluding any haematologic malignancy). Tumour is positive for Lewis Y expression by immunohistochemistry - defined as a staining of >= 10 % of tumour cells positive for LeY expression. For the purposes of tumour screening, where possible the most recently available tumour sample should be utilised. A new biopsy is not mandatory where archival tissue is available, but may be considered. * Patient is >=18 years. * Patient has an ECOG performance status of 0 - 1 * Patient has provided written confirmation of informed consent on participant information and consent form * Life expectancy of >= 12 weeks * Patient has adequate organ function satisfying all of the following: * Liver: bilirubin <1.5x upper limit of normal (ULN) unless patient has known Gilbert's syndrome; * AST/ALT <=2.5 x ULN except in patients with known liver metastases where AST/ALT<=5.0 * Kidney: either serum creatinine <1.5x ULN or creatinine clearance > 50ml/min. Creatinine clearance is either derived using the Cockcroft-Gault formula or may be measured by 24 hour urine collection or nuclear medicine assessment. * Lung: Adequate pulmonary function defined by SaO2 >91% on room air and <= grade I dyspnoea. * Cardiac: LVEF >= 40% as confirmed by echocardiogram or multiple uptake gated acquisition (MUGA) * Adequate bone marrow reserve as defined as: * Absolute neutrophil count (ANC) >= 1.0 x 10e9/L * Absolute lymphocyte count >= 0.5 x 10e9/L * Platelets >= 100 x 10e9/L * Haemoglobin >80g/L * WCC <30 x 10e9/L * Patient is deemed capable and willing to undergo the planned study procedures in the view of the principal investigator. * Women of childbearing potential (defined as all women physiologically capable of becoming pregnant) and all male participants must agree to use highly effective methods of contraception for one year following LeY CART therapy. * Patient has measurable disease as per RECIST 1.1. Exclusion Criteria: Patients who meet any of the following criteria will be excluded from participation in this study: * Patients with known active central nervous system (CNS) involvement by malignancy. Patients with previous treated and/or neurologically stable disease will be eligible. * Prior chimeric antigen receptor T (CART) cell therapy * Patient has been given chemotherapy and/or G-CSF in the last 4 weeks or is planned to receive such therapy prior to apheresis of PBMC. Patients can only receive cytotoxic drugs as per the schedule of treatment for this protocol. * Patient has had immunosuppressive therapy within 4 weeks of apheresis. Therapeutic doses of steroids (defined as > 20 mg/day of Prednisolone (or equivalent) must be able to be stopped > 7 days prior to leukapheresis and 72 hours prior to LeY CART cell infusion Physiologic doses of steroid (e.g. Prednisolone <10mg or equivalent), topical and inhaled steroids are permitted. * Patient who are eligible for potentially curative therapy * Uncontrolled active or latent Hepatitis B or active Hepatitis C or HIV * Patients with uncontrolled systemic fungal, bacterial, viral or other infection despite appropriate antibiotics. * History or presence of active clinically relevant CNS pathology such as epilepsy, aphasia, severe brain injury, dementia, Parkinson's disease, cerebellar disease or psychosis. * Radiation therapy within 2 weeks prior to registration * Patient has an active haematologic malignancy (any lymphoma, leukaemia, multiple myeloma or myelodysplastic syndrome) * Patient has a history of significant pulmonary disease (including radiation pneumonitis) or known, biopsy proven autoimmune inflammatory disease of the gastrointestinal tract. * Unstable angina or myocardial infarct within 6 months prior to screening. * Patient has known clinically significant autoimmune disease with positive serology for RHF (>20kU/L) or ANA (titre >1:40). * Women of child bearing potential (WOCBP) who are unwilling or unable to use an effective method of contraception to avoid pregnancy for the entire study period and for at least 12 months after completion of study treatment. * Women who are pregnant or breastfeeding. * Men who are unwilling or unable to use an acceptable method of contraception for the entire study period and for at least 12 months after completion of study treatment if their sexual partners are WOCBP. * Patient has a serious uncontrolled medical disorder, psychological or social factors that which would impair the ability to receive protocol therapy and follow up. Sex : ALL Ages : - Minimum Age : 18 Years - Age Group (Child: birth-17, Adult: 18-64, Older Adult: 65+) : ADULT, OLDER_ADULT Accepts Healthy Volunteers: No

{ "NCT_ID" : "NCT05510596", "Brief_Title" : "Magnetic Resonance Imaging in Immune Effector Cell-Associated Neurotoxicity Syndrome", "Official_title" : "Contribution of Magnetic Resonance Imaging in Immune Effector Cell-Associated Neurotoxicity Syndrome", "Conditions" : ["Lymphoma, B-Cell", "Neurotoxicity"], "Interventions" : ["Other: Blood withdrawal", "Other: Neuropsychological tests", "Other: Magnetic Resonance Imaging with contrast injection"], "Location_Countries" : ["France"], "Study_Design" : { "Study_Type" : "INTERVENTIONAL", "Phase" : ["NA"], "Primary_Purpose" : "DIAGNOSTIC", "Allocation" : "NA", "Interventional Model" : "SINGLE_GROUP", "Masking" : "NONE" } }

#Study Description Brief Summary The treatment of large-cell B-cell lymphomas refractory to more than 2 lines of therapy has recently been revolutionized by the use of immunotherapies consisting of autologous genetically modified cells or CAR-T CELLS (chimeric antigen receptor-T cells), which very significantly increase progression-free survival and overall survival. Nevertheless, this therapy is frequently associated with cytokine release syndrome and in approximately 20% to 60% of patients with neurological complications that can sometimes be dramatic and are associated with a significant mortality rate. The mechanisms behind this neurotoxicity are unclear. Despite the frequent occurrence of neurological toxicity characterized in particular by headache, tremor, and encephalopathy that is most often transient, brain imaging by CT or, preferably, MRI are most often normal. The rare abnormalities that have been identified suggest the presence of cytotoxic edema associated with the existence of transient modifications of the blood-brain barrier. To date, the management of neurotoxicity associated with CAR-T CELLS remains empirical. It combines early management of cytokine release syndrome (by administration of anti-IL6) and treatment with corticosteroids, the objective of which would be to control neurotoxicity more specifically. A better understanding of the pathophysiological mechanisms associated with this neurotoxicity appears essential today in order to be able to propose adapted prevention and treatment methods. Main objectives are to compare tissue permeability by quantitative MRI measurement of Ktrans to the theoretical peak of neurotoxicity between patients with CAR-T Cell-induced neurotoxicity and those without neurotoxicity and to Study, by MRI, the evolution of tissue microcirculatory parameters (from D-3 to D7) between groups of patients with or without the occurrence of neurotoxicity associated with CAR-T CELL treatment. For this purpose, 25 subjects will be included (the investigators hypothesize 40% with treatment-induced neurological impairment). Detailed Description The treatment of large-cell B-cell lymphomas refractory to more than 2 lines of therapy has recently been revolutionized by the use of immunotherapies consisting of autologous genetically modified cells or CAR-T CELLS (chimeric antigen receptor-T cells), which very significantly increase progression-free survival and overall survival. Nevertheless, this therapy is frequently associated with cytokine release syndrome and in approximately 20% to 60% of patients with neurological complications that can sometimes be dramatic and are associated with a significant mortality rate. The mechanisms behind this neurotoxicity are unclear but may include : * A 'systemic' toxicity associated with the cytokine release syndrome. This toxicity would thus be favoured by the associated inflammatory response syndrome manifested in particular by hyperthermia, changes in blood pressure, and an increase in CRP, ferritin and the number of white blood cells. * A breakdown of the blood-brain barrier, as evidenced by increased protein levels, cellularity and cytokine levels in the cerebrospinal fluid. Among other things, this rupture could be promoted by the synthesis of proinflammatory cytokines (IL6, TNF-alpha, IFN-gamma) that would promote endothelial activation. * Direct toxicity to neurons and/or microglial cells. Despite the frequent occurrence of neurological toxicity characterized in particular by headache, tremor, and encephalopathy that is most often transient, brain imaging by CT or, preferably, MRI are most often normal. The rare abnormalities that have been identified suggest the presence of cytotoxic edema associated with the existence of transient modifications of the blood-brain barrier. To date, the management of neurotoxicity associated with CAR-T CELLS remains empirical. It combines early management of cytokine release syndrome (by administration of anti-IL6) and treatment with corticosteroids, the objective of which would be to control neurotoxicity more specifically. A better understanding of the pathophysiological mechanisms associated with this neurotoxicity appears essential today in order to be able to propose adapted prevention and treatment methods. Objectives: Main: \* To Compare tissue permeability by quantitative MRI measurement of Ktrans to the theoretical peak of neurotoxicity between patients with CAR-T Cell-induced neurotoxicity and those without neurotoxicity. Secondary: * To Study, by MRI, the evolution of tissue microcirculatory parameters (from D-3 to D7) between groups of patients with or without the occurrence of neurotoxicity associated with CAR-T CELL treatment. * To Correlate the values of the MRI parameters with the usual clinical and biological parameters known to be associated with the occurrence of neurotoxicity (at D0 and theoretical peak). * To Correlate the values of the MRI parameters with the values (at D0 and at NADIR) of a panel of cytokines of interest (V-PLEX Neuroinflammation Panel Human 1 Kit, Meso Scale Discovery®). #Intervention - OTHER : Magnetic Resonance Imaging with contrast injection - Magnetic Resonance Imaging with contrast injection - OTHER : Blood withdrawal - Blood withdrawal : serum, plasma, cytokine assay - OTHER : Neuropsychological tests - Neuropsychological tests

#Eligibility Criteria: Inclusion Criteria: * Subject aged from 18 years * Subject able to understand the nature, purpose and methodology of the study * Subject with diffuse large B-cell lymphoma to be treated with axicabtagene ciloleucel, tisagenlecleucel or brexucabtagene autoleucel for their lymphoma. Exclusion Criteria: * Refusal to sign the informed consent * Subject presenting a cerebral localization of his lymphoma * Contraindication to the realization of an MRI (metallic foreign body, pace-maker, cochlear implants) * Claustrophobic subject * Subject with a neurodegenerative disease (Parkinson's, Alzheimer's...) * Subject with psychiatric disorders such as psychosis, except for anxiety-depressive episodes * Subject with a systemic pathology with neurological manifestation * Subject with a previous or evolving neurological pathology * Subject with or with a history of severe head trauma (group 2 or 3 according to the Masters classification) * Contraindication to the use of gadoline contrast products (severe renal insufficiency, liver transplantation, known or suspected hypersensitivity to the product) * Pregnant or breastfeeding women * Patient under tutelage * Patient under curatorship * Patient deprived of liberty * Not a beneficiary of a social security system Sex : ALL Ages : - Minimum Age : 18 Years - Age Group (Child: birth-17, Adult: 18-64, Older Adult: 65+) : ADULT, OLDER_ADULT Accepts Healthy Volunteers: No

{ "NCT_ID" : "NCT04605666", "Brief_Title" : "CD19-CAR-T2 Cells for CD19 Positive B Cell Malignancies", "Official_title" : "CD19-Chimeric Antigen Receptor-T2 Cells for CD19 Positive Relapsed/Refractory B Cell Leukemia/Lymphoma", "Conditions" : ["B Cell Leukemia", "B Cell Lymphoma"], "Interventions" : ["Biological: CD19-CAR-T2 Cells"], "Location_Countries" : ["China"], "Study_Design" : { "Study_Type" : "INTERVENTIONAL", "Phase" : ["PHASE2"], "Primary_Purpose" : "TREATMENT", "Allocation" : "NA", "Interventional Model" : "SINGLE_GROUP", "Masking" : "NONE" } }

#Study Description Brief Summary Chimeric antigen receptor T cells (CAR-T cells) has been recognized a promising treatment option for treating B cell derived malignancy. The purpose of this study is to evaluate the efficacy and safety of third-generation anti-CD19 CAR T-cells (CD19-CAR-T2 Cells) in patients with CD19+ relapsed or refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL) and B-cell Non Hodgkin Lymphoma (B-NHL). #Intervention - BIOLOGICAL : CD19-CAR-T2 Cells - CD19-CAR-T2 T cells will be infused over 10-15 minutes on Day 0.

#Eligibility Criteria: Inclusion Criteria: * Patient with relapsed and/or refractory CD19+ B-cell leukemia or lymphoma * Eastern Cooperative Oncology Group (ECOG) performance status <2 * ALT/ AST <3 x normal * Bilirubin < 2.0 mg/dl * Creatinine < 2.5 mg/dl and less than 2.5x normal for age * LVEF< 45% * Accept white blood cell collection * Provide informed consent Exclusion Criteria: * Previous treatment with investigational gene or cell therapy medicine products * Active hepatitis B , hepatitis C or HIV infection * Uncontrolled active infection * Presence of grade 2 <= age <= 4 acute or extensive chronic GVHD * Any uncontrolled active medical disorder that would preclude participation as outlined. * Received non-diagnostic purposes major surgery within the past 4 weeks * Participated in any other clinical study within the past 4 weeks * Used murine biological products (except blinatumomab), unless it is proved no anti-mouse antibodies exist. * Pregnancy or breast-feeding women * Use of prohibited drugs: * Steroids: Therapeutic doses of steroids must be stopped > 72 hours prior to CD19-CAR-T2 Cells infusion * Allogeneic cellular therapy: Any donor lymphocyte infusions (DLI) must be completed > 4 weeks prior to CD19-CAR-T2 Cells infusion * GVHD therapies: Any drug used for GVHD must be stopped > 4 weeks prior to CD19-CAR-T2 Cells infusion * Any situation that may increase the risk of the test or interfere with the test results Sex : ALL Ages : - Minimum Age : 18 Years - Maximum Age : 85 Years - Age Group (Child: birth-17, Adult: 18-64, Older Adult: 65+) : ADULT, OLDER_ADULT Accepts Healthy Volunteers: No

{ "NCT_ID" : "NCT04835519", "Brief_Title" : "Phase I/II Study of Enhanced CD33 CAR T Cells in Subjects With Relapsed or Refractory Acute Myeloid Leukemia", "Official_title" : "Open-Label, Nonramdominzed, Single-Arm Phase I/II Study to Evaluate the Safety and Tolerability of Functionally Enhanced CD33 CAR T Cells in Subjects With Relapsed or Refractory Acute Myeloid Leukemia", "Conditions" : ["Acute Myeloid Leukemia", "Relapse Leukemia", "Refractory Acute Myeloid Leukemia"], "Interventions" : ["Biological: chimeric antigen receptor T cell"], "Location_Countries" : ["China"], "Study_Design" : { "Study_Type" : "INTERVENTIONAL", "Phase" : ["PHASE1", "PHASE2"], "Primary_Purpose" : "TREATMENT", "Allocation" : "NA", "Interventional Model" : "SINGLE_GROUP", "Masking" : "NONE" } }

#Study Description Brief Summary This is a open-label, nonramdominzed, single-arm, Phase I/II Study to evaluate safety and tolerability of functionally enhanced CD33 CAR-T cells in subjects with relapsed or refractory acute myeloid leukemia. 25 subjects will be enrolled. Subjects will be pretreated with chemotherapy prior to infusion of CAR T cells: about 5 days before cells transfusion, the patients who planned to reinfuse CAR T cells were treated with fluorodarabine 30 mg/m\^2( body surface area) and cyclophosphamide 250 mg/m\^2( body surface area) for 3 days. Then the Bayesian optimal interval phase I/II (Boin12) trial design will be used in this study: The protocol preset 2 dose levels: Dose 1 (DL-1) was 5×10\^5 (±20%) CAR T cells/kg, and dose 2 (DL-2) was 1×10\^6 (±20%) CAR T cells/kg. Phase I was the dose exploration phase. After determining the optimal biological dose (OBD), phase II will be expanded at the OBD dose by 10 cases, enrollment will reach 25 cases, and the trial will be discontinued. Moreover, the first 3 enrolled subjects per dose group will be on one by one dosing regimen. The expected initial dose of 5×10\^5 (±20%) CAR T cells/kg could not be achieved due to preparation problems and should be placed in the reduced dose group. The number of cells will be collected by the above regimen as far as possible. If this is not possible, subjects can still enter the study upon investigator consideration but require documentation of dosing. The lowest dose is 1×10\^5 CAR T cells/kg (±20%), and the highest dose is 1×10\^6 CAR T cells/kg (±20%). If the dose is out of the range mentioned above, entry into the trial will not be considered. #Intervention - BIOLOGICAL : chimeric antigen receptor T cell - Subjects will be pretreated with chemotherapy prior to infusion of CAR T cells: about 5 days before cells transfusion, the patients who planned to reinfuse CAR T cells were treated with fluorodarabine 30 mg/m\^2( body surface area) and cyclophosphamide 250 mg/m\^2( body surface area) for 3 days. Then this study will be using the Bayesian optimal interval phase I/II (Boin12) trial design. The protocol preset 2 dose levels: Dose 1 (DL-1) was 5×10\^5 (±20%) CAR T cells/kg, and dose 2 (DL-2) was 1×10\^6 (±20%) CAR T cells/kg. If the above dose cannot be met, subjects can still enter the study upon investigator consideration but require documentation of dosing. The lowest dose is 1×10\^5 CAR T cells/kg (±20%), and the highest dose is 1×10\^6 CAR T cells/kg (±20%). If the dose is out of the range mentioned above, entry into the trial will not be considered.

#Eligibility Criteria: Inclusion Criteria: In order to be eligible to participate in this study, an individual must meet all of the following criteria: * Candidates with relapse or refractory CD33+ acute myeloid leukemia, who have progressed on after treatment with all standard therapies or intolerant of standard care, have limited prognosis with currently available therapies and had no available curative treatment options (such as HSCT or chemotherapy) * Male or female, aged 1 <= age <= 70 years * No serious allergic constitution * Eastern Cooperative Oncology Group (ECOG) performance status (Oken et al.,1982) score 0 to 2 * Have life expectancy of at least 60 days based on investigator's judgement * CD33 positive in bone marrow or cerebrospinal fluid (CSF) by flow cytometry, or CD33 positive in tumor tissues by immunohistochemistry; (CD33 positive criteria: Flow cytometry: Positive: > 80% of tumor cells expressed CD33 and the MFI of CD33 is the same as that in normal myeloid cells; Dim: > 80% of tumor cells expressed CD33, but the MFI of CD33 is lower than that in normal myeloid cells as least as 1log; Partial positive: 20 <= age <= 80% of tumor cells expressed CD33 and the MFI of CD33 is the same as that in normal myeloid cells. Tumor tissue immunohistochemistry: Positive > 30% tumor cells expressed CD33); * Provide a signed informed consent before any screening procedure; subjects who voluntarily participate in the study should have the ability to understand and sign the informed consent form and be willing to follow the study visit schedule and relevant study procedure, as specified in the protocol. Candidates aged 19 <= age <= 70 years need to be sufficiently conscious and able to sign the treatment consent form and voluntary consent form. Pediatric patients aged 1 <= age <= 7 years could be recruited after signing an informed consent form by a legal surrogate (Guardian); pediatric patients aged 8 <= age <= 18 years need to be sufficiently conscious and voluntarily signed an informed consent form, and their legal surrogates (guardians) were also required to sign a written informed consent form. Exclusion Criteria: An individual who meets any of the following criteria will be excluded from participation in this study: * Intracranial hypertension or disorder of consciousness * Symptomatic heart failure or severe arrhythmia * Symptoms of severe respiratory failure * Complicated with other types of malignant tumors * Diffuse intravascular coagulation * Serum creatinine and / or blood urea nitrogen >= 1.5 times of the normal value * Suffering from septicemia or other uncontrollable infections * Patients with uncontrollable diabetes * Severe mental disorders * Obvious and active intracranial lesions were detected by cranial magnetic resonance imaging (MRI) * Have received organ transplantation (excluding hematopoietic stem cell transplantation); * Reproductive-aged female patients with positive blood HCG test * Screened to be positive of infection of hepatitis (including hepatitis B and C), AIDS or syphilis * Patients with tumor burden higher than 30% requiring reinfusion of autologous CAR-T cells. Sex : ALL Ages : - Minimum Age : 1 Year - Maximum Age : 70 Years - Age Group (Child: birth-17, Adult: 18-64, Older Adult: 65+) : ADULT, CHILD, OLDER_ADULT Accepts Healthy Volunteers: No

{ "NCT_ID" : "NCT04134117", "Brief_Title" : "Tisagenlecleucel in Primary CNS Lymphoma", "Official_title" : "Pilot Study of Tisagenlecleucel, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, in Patients with Primary Central Nervous System Lymphoma", "Conditions" : ["Primary CNS Lymphoma", "Refractory Primary CNS Lymphoma", "Relapsed Primary CNS Lymphoma"], "Interventions" : ["Biological: Tisagenlecleucel"], "Location_Countries" : ["United States"], "Study_Design" : { "Study_Type" : "INTERVENTIONAL", "Phase" : ["PHASE1"], "Primary_Purpose" : "TREATMENT", "Allocation" : "NA", "Interventional Model" : "SINGLE_GROUP", "Masking" : "NONE" } }

#Study Description Brief Summary In this study, is researching the safety of tisagenlecleucel in participants with primary central nervous system lymphoma. . -The name of the study intervention is tisagenlecleucel. Detailed Description This research study is a Pilot Study, which is the first time investigators are examining this intervention in people with primary central nervous system lymphoma. * The name of the study intervention is tisagenlecleucel. Tisagenlecleucel is an investigational treatment that uses the participants own immune cells, called T cells, to try to kill the cancerous cells * The research study procedures include screening for eligibility and study treatment including, leukapheresis, evaluations, and follow up visits. * The study treatment will be one day and participants will be followed for up to 2 years. * It is expected that about 6 people will take part in this research study #Intervention - BIOLOGICAL : Tisagenlecleucel - One time single predetermined dose level CAR-positive T cells will be utilized based on the FDA approved product label. - Other Names : - KYMRIAH

#Eligibility Criteria: Inclusion Criteria: Primary CNS Lymphoma in high risk elderly patients * New diagnosis of primary CNS lymphoma. * Voluntarily sign informed consent form(s) * >=60 years at the time of signing informed consent * Eastern Cooperative Oncology Group (ECOG) performance status 0 - 2 * Have failed or are unable to tolerate definitive first-line methotrexate based therapy as defined by: * Grade 3+ AKI and/or transaminitis preventing repeat treatment exposure and/or, * Failure to achieve a complete response (per IPCG) following two cycles of first line therapy, --- Definitive first-line therapies must include high dose methotrexate-based therapy but may also include temozolomide, high dose cytarabine, pemetrexed, lenalidomide, ibrutinib and rituximab. * Whole-brain irradiation, lenalidomide monotherapy and ibrutinib monotherapy are considered first line therapy if patient was not eligible for methotrexate-based chemotherapy at time of initial treatment but now meets study eligibility criteria. * Adequate absolute lymphocyte count (ALC > 500 cells/ul) within one week of apheresis. * Adequate bone marrow function defined by absolute neutrophil count (ANC) >1000 cells/mm3without growth factor support, and untransfused platelet count >50,000 mm3 within 7 days. * Left ventricular ejection fraction >40% * Adequate hepatic function defined by aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) <2.5 × upper limit of normal (ULN) and direct bilirubin <1.5 × ULN * Adequate renal function defined by creatinine clearance >30 ml/min using the Cockcroft-Gault formula * International ratio (INR) or partial thromboplastin time (PTT) <1.5 × ULN, unless on a stable dose of anticoagulant for a thromboembolic event. * The effects of tisagenlecleucel T cells on the developing human fetus are unknown. For this reason, women of child-bearing potential and men with partners of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to leukapheresis for at least 1-year post tisagenlecleucel infusion and until CAR T cells are no longer present by qPCR on two consecutive tests. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men with partners of childbearing potential treated or enrolled on this protocol must also agree to use adequate contraception prior to leukapheresis and until 4 months after tisagenlecleucel T cells administration. * Ability and willingness to adhere to the study visit schedule and all protocol requirements Relapsed/Refractory Primary CNS Lymphoma * Diagnosis of relapsed/refractory PCNSL having received at least one prior line of CNS directed therapy. * Voluntarily sign informed consent form(s) * >=18 years at the time of signing informed consent * Eastern Cooperative Oncology Group (ECOG) performance status 0 <= age <= 2 * Adequate absolute lymphocyte count (ALC > 500 cells/ul) within one week of apheresis. * Adequate bone marrow function defined by absolute neutrophil count (ANC) >1000 cells/mm3without growth factor support, untransfused platelet count >50,000 mm3, and untransfused hemoglobin >9 g/dL. * Left ventricular ejection fraction >40% * Adequate hepatic function defined by aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) <2.5 × upper limit of normal (ULN) and direct bilirubin <1.5 × ULN * Adequate renal function defined by creatinine clearance >30 ml/min using the Cockcroft-Gault formula * International ratio (INR) or partial thromboplastin time (PTT) <1.5 × ULN, unless on a stable dose of anticoagulant for a thromboembolic event. * The effects of tisagenlecleucel T cells on the developing human fetus are unknown. For this reason, women of child-bearing potential and men with partners of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to leukapheresis for at least 1-year post tisagenlecleucel infusion and until CAR T cells are no longer present by qPCR on two consecutive tests. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men with partners of childbearing potential treated or enrolled on this protocol must also agree to use adequate contraception prior to leukapheresis and until 4 months after tisagenlecleucel T cells administration. * Ability and willingness to adhere to the study visit schedule and all protocol requirements Inclusion Criteria for Lymphodepletion/Cell Infusion: * No Active, uncontrolled, systemic bacterial, viral, or fungal infection. * Adequate renal function defined by creatinine clearance >30 ml/min using the Cockcroft-Gault formula Exclusion Criteria: * Prior treatment with an any investigational cellular therapy. * Ongoing treatment with chronic immunosuppressants (e.g., cyclosporine). Systemic steroids are allowed up to a dose of dexamethasone 4mg daily or equivalent. * Ongoing systemic immunosuppression for acute and/or chronic GVH as a result of previous allogeneic bone marrow transplant. * Significant co-morbid condition or disease which in the judgment of the Principal Investigator would place the subject at undue risk or interfere with the study; examples include, but are not limited to, cirrhotic liver disease, sepsis, and/or recent significant traumatic injury. * Active, uncontrolled, systemic bacterial, viral, or fungal infection. * Active hepatitis B or hepatitis C infection. * HIV infection. * Subjects with a history of class III or IV congestive heart failure or non- ischemic cardiomyopathy. * Subjects with second malignancies if the second malignancy has required therapy in the last 3 years or is not in complete remission; exceptions to this criterion include successfully treated non-metastatic basal cell or squamous cell skin carcinoma, or prostate cancer that does not require therapy other than hormonal therapy. * Pregnant or lactating women * Live virus vaccines within 2 weeks prior to planned start of lymphodepleting chemotherapy. Sex : ALL Ages : - Minimum Age : 18 Years - Age Group (Child: birth-17, Adult: 18-64, Older Adult: 65+) : ADULT, OLDER_ADULT Accepts Healthy Volunteers: No

{ "NCT_ID" : "NCT03919526", "Brief_Title" : "Anti-CD19/CD22 Bispecific Chimeric Antigen Receptor（CAR)-T Cell Therapy for Measurable Residual Disease(MRD) Positive ALL", "Official_title" : "The Safety and Clinical Efficacy of Human CD19/CD22 Bispecific Chimeric Antigen Receptor (CAR)-T Cell Therapy for Subjects With Measurable Residual Disease(MRD)-Positive B Cell Acute Lymphoblastic Leukemia", "Conditions" : ["MRD-positive", "Acute Lymphoblastic Leukemia"], "Interventions" : ["Drug: Fludarabine", "Drug: Cyclophosphamide", "Biological: anti-CD19/CD22 CAR-T cells"], "Location_Countries" : ["China"], "Study_Design" : { "Study_Type" : "INTERVENTIONAL", "Phase" : ["PHASE1"], "Primary_Purpose" : "TREATMENT", "Allocation" : "NA", "Interventional Model" : "SINGLE_GROUP", "Masking" : "NONE" } }

#Study Description Brief Summary To evaluate the safety and efficacy of CD19/CD22 Bispecific chimeric antigen receptor (CAR)-T for the treatment of measurable residual disaese (MRD)-positive B cell acute lymphoblastic leukemia. Patients will be given a conditioning chemotherapy regimen of fludarabine and cyclophosphamide followed by a single infusion of CD19/CD22 CAR+ T cells. Detailed Description Participants with MRD-positive B cell acute lymphoblastic leukemia can participate if all eligibility criteria are met. Tests required to determine eligibility include disease assessments, a physical exam, Electrocardiograph, CT/MRI , and blood draws. Participants receive chemotherapy prior to the infusion of CD19/CD22 CAR+ T cells. After the infusion, participants will be followed for side effects and effect of CD19/CD22 CAR+ T cells. Study procedures may be performed while hospitalized. #Intervention - BIOLOGICAL : anti-CD19/CD22 CAR-T cells - Retroviral vector-transduced autologous T cells to express anti-CD19 and anti-CD22 CARs - DRUG : Fludarabine - 30mg/m2/d - DRUG : Cyclophosphamide - 300mg/m2/d

#Eligibility Criteria: Inclusion Criteria: * (1) CD19 positive/CD22 positive, or CD19-CD22 positive B-cell acute lymphoblastic leukemia; * (2)18 to 70 Years Old, Male and female; * (3) Expected survival > 12 weeks; * (4) ECOG score 0 <= age <= 2; * (5) Bone marrow examination clearly diagnosed as B-cell acute lymphoblastic leukemia and who met one of the following conditions: 1. Recurrent patients who achieves MRD-positive CR or CRi after standard therapy; 2. Those who achieves CR, but failed to achieve MRD-negative after at least 2 courses of consolidation therapy; 3. For Ph-positive ALL patients, a history of at least one TKI application is required in addition to two standard chemotherapy treatments * (6) The venous access required for collection can be established and mononuclear cell collection can be determined by the investigators; * (7) Liver, kidney and cardiopulmonary functions meet the following requirements: 1. Creatinine is in the normal range; 2. Left ventricular ejection fraction >50%; 3. Baseline oxygen saturation>92%; 4. Total bilirubin <= 2×ULN; 5. ALT and AST <= 2.5×ULN; * (8) Able to understand and sign the Informed Consent Document. Exclusion Criteria: * (1) Malignant tumors other than acute lymphoblastic leukemia within 5 years prior to screening, in addition to adequately treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, localized prostate cancer after radical resection, and ductal carcinoma in situ after radical resection; * (2) Subjects with positive HBsAg or HBcAb and peripheral blood HBV DNA titer detection >= 1 × 102 copy number / L; HCV antibody positive and peripheral blood HCV RNA positive; HIV antibody positive; CMV DNA positive; syphilis positive; * (3) Any instability of systemic disease, including but not limited to unstable angina, cerebrovascular accident, or transient cerebral ischemic (within 6 months prior to screening), myocardial infarction (within 6 months prior to screening), congestive heart failure (New York heart association (NYHA) classification >= III), need drug therapy of severe arrhythmia, liver, kidney, or metabolic disease; * (4) Active or uncontrollable infection requiring systemic therapy within 14 days prior to enrollment; * (5) Pregnant or lactating woman, and female subject who plans to have a pregnancy within 1 year after cell transfusion, or male subject whose partner plans to have a pregnancy within 1 year after cell transfusion; * (6) Received CAR-T treatment or other gene therapies before enrollment; * (7) Patients with symptoms of central nervous system; * (8) Subjects who are receiving systemic steroid treatment and requiring long-term systemic steroid treatment during the treatment as determined by the investigator before screening (except inhalation or topical use); And subjects treated with systemic steroids (except inhalation or topical use) within 72h prior to cell transfusion; * (9) The investigators consider other conditions unsuitable for enrollment. Sex : ALL Ages : - Minimum Age : 18 Years - Maximum Age : 70 Years - Age Group (Child: birth-17, Adult: 18-64, Older Adult: 65+) : ADULT, OLDER_ADULT Accepts Healthy Volunteers: No

{ "NCT_ID" : "NCT03389035", "Brief_Title" : "Transposon-manipulated Allogeneic CARCIK-CD19 Cells in Pediatric and Adult Patients With r/r ALL Post HSCT", "Official_title" : "Phase 1-2a Trial to Determine the Feasibility and Safety of a Single Dose of Transposon-manipulated Allogeneic CARCIK-CD19 Cells in Adult and Pediatric Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia, After Hematopoietic Stem Cell Transplantation", "Conditions" : ["Acute Lymphoblastic Leukemia, in Relapse"], "Interventions" : ["Biological: CARCIK-CD19"], "Location_Countries" : ["Italy"], "Study_Design" : { "Study_Type" : "INTERVENTIONAL", "Phase" : ["PHASE1", "PHASE2"], "Primary_Purpose" : "TREATMENT", "Allocation" : "NA", "Interventional Model" : "SEQUENTIAL", "Masking" : "NONE" } }

#Study Description Brief Summary This is a single arm, open-label, multi-center, phase 1-2a study to determine the Maximum Tolerated Dose and/or the Recommended Phase 2 Dose and the safety of CARCIK-CD19 in adult and pediatric patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. #Intervention - BIOLOGICAL : CARCIK-CD19 - Allogeneic (donor-derived) Cytokine Induced Killer (CIK) cells transduced with a transposon CD19 Chimeric Antigen Receptor (CAR) gene

#Eligibility Criteria: Inclusion Criteria: * Children (1 <= age <= 17) and adults (18 <= age <= 75 years); * Relapsed or refractory adult and pediatric B-cell precursor ALL after HSCT; * Evidence of CD19 tumor expression in bone marrow and/or peripheral blood by flow cytometry; * Bone marrow with >= 5% lymphoblasts by morphologic assessment at screening; * No evidence of overall aGVHD > Grade I or chronic GVHD (cGVHD) greater than mild at time of enrollment and in the previous 30 days; * No longer taking immunosuppressive agents for at least 30 days prior to enrollment; Exclusion Criteria: * Patients with GVHD Grades II-IV; * Any cell therapy in the last 30 days; Sex : ALL Ages : - Minimum Age : 1 Year - Maximum Age : 75 Years - Age Group (Child: birth-17, Adult: 18-64, Older Adult: 65+) : ADULT, CHILD, OLDER_ADULT Accepts Healthy Volunteers: No

{ "NCT_ID" : "NCT04260945", "Brief_Title" : "CD19/CD20 Dual-CAR-T in B-cell Leukemia Patients", "Official_title" : "CD19/CD20 Dual-CAR-T for Patients With B-cell Leukemia", "Conditions" : ["B-cell Leukemia"], "Interventions" : ["Biological: CD19/CD20 Dual-CAR-T cells"], "Location_Countries" : ["China"], "Study_Design" : { "Study_Type" : "INTERVENTIONAL", "Phase" : ["PHASE1"], "Primary_Purpose" : "TREATMENT", "Allocation" : "NA", "Interventional Model" : "SINGLE_GROUP", "Masking" : "NONE" } }

#Study Description Brief Summary This is a single center, single arm, open-label, phase I study to evaluate the safety and efficacy of CD19/CD20 Dual-CAR-T cells in patients with refractory and relapsed B-cell leukemia. Detailed Description This Phase I study is designed as a pilot trial evaluating the safety and efficacy of CD19/CD20 Dual-CAR-T cell therapy in subjects with refractory and relapsed B cell leukemia. Subjects will receive cytoreductive chemotherapy with cyclophosphamide and fludarabine on days -5, -4 and -3 followed by infusion of CD19/CD20 Dual-CAR-T cells. Safety and efficacy of CD19/CD20 Dual-CAR-T cells therapy will be monitored. The purpose of current study is to determine the clinical efficacy and safety of CD19/CD20 Dual-CAR-T cells therapy in patients with refractory and relapsed B-cell leukemia. #Intervention - BIOLOGICAL : CD19/CD20 Dual-CAR-T cells - CD19/CD20 Dual-CAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of CAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest for 2 days before infusion.CD19/CD20 Dual-CAR-T cells will be intravenously infused with a escalated dose of 0.6-3×106 cells/kg.

#Eligibility Criteria: Inclusion Criteria: * Relapsed and refractory B-cell acute malignancies with: * Relapsed after competed remission, could not get competed remission after at more than 1 course of chemotherapy (including MRD>=0.1%); * MRD>=0.1% after allogeneic hematopoietic stem cell transplantation(HSCT), or recurrence after complete remission or MRD >= 0.1% after HSCT; * Refractory: at least two courses of chemotherapy did not achieve complete remission or MRD >= 0.1%; * Patients must have evaluable evidence of disease, including minimal residual disease (MRD); * Ph + patients who meet the following criteria can register:Failure to tolerate TKI or TKI treatment failure, or failure to transplant; * Double positive expression of CD19 / CD20 in B cells; * Ages 1 <= age <= 70, including boundary values; * ECOG score 0 <= age <= 3 points; * Women of childbearing age (15 <= age <= 49 years) must receive a pregnancy test within 7 days prior to initiation of treatment and the results are negative; male and female patients with fertility must use an effective contraceptive to ensure 3 months after discontinuation of treatment during the study period not pregnant inside. * Patients who voluntarily sign informed consent and are willing to comply with treatment plans. Exclusion Criteria: * patients with organ failure: * Heart: NYHA heart function grade IV; * Liver: Grade C that achieves Child-Turcotte liver function grading; * Kidney: kidney failure and uremia; * Lung: symptoms of respiratory failure; * Brain: a person with a disability; * Active infections that are difficult to control; * Human immunodeficiency virus (HIV) positive; * Liver and kidney function: total bilirubin > 5 × ULN, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) > 5 × ULN, serum creatinine clearance rate 60mL / min; * GVHD >= 2 or anti-GVHD treatment; * Received allogeneic cell therapy within 4 weeks, such as donor lymphocyte infusion; * Subject received anti-tumor treatment (chemotherapy, mAb, or hormone) for less than 1 week; * Central nervous system white blood that is symptomatic or uncontrolled by systemic chemotherapy and intrathecal chemotherapy (a large number of tumor cells in CSF, white blood cell count >15WBCs/mL); * intracranial hypertension or unconsciousness; respiratory failure; diffuse vascular internal coagulation; * pregnant or lactating women; * The patient does not agree to use effective contraception during the treatment period and for the next 3 months; * Patients who participate in other clinical studies at the same time; * The investigator believes that there are other factors that are not suitable for inclusion or influence the subject's participation or completion of the study. Sex : ALL Ages : - Minimum Age : 1 Year - Maximum Age : 70 Years - Age Group (Child: birth-17, Adult: 18-64, Older Adult: 65+) : ADULT, CHILD, OLDER_ADULT Accepts Healthy Volunteers: No

{ "NCT_ID" : "NCT04026737", "Brief_Title" : "Cardiovascular Effects of CART Cell Therapy", "Official_title" : "Cardiovascular Effects of Chimeric Antigen Receptor T-Cell (CART Cell) Therapy: an Observational Prospective Study", "Conditions" : ["Leukemia", "Lymphoma", "Cardiotoxicity", "Risk Factor, Cardiovascular", "Immunotherapy"], "Location_Countries" : ["United States"], "Study_Design" : { "Study_Type" : "OBSERVATIONAL", } }

#Study Description Brief Summary This is an observational study aiming to prospectively define the rate of occurrence, natural history and progression of cardiac dysfunction in adults, and to identify the patients at high risk of developing cardiovascular events. The study enrolls patients prior to infusion with CART cell therapy and follows them with serial echocardiography, cardiac biomarkers, clinical data, and quality of life questionnaire. Detailed Description Patients have echo, blood draw, and QoL survey prior to CART infusion, then 2 days, 1 week, 1 month and 6 months following CART infusion. If patients experiences CRS, study team acquires echo within 72 hours of onset. As part of an optional substudy, patients wear an event monitor for 10 days, starting day of CART infusion.

#Eligibility Criteria: Inclusion Criteria: * At least 18 years * Diagnosed with CD19+ malignancy undergoing treatment with CART cells Exclusion Criteria: * Unable to provide informed consent Sex : ALL Ages : - Minimum Age : 18 Years - Age Group (Child: birth-17, Adult: 18-64, Older Adult: 65+) : ADULT, OLDER_ADULT Accepts Healthy Volunteers: No

{ "NCT_ID" : "NCT03054298", "Brief_Title" : "CAR T Cells in Mesothelin Expressing Cancers", "Official_title" : "Phase I Study of Human Chimeric Antigen Receptor Modified T Cells in Patients With Mesothelin Expressing Cancers", "Conditions" : ["Lung Adenocarcinoma", "Ovarian Cancer", "Peritoneal Carcinoma", "Fallopian Tube Cancer", "Mesotheliomas Pleural", "Mesothelioma Peritoneum"], "Interventions" : ["Biological: huCART-meso cells"], "Location_Countries" : ["United States"], "Study_Design" : { "Study_Type" : "INTERVENTIONAL", "Phase" : ["PHASE1"], "Primary_Purpose" : "TREATMENT", "Allocation" : "NON_RANDOMIZED", "Interventional Model" : "SEQUENTIAL", "Masking" : "NONE" } }

#Study Description Brief Summary Phase I study to establish safety and feasibility of both intravenous administration and local delivery of lentiviral transduced huCART-meso cells with or without lymphodepletion. Detailed Description This is a Phase I study evaluating the safety and feasibility of both intravenous administration and local delivery of lentiviral transduced huCART-meso cells with and without lymphodepleting chemotherapy. * Cohort 1 (N=3-6): will receive a single dose of 1-3x10\^7 huCARTmeso cells/m\^2 on day 0 without any conditioning chemotherapeutic regimen. * Cohort 2 (N=3-6): will receive a single dose of 1-3x10\^7 huCARTmeso cells/m\^2 on day 0, following a flat dose of 1 gram/m2 of cyclophosphamide administered 2-4 days prior to huCARTmeso cells (day -4 to day -2). * Cohort 3 (N=3-6): will receive a single dose of 1-3x10\^8 /m\^2 lentiviral transduced huCART-meso cells on day 0 without any conditioning chemotherapeutic regimen. \*\*Cohort 3 permanently closed\*\* * Cohort 4 subjects (N=3-6) will receive a single dose of 1-3x10\^8 /m\^2 lentiviral transduced huCART-meso cells on day 0, following a flat dose of 1 gram/m\^2 of cyclophosphamide administered 2-4 days prior to huCART-meso cells (day -4 to day -2). \*\*Cohort 4 permanently closed\*\* * Cohort 5 (N=up to 6): will receive a single dose of 1-3x10\^7 huCARTmeso cells/m\^2 on day 0 by intrapleural infusion (IP) through an indwelling pleural catheter without any conditioning chemotherapeutic regimen. The safety of this dose level has been established by Cohorts 1 and 2. * Cohort 6 (N=up to 6): will receive a dose of 1-3x10\^7 huCARTmeso cells/m\^2 via IV infusion on Day 0, following a flat dose of 1 gram/m\^2 of cyclophosphamide administered 2-4 days prior to huCART-meso cells (\~Day -4 to -2). This initial infusion may be followed by up to two additional IV infusions of huCART-meso cells at the same dose level, given between 21-42 days apart, if the subject meets eligibility to receive additional infusions. Cyclophosphamide will not be repeated prior to subsequent doses of huCART-meso cells. Enrollment into Cohort 6 will occur in parallel with Cohort 5. * Cohort 7 (N = up to 6): will receive a single dose of 1-3x10\^7 huCART-meso cells/m\^2 via intraperitoneal (i.p.) administration, following lymphodepleting chemotherapy with cyclophosphamide 300 mg/m\^2/day and fludarabine 30 mg/m\^2/day given over 3 days by intravenous infusion. Lymphodepleting chemotherapy will be scheduled such that the last day of chemotherapy is 3 days (+/- 1 day) prior to the 1st infusion of huCART-meso cells. This initial i.p. infusion may be followed by up to two additional infusions of huCART-meso cells via intravenous (IV) administration at the same dose level, given between 21-42 days apart. The subject must meet eligibility to receive additional infusions. Lymphodepleting chemotherapy will not be repeated prior to additional infusions of huCART-meso cells. The Maximum Tolerated Dose (MTD) is defined as the dose at which 0-1 DLT occurs in 6 evaluable subjects tested within the dose range of this study. The maximum tolerated dose has been established as 1-3x10\^7 huCARTmeso cells/m\^2. Adverse events will be collected and evaluated during the protocol specified adverse event reporting period #Intervention - BIOLOGICAL : huCART-meso cells - Intravenous administration or local delivery of lentiviral transduced huCART-meso cells in 7 cohorts with or without lymphodepletion..

#Eligibility Criteria: Inclusion Criteria * Histologically confirmed cancer (one of the following): 1. Cohorts 1 <= age <= 4 and Cohort 6 participants: **Note: Cohorts 3 and 4 permanently closed** * Metastatic or recurrent lung adenocarcinoma. * Persistent or recurrent serous epithelial ovarian cancer or primary peritoneal carcinoma or fallopian tube carcinoma * Malignant pleural and peritoneal mesothelioma (histologically confirmed epithelial) 2. Cohort 5 participants: **Note: As of 1-Feb-2021 lung adenocarcinoma patients are no longer being enrolled in this trial** * Metastatic or recurrent lung adenocarcinoma with documented pleural effusion * Persistent or recurrent serous epithelial ovarian cancer or primary peritoneal carcinoma or fallopian tube carcinoma with documented pleural effusion * Malignant pleural and peritoneal mesothelioma (histologically confirmed epithelial) with documented pleural effusion 3. Cohort 7 patients: * Persistent or recurrent serous epithelial ovarian cancer or primary peritoneal carcinoma or fallopian tube carcinoma with evidence of ascites * Malignant peritoneal mesothelioma (histologically confirmed epithelial) * CRITERIA HAS BEEN RETIRED * Failure of at least one prior standard of care chemotherapy for advanced stage disease. ALLOWANCE FOR PRIOR PD-1 or PDL-1 THERAPIES REMOVED. * Patients must have measurable disease as defined by RECIST 1.1 criteria or modified RECIST criteria (mesothelioma only). * Subjects with asymptomatic CNS metastases that have been treated (and are off steroids for the treatment of CNS disease) are allowed. They must meet the following at the time of enrollment: 1. No concurrent treatment for the CNS disease 2. No progression of CNS metastasis on MRI at screening scans 3. No evidence of leptomeningeal disease or cord compression * Subjects >= 18 years. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Satisfactory organ and bone marrow function as defined by the following: * Absolute neutrophil count >= 1,000/μl * Platelets >=75,000/μl * Hemoglobin >= 8 g/dL * Direct bilirubin <= 2.0 mg/dl unless secondary to bile duct obstruction by tumor or Gilbert's syndrome with a direct bilirubin of less that 3.0 mg/dl is allowed. * Creatinine <= 1.5x the institutional normal upper limit * Albumin >= 2 * Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) <= 5x the institutional normal upper limit * Cardiac ejection fraction of >=40% as measured by resting echocardiogram, with no clinically significant pericardial effusion. * Blood coagulation parameters: PT such that international normalized ratio (INR) is <= 1.5 and a PTT <= 1.2 time the upper limit of normal unless the patient is therapeutically anti-coagulated for history of cancer-related thrombosis and has stable coagulation parameters. * Provide written informed consent. * Subjects of reproductive potential must agree to use acceptable birth control methods. Exclusion Criteria * Sarcomatoid and biphasic mesothelioma. * Known leptomeningeal carcinomatosis or spinal cord compression. Screening for this is not required unless suspicious symptoms. * Subjects with symptomatic CNS metastases are excluded. * EXCLUSION CRITERIA HAS BEEN RETIRED * Active invasive cancer other than the one of the three cancers in this study. Subjects with active non-invasive cancers (such as non-melanoma skin cancer, superficial cervical and bladder and prostate cancer with PSA level < 1.0) are not excluded. * HIV infection * Active hepatitis B or hepatitis C infection * Active autoimmune disease (including but not limited to: systemic lupus erythematosus, Sjogren's syndrome, rheumatoid arthritis, psoriasis, multiple sclerosis, inflammatory bowel disease, etc.) requiring immunosuppressive therapy within four (4) weeks prior to eligibility confirmation by physician-investigator, with the exception of thyroid replacement. * Patients with ongoing or active infection. * Dependence on systemic steroids or immunosupressant medications. * Patients requiring supplemental oxygen therapy. * Prior therapy with lentiviral gene modified cells. * History of allergy or hypersensitivity to study product excipients (human serum albumin, DMSO, and Dextran 40) * Any clinically significant pericardial effusion, Class II-IV cardiovascular disability according to the New York Heart Association Classification or other cardiovascular condition that would preclude assessment of mesothelin induced pericarditis, or which may worsen as a result of expected toxicities in this study. This determination will be made by a cardiologist if cardiac issues are suspected. * Any clinically significant pleural or peritoneal effusion that cannot be drained with standard approaches. An indwelling drainage device placed prior to eligibility confirmation by physician / investigator is acceptable. * Pregnant or breastfeeding women. * EXCLUSION HAS BEEN RETIRED * EXCLUSION HAS BEEN RETIRED * Subjects with significant lung disease as follows: * Subjects with radiographic evidence of greater than lobar lymphangitic pulmonary involvement, greater than lobar bronchial wall thickening suggestive of peribronchial lymphatic disease extension, and/or evidence of extensive bilateral parenchymal metastatic burden. * Subjects with radiographic and/or clinical evidence of active radiation pneumonitis. * Subjects with radiographic evidence of underlying interstitial lung disease, including evidence of unresolved drug toxicity from any agent (e.g. chemotherapy, targeted agents, amiodarone, nitrofurantoin, etc.) Sex : ALL Ages : - Minimum Age : 18 Years - Age Group (Child: birth-17, Adult: 18-64, Older Adult: 65+) : ADULT, OLDER_ADULT Accepts Healthy Volunteers: No

{ "NCT_ID" : "NCT03483688", "Brief_Title" : "A PhaseⅠb Study Evaluating Safety and Efficacy of C-CAR011 Treatment in B- NHL Subjects", "Official_title" : "A Phase Ⅰb Study Evaluating Safety and Efficacy of Anti-CD19 Chimeric Antigen Receptor T-cell (C-CAR011) Treatment in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma", "Conditions" : ["B-cell Non-Hodgkin Lymphoma"], "Interventions" : ["Biological: CD19-directed CAR-T cells"], "Location_Countries" : ["China"], "Study_Design" : { "Study_Type" : "INTERVENTIONAL", "Phase" : ["PHASE1"], "Primary_Purpose" : "TREATMENT", "Allocation" : "NA", "Interventional Model" : "SINGLE_GROUP", "Masking" : "NONE" } }

#Study Description Brief Summary This is a single arm, single-center, non-randomized study to evaluate the safety and efficacy of C-CAR011 therapy in relapsed or refractory B cell Non-Hodgkin Lymphoma (NHL). Detailed Description The study will include the following sequential phases: Screening, Pre- Treatment (Cell Product Preparation; Lymphodepleting Chemotherapy), Treatment and Follow-up #Intervention - BIOLOGICAL : CD19-directed CAR-T cells - CD19-directed CAR-T cells single infusion intravenously at a target dose of 0.5-5.0 x 10\^6 anti-CD19 CAR+ T cells/kg - Other Names : - Anti-CD19 chimeric antigen receptor T cells (C- CAR011)

#Eligibility Criteria: Inclusion Criteria: * Volunteered to participate in this study and signed informed consent. * Age 18 <= age <= 70 years, male or female. * Relapse or refractory B cell non-Hodgkin's lymphoma ,Histologically diagnosed as DLBCL,follicular lymphoma and Mantle cell lymphoma according to the NCCN. nonHodgkin's lymphoma Clinical Practice Guidelines (2017 Version 1) 1. DLBCL and Follicular Lymphoma (stage Ⅲ-Ⅳ, grade Ⅲb). 1. Progressive disease after the last standard chemotherapy regimens. 2. Stable disease after the last standard chemotherapy regimens(at least 4 cycles of first-line therapy or 2 cycles of later-line therapy). 3. Relapse or progressive disease within 12 months after autologous stem cell transplantation (SCT). 2. Follicular lymphoma (stage Ⅲ-Ⅳ) (gradeⅠ-Ⅲa) 1. Relapse or progressive disease within 1 year after the last standard chemotherapy regimens(At least 2 combination chemotherapy regimens). 2. Stable disease after the last standard chemotherapy regimens(at least 2 cycles of combination chemotherapy regimens). 3. Mantle cell lymphoma 1. Relapse after 1st CR or persistent disease, and not eligible or appropriate for SCT. 2. Relapse or progressive disease within 1 year after the last chemotherapy regimens(at least 4 cycles of first-line therapy or 2 cycles of later- line therapy). 3. Relapse or progressive disease within 12 months after autologous SCT. * All subjects must have received anti-CD20 monoclonal antibody (unless tumor is CD20-negative) and anthracycline-containing chemotherapy regimens according to NCCN non-Hodgkin lymphoma Clinical Practice Guidelines (2017 Version 1). * At least one measurable lesion per revised IWG Response Criteria (the longest diameter of the tumor >= 1.5cm). * Expected survival >= 12 weeks. * ECOG score 0 <= age <= 1. * Left ventricular ejection fraction (LVEF) >= 50% (detected by echocardiography). * No active pulmonary infections, normal pulmonary function and oxygen saturation >= 92% on room air. * At least 2 weeks from receiving previous treatment (radiotherapy or chemotherapy) prior to leukapheresis. * No contraindications of leukapheresis. * Female subjects in childbearing age, their serum or urine pregnancy test must be negative, and must agree to take effective contraceptive measures during the trial. Exclusion Criteria: * History of allergy to cellular products. * Laboratory tests: absolute neutrophil count < 1.0 × 10^9 /L, platelet count < 50×10^9 /L, serum albumin < 30 g/L,serum bilirubin > 1.5 ULN, serum creatinine > ULN, ALT/AST > 3 ULN. * History of CAR T cell therapy or any other genetically modified T cell therapy. * Relapse after allogeneic hematopoietic stem cell transplantation. * Active infections that require treatment (uncomplicated urinary tract infections and bacterial pharyngitis are allowed), prophylactic antibiotic, antiviral and antifungal treatment are permitted. * Hepatitis B or hepatitis C virus infection (including carriers), syphilis, as well as acquired or congenital immune deficiency diseases, including but not limited to HIV infection. * Class III or IV heart failure according to the NYHA Heart Failure Classifications. * QT interval prolongation >= 450 ms. * History of epilepsy or other central nervous system disorders. * Evidence of CNS lymphoma by head enhancement scan or magnetic resonance imaging. * History of other primary cancers, with the following exceptions. 1. Excisional non-melanoma (e.g. cutaneous basal cell carcinoma). 2. Cured in situ carcinoma (e.g. cervical cancer, bladder cancer, breast cancer). * Autoimmune diseases that require treatment, immune deficiency diseases or other diseases that require immunosuppressive therapy. * Used of systemic steroids within two weeks (using inhaled steroids is an exception). * Women who are pregnant or lactating, or who have breeding intent in 6 months. * Participated in any other clinical trial within three months. * Any situation that investigators believe the risk of the subjects is increased or results of the trial are disturbed. Sex : ALL Ages : - Minimum Age : 18 Years - Maximum Age : 70 Years - Age Group (Child: birth-17, Adult: 18-64, Older Adult: 65+) : ADULT, OLDER_ADULT Accepts Healthy Volunteers: No

{ "NCT_ID" : "NCT03287817", "Brief_Title" : "CD19/22 CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma", "Official_title" : "A Single Arm, Open-label, Multi-centre, Phase I/II Study Evaluating the Safety and Clinical Activity of AUTO3, a CAR T Cell Treatment Targeting CD19 and CD22 With Anti PD1 Antibody in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma", "Conditions" : ["Diffuse Large B Cell Lymphoma", "Relapsed Diffuse Large B-Cell Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma", "DLBCL"], "Interventions" : ["Biological: AUTO3"], "Location_Countries" : ["United States", "United Kingdom"], "Study_Design" : { "Study_Type" : "INTERVENTIONAL", "Phase" : ["PHASE1", "PHASE2"], "Primary_Purpose" : "TREATMENT", "Allocation" : "NA", "Interventional Model" : "SINGLE_GROUP", "Masking" : "NONE" } }

#Study Description Brief Summary The purpose of this study is to test the safety and efficacy of AUTO3, a CAR T cell treatment targeting CD19 and CD22 followed by limited duration of anti-PD1 antibody in patients with DLBCL Detailed Description The study will consist of 2 phases, a Phase I or dose escalation and expansion phase, and a Phase II. Patients with relapsed or refractory DLBCL will be enrolled in both phases of the study. Eligible patients will undergo leukapheresis in order to harvest T cells, which is the starting material for the manufacture of the autologous CAR T product AUTO3 which is a CD19 and CD22 dual targeting CAR T cell product. Following pre-conditioning by a chemotherapeutic regimen, the patient will receive AUTO 3 intravenously as a single dose and in addition a limited duration of treatment with an anti-PD1 antibody (either as part of the pre-conditioning regimen or consolidation). Patients will then enter a 36-month follow-up period. #Intervention - BIOLOGICAL : AUTO3 - Following preconditioning with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with doses from 50 x 10⁶ to 900 x 10⁶ CD19/ CD22 Chimeric Antigen Receptor (CAR) positive T cells followed by limited duration of anti-PD1 antibody (pembrolizumab).

#Eligibility Criteria: Inclusion Criteria: * Male or female, aged >=18 years. * Willing and able to give written, informed consent. * Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to 1. * Histologically confirmed DLBCL and large B cell lymphoma (at last relapse) subsets, including: Phase I and Phase II Cohort 1: 1. DLBCL, not otherwise specified (NOS), per World Health Organisation classification and DLBCL with MYC and BCL2 and/or BCL6 rearrangements (double/triple hit). 2. Transformed DLBCL from FL. 3. High-grade B cell lymphoma with MYC expression (excluding Burkitt's lymphoma) Phase I and Phase II Cohort 2: 4. Transformed DLBCL from other indolent lymphomas (excluding Richter's transformation). 5. Primary mediastinal large B cell lymphoma. * Chemotherapy-refractory disease, defined as one or more of the following: 1. Stable disease (<=12 months) or progressive disease as best response to most recent chemotherapy containing regimen. Refractory disease after frontline chemo-immunotherapy is allowed. 2. Disease progression or recurrence in <=12 months of prior autologous haematopoietic stem cells transplantation (ASCT). OR * Relapse after >=two lines of therapy or after ASCT. At a minimum: 1. Patients must have received rituximab or another anti-CD20 monoclonal antibody (unless Investigator determines that tumour is CD20-negative) and an anthracycline-containing chemotherapy regimen. 2. Patients must have either failed ASCT, or be ineligible for or not consenting to ASCT. 3. Patients with transformed DLBCL must have received at least one line of therapy after transformation to DLBCL. * PET-positive disease per Lugano classification. * For females of childbearing potential, a negative serum or urine pregnancy test must be documented at screening, prior to pre-conditioning and confirmed before receiving the first dose of study treatment. For females who are not postmenopausal or surgically sterile, highly effective methods of contraception must be used during the treatment period and for at least 12 months after the last dose of study treatment. * For males, it must be agreed that that two acceptable methods of contraception are used. * Adequate renal, hepatic, pulmonary, and cardiac function defined as: 1. Creatinine clearance >=40 cc/min. 2. Serum alanine aminotransferase / aspartate aminotransferase <=2.5 x ULN. 3. Total bilirubin <=1.5 x ULN, except in subjects with Gilbert's syndrome. 4. LVEF >=50% (by ECHO or MUGA) unless the institutional lower limit of normal is lower. 5. Baseline oxygen saturation >92% on room air and <=Grade 1 dyspnoea. * Patient has adequate BM function without requiring ongoing blood product or granulocyte-colony stimulating factor support and meets the following criteria: 1. Absolute neutrophil count >=1.0 × 109/L. 2. Absolute lymphocyte count >=0.3 × 109/L (at enrolment and prior to leukapheresis). 3. Haemoglobin >=80 g/L. 4. Platelets >=75 × 109/L * No contra-indications for leukapheresis. Exclusion Criteria: * Prior allogeneic haematopoietic stem cell transplant. * Females who are pregnant or lactating. * History or presence of clinically relevant CNS pathology such as epilepsy, paresis, aphasia, stroke within prior 3 months, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, uncontrolled mental illness, or psychosis. * Patients with active CNS involvement by malignancy. Patients with history of CNS involvement with malignancy may be eligible if CNS disease has been effectively treated and provided treatment was at least 4 weeks prior to enrolment (at least 8 weeks prior to AUTO3 infusion). * Clinically significant, uncontrolled heart disease or a recent (within 12 months) cardiac event. 1. Uncontrolled cardiac arrhythmia (patients with rate-controlled atrial fibrillation are not excluded). 2. Evidence of pericardial effusion * Patients with a history (within 3 months) or evidence of deep vein thrombosis or pulmonary embolism requiring ongoing therapeutic anticoagulation at the time of pre-conditioning. * Patients with active gastrointestinal bleeding. * Patients with any major surgical intervention in the last 3 months. * Active bacterial, viral or fungal infection requiring systemic treatment. Active or latent hepatitis B infection or hepatitis C infection. Testing positive for human immunodeficiency virus, human T cell lymphotropic virus (HTLV1 and 2) or syphilis. * History of autoimmune disease resulting in end organ injury or requiring systemic immunosuppression/systemic disease modifying agents within the last 24 months. * Patients with a known history or prior diagnosis of optic neuritis or other immunologic or inflammatory disease affecting the CNS. * Evidence of active pneumonitis on chest computed tomography (CT) scan at screening or history of drug-induced pneumonitis, idiopathic pulmonary fibrosis, organising pneumonia, or idiopathic pneumonitis. * History of other malignant neoplasms unless disease free for at least 24 months (carcinoma in situ, non-melanoma skin cancer, breast or prostate cancer on hormonal therapy allowed). * Prior treatment with PD1, PD-L1, or cytotoxic T lymphocyte-associated protein-4-targeted therapy, or tumour necrosis factor (TNF) receptor superfamily agonists within 6 weeks prior to AUTO3 infusion. * Prior treatment with investigational or approved gene therapy or cell therapy products until a dose level has treated at least three patients and has been declared safe. * Prior CD19 or CD22 targeted therapy. * The following medications are excluded: 1. Steroids: Therapeutic doses of corticosteroids within 7 days of leukapheresis or 72 hours prior to AUTO3 administration. However, physiological replacement, topical, and inhaled steroids are permitted. 2. Immunosuppression: Immunosuppressive medication must be stopped >=2 weeks prior to leukapheresis or AUTO3 infusion. 3. Cytotoxic chemotherapies within 2 weeks of AUTO3 infusion and 1 week prior to leukapheresis (2 weeks for lymphodepleting chemotherapy). 4. Antibody therapy use including anti-CD20 therapy within 2 weeks prior to AUTO3 infusion, or 5 half-lives of the respective antibody, whichever is shorter. 5. Granulocyte-colony stimulating factor less than 10 days prior to leukapheresis. 6. Live vaccine <=4 weeks prior to enrolment. 7. Prophylactic intrathecal therapy: Methotrexate within 4 weeks and other intrathecal chemotherapy (e.g. Ara-C) within 2 weeks prior to starting pre-conditioning chemotherapy. * Prior limited radiation therapy within 4 weeks of AUTO3 infusion or within 24 weeks for definitive radiation to chest. * Research participants receiving any other investigational agents, or concurrent biological, chemotherapy, or radiation therapy. * Known allergy to albumin, dimethyl sulphoxide (DMSO), cyclophosphamide or fludarabine, pembrolizumab or tocilizumab. * Any contraindications to receive anti-PD1 antibody pembrolizumab will be excluded from cohorts requiring administration of pembrolizumab. * Patients, who in the opinion of the Investigator, may not be able to understand or comply with the safety monitoring requirements of the study. * Any other condition that in the Investigator's opinion would make the patient unsuitable for the clinical trial. Phase I outpatient cohort: * Subjects who do not have caregiver support (in line with institutional outpatient transplant guidelines) for outpatient/ambulatory care setting. * Subjects who are staying greater than 60 minutes (or whatever is permissible per institutional outpatient transplant guidelines) from the clinical trial site at the time of treatment. For AUTO3 Infusion: Patients meeting any of the following exclusion criteria must not be treated with AUTO3 or have treatment delayed until they no longer meet these criteria: * Severe intercurrent infection. * Requirement for supplementary oxygen or active pulmonary infiltrates. * Clinical deterioration of organ function (renal and hepatic) exceeding the criteria set at study entry. Sex : ALL Ages : - Minimum Age : 18 Years - Age Group (Child: birth-17, Adult: 18-64, Older Adult: 65+) : ADULT, OLDER_ADULT Accepts Healthy Volunteers: No

{ "NCT_ID" : "NCT04572308", "Brief_Title" : "Cell Therapy for CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD7-Specific CAR-T Cells", "Official_title" : "Cell Therapy for CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD7-Specific CAR-T Cells", "Conditions" : ["T-cell Acute Lymphoblastic Leukemia/Lymphoma"], "Interventions" : ["Biological: CD7 CAR-T"], "Location_Countries" : ["China"], "Study_Design" : { "Study_Type" : "INTERVENTIONAL", "Phase" : ["PHASE1"], "Primary_Purpose" : "TREATMENT", "Allocation" : "NA", "Interventional Model" : "SINGLE_GROUP", "Masking" : "NONE" } }

#Study Description Brief Summary This is an open, single-arm, clinical study to evaluate efficacy and safety of anti CD7 CAR-T cell in the treatment of relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (TLBL). Detailed Description The CARs consist of an anti-CD7 single-chain variable fragment（scFv）, a portion of the human CD137（4-1BB） molecule, and the intracellular component of the human CD3ζ molecule. Prior to CAR-T cell infusion, the patients will be subjected to preconditioning treatment. After CAR-T cell infusion, the patients will be evaluated for adverse reactions and efficacy. The Main research objectives: To evaluate the safety and efficacy of CD7 CAR-T cells in patients with relapsed or refractory T-ALL/LBL The Secondary research objectives: To investigate the cytokinetic characteristics of CD7 CAR-T cells in patients with relapsed or refractory T-ALL/LBL #Intervention - BIOLOGICAL : CD7 CAR-T - Patients will be treated with CD7 CAR-T cells Biological: CD7 CAR-T; Drug: Cyclophosphamide,Fludarabine; Procedure: Leukapheresis;

#Eligibility Criteria: Inclusion Criteria: * Diagnosis of refractory or relapsed T-cell acute lymphoblastic leukemia (T-ALL) or lymphoblastic lymphoma (T-LBL) according to the NCCN 2019.V2 Guideline. Refractory T-ALL is defined as a patient who has failed to achieve complete remission after induction therapy. Relapsed T-ALL is defined as the reappearance of blasts (5%) in either peripheral blood or bone marrow. Patients whose tumor burden >5% blasts, or who have persistent positive minimal residual disease (MRD), or have reappearance of extramedullary lesions are also considered eligible. * CD7-positive tumor (>=70% CD7 positive blasts by flow cytometry or immunohistochemistry (tissue) assessed by a CLIA certified Flow Cytometry/Pathology laboratory). tumors burden >5%,or MRD+， or new extramedullary lesions reappeared. * Life expectancy greater than 12 weeks * KPS or Lansky score>=60 * HGB>=70g/L * oxygen saturation of blood>90% * Total bilirubin (TBil)<=3 × upper limit normal, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <= 5×upper limit of normal * Informed consent explained to, understood by and signed by patient/guardian. Exclusion Criteria: * Any of the following cardiac criteria: Atrial fibrillation/flutter; Myocardial infarction within the last 12 months; Prolonged QT syndrome or secondary prolonged QT, per investigator discretion. Cardiac echocardiography with LVSF (left ventricular shortening fraction)<30% or LVEF(left ventricular ejection fraction)<50%; or clinically significant pericardial effusion. Cardiac dysfunction NYHA(New York Heart Association) III or IV (Confirmation of absence of these conditions on echocardiogram within 12 months of treatment) * Has an active GvHD; * Has a history of severe pulmonary function damaging; * With other tumors which is/are in advanced malignant and has/have systemic metastasis; * Severe or persistent infection that cannot be effectively controlled； * Presence of severe autoimmune diseases or immunodeficiency disease; * Patients with active hepatitis B or hepatitis C([HBVDNA+]or [HCVRNA+]); * Patients with HIV infection or syphilis infection; * Has a history of serious allergies to biological products (including antibiotics); * Clinically significant viral infection or uncontrolled viral reactivation of EBV(Epstein-Barr virus), CMV(cytomegalovirus), ADV(adenovirus), BK-virus, or HHV(human herpesvirus)-6. * Presence of any symtomatic CNS disorder such as an uncontrolled seizure disorder, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease with CNS involvement; * Received allogeneic hematopoietic stem cell transplantation within 6 months; * Being pregnant and lactating or having pregnancy within 12 months; * Any situations that the researchers believe will increase the risks for the subject or affect the results of the study. Sex : ALL Ages : - Minimum Age : 2 Years - Maximum Age : 65 Years - Age Group (Child: birth-17, Adult: 18-64, Older Adult: 65+) : ADULT, CHILD, OLDER_ADULT Accepts Healthy Volunteers: No

{ "NCT_ID" : "NCT03029338", "Brief_Title" : "CD19 CAR T Cells in Patients With Relapsed or Refractory CD19 Positive B-cell Lymphoma", "Official_title" : "CD19 CAR T Cells in Patients With Relapsed or Refractory CD19 Positive B-cell Lymphoma", "Conditions" : ["Lymphomas Non-Hodgkin's B-Cell", "Relapse"], "Interventions" : ["Biological: CD19 CAR T cells"], "Location_Countries" : ["China"], "Study_Design" : { "Study_Type" : "INTERVENTIONAL", "Phase" : ["PHASE1"], "Primary_Purpose" : "TREATMENT", "Allocation" : "NA", "Interventional Model" : "SINGLE_GROUP", "Masking" : "NONE" } }

#Study Description Brief Summary In this single-center, open-label, no control, prospective clinical trial, a total of 10 relapsed or refractory CD19 positive B-cell Non-Hodgkin Lymphoma (NHL) patients will be enrolled.CD19 CAR T cells(total dose of 2×10\^6/kg-1×10\^7/kg) will be intravenously infused to patient in a three-day split-dose regimen: 10% on day 0, 30% on day 1 and 60% on day 2. The purpose of current study is to determine the clinical efficacy and safety of CD19 CAR T cells in patients with relapsed or refractory CD19 positive B-cell lymphoma. Detailed Description In this single-center, open-label, nonrandomized, no control, prospective clinical trial, a total of 10 relapsed or refractory CD19+ B-cell Non-Hodgkin Lymphoma (NHL) patients will be enrolled. CD19 CAR T cells transduced with a lentiviral vector to express anti-CD19 scFv TCRζ:4-1BB, will be administered by i.v. injection in a three-day split-dose regimen: 10% on day 0, 30% on day 1 and 60% on day 2. Side effects of CD19 CAR T cells therapy will be monitored. The purpose of current study is to determine the clinical efficacy and safety of CD19 CAR T cells therapy in patients with relapsed or refractory CD19 positive B-cell lymphoma. #Intervention - BIOLOGICAL : CD19 CAR T cells - CD19 CAR T cells was transduced with a lentiviral vector to express anti-CD19 scFv TCRζ:4-1BB.

#Eligibility Criteria: Inclusion Criteria: * Patients aged 18 <= age <= 70 with relapsed or refractory CD19 positive B-cell lymphoma. * Eastern Cooperative Oncology Group (ECOG) Performance status 0 <= age <= 2. * Adequate end organ function as defined by: Total bilirubin <= 1.5 x upper limit of normal（ULN）; Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <= 2.5 x ULN; Creatinine <= 1.5 x ULN or any serum creatinine level associated with a measured or calculated creatinine clearance of >= 40ml/min. * Male and female of reproductive potential must agree to use birth control during the study and for at least 6 weeks post study. * Patients should sign informed consent form. Exclusion Criteria: * Patients with central nervous system involvement by lymphoma. * Prior chemotherapy within 2 weeks before enrollment with the following exceptions: steroids, hydroxyurea, oral mercaptopurine, methotrexate, vincristine and thioguanine are permitted within 2 weeks of enrollment as maintenance or to reduce tumor load. * Prior allogeneic hematopoietic stem cell transplant (HSCT) <= 4 months before enrollment. Patients must have completed immunosuppression therapy prior to enrollment. At enrollment, patients must not have>= grade 2 acute GVHD, or either moderate or severe limited chronic GVHD, or extensive GVHD of any severity. * Known systemic vasculitides, primary or secondary immunodeficiency(such as HIV infection or severe inflammatory disease). * Major surgery within 4 weeks before enrollment. * Impaired cardiac function:Ejection fraction <=45 % on MUGA scan. QTc interval > 450msecs on baseline ECG. Myocardial infarction within 6 months prior to starting study; other clinically significant heart disease (e.g. unstable angina, congestive heart failure or uncontrolled hypertension, uncontrolled arrhythmias). * Administration of live vaccine <= 4 weeks before enrollment. * Other concurrent severe and/or uncontrolled medical conditions: Patients with another primary malignant disease, except those that do not currently require treatment; acute or chronic liver, pancreatic or severe renal disease; another severe and/or life-threatening medical disease. Sex : ALL Ages : - Minimum Age : 18 Years - Maximum Age : 70 Years - Age Group (Child: birth-17, Adult: 18-64, Older Adult: 65+) : ADULT, OLDER_ADULT Accepts Healthy Volunteers: No

{ "NCT_ID" : "NCT04169022", "Brief_Title" : "AML Cell Immunotherapy Using Chimeric Antigen Receptor T-cells", "Official_title" : "Targeting Interleukin 1 Receptor Accessory Protein (IL1RAP) Expressing Acute Myeloid Leukemic (AML) Cells by Chimeric Antigen Receptor (CAR) Engineered T-cells", "Conditions" : ["Acute Myeloid Leukemia"], "Interventions" : ["Other: Sample collection"], "Location_Countries" : ["France"], "Study_Design" : { "Study_Type" : "INTERVENTIONAL", "Phase" : ["NA"], "Primary_Purpose" : "SCREENING", "Allocation" : "NON_RANDOMIZED", "Interventional Model" : "PARALLEL", "Masking" : "NONE" } }

#Study Description Brief Summary AML is one of the most aggressive forms of leukemia, where bone marrow transplantation remains the gold standard treatment, with its known associated toxicities and related mortality. Despite progress in the treatment of leukemic malignancies, especially the emergence of targeted- and immuno-therapies arising from biological genomic knowledge, there remains a need to provide additional strategies for refractory/relapsing (R/R) patients Aim of this study is to collect biological samples of AML patients in order to validate our Chimeric Antigen Receptor T-cells immunotherapy approach #Intervention - OTHER : Sample collection - Sample collection blood and/or bone marrow

#Eligibility Criteria: Inclusion Criteria: * AML patients adults and pediatrics Exclusion Criteria: * AML3 Sex : ALL Ages : - Age Group (Child: birth-17, Adult: 18-64, Older Adult: 65+) : ADULT, CHILD, OLDER_ADULT Accepts Healthy Volunteers: No

{ "NCT_ID" : "NCT03874897", "Brief_Title" : "Chimeric Antigen Receptor T Cells Targeting claudin18.2 in Solid Tumors.", "Official_title" : "An Open Label, Single/Multiple Dose Exploratory Clinical Study to Evaluate the Safety, Efficacy, and Cytokinetics of Autologous Humanized Anti-claudin18.2 Chimeric Antigen Receptor T Cell in Advanced Solid Tumor Subjects", "Conditions" : ["Advanced Solid Tumor"], "Interventions" : ["Drug: CAR-CLDN18.2 T-Cells", "Drug: PD-1 Monoclonal Antibody", "Drug: Chemotherapy"], "Location_Countries" : ["China"], "Study_Design" : { "Study_Type" : "INTERVENTIONAL", "Phase" : ["PHASE1"], "Primary_Purpose" : "TREATMENT", "Allocation" : "NON_RANDOMIZED", "Interventional Model" : "SINGLE_GROUP", "Masking" : "NONE" } }

#Study Description Brief Summary An open label, single/multiple dose exploratory clinical study to evaluate the safety, efficacy, and pharmacokinetics of autologous humanized anti-claudin18.2 chimeric antigen receptor T cell in advanced solid tumor. Detailed Description This study is an open, single/multiple infusion, dose escalation/dose regimen finding study to assess the safety and pharmacokinetics of CAR-CLDN18.2 T cell therapy, and to obtain the preliminary efficacy results in subjects who have been diagnosed with advanced solid tumor with positive claudin 18.2 expression and failed to standard systemic treatment. #Intervention - DRUG : CAR-CLDN18.2 T-Cells - Preconditioning with fludarabine, cyclophosphamide, based chemotherapy regimen at sub-clinical doses • Chimeric Antigen Receptor T Cells Targeting Claudin18.2 - Other Names : - Chimeric Antigen Receptor T Cells Targeting Claudin18.2 - DRUG : PD-1 Monoclonal Antibody - Chimeric Antigen Receptor T Cells Targeting Claudin18.2 with PD-1 - Other Names : - Toripalimab - DRUG : Chemotherapy - First-line systemic therapy according to physician's choice

#Eligibility Criteria: Inclusion Criteria: * Aged 18 <= age <= 75, male or female; * Subjects with pathologically confirmed solid tumors (ie, advanced gastric cancer, esophagogastricgastroesophageal junction cancer, and pancreatic cancer) and have been failed to at least first-one prior line of systemic treatment; * Tumor tissue samplessample was positive for claudin 18.2 positive through for claudin18.2 IHC staining;assay(>=2+, and >=40%); * Estimated life expectancy > 12 weeks; * According to the RECIST 1.1, there is at least one measurable or unmeasurable tumor lesionslesion； * ECOG physical status score 0 ~ 1, within 24 hours prior to apheresis, and at baseline (prior to pre-treatment); * Sufficient venous access for mononuclear cell collection (abbreviation: apheresis) * Subjects should have adequate organ functions before screening and pre-treatment (at baseline). * Female subjects of childbearing age must undergo a serum pregnancy test at screening and prior to preconditioning and the results must be negative, and are willing to use a very effective and reliable method of contraception within 1 year after the last study treatment. The methods that can be used are: bilateral tubal ligation / bilateral salpingectomy or bilateral tubal occlusion; or approved oral, injection or hormone-imparting contraceptive methods; or barrier contraceptive method: containing spermicidal foam / Gel/film/cream/suppository condom or occlusive cap (diaphragm or cervix/cap); * Men who have actively sexual intercourse with women with child-bearing potential, must agree to use barrier-based contraception if they have no vasectomy, for example, a condom containing a spermicidal foam/gel/film/paste/suppository, or use a contraceptive method for their spouse (see article 9 of the inclusion criteria). Moreover, all men are absolutely forbidden to donate sperm within 1 year after receiving the last study treatment infusion； * Subject participates in this clinical trial and sign Informed Consent Form voluntarily. Exclusion Criteria: * Pregnant or lactating women; * HIV, Treponema pallidum or HCV serologically positive; * Any uncontrollable active infection, including but not limited to active tuberculosis, HBV infection (HBsAg positive, or HBcAb positive and HBV DNA positive); * Subjects have clinically significant thyroid dysfunction determined by investigator (serum thyroid hormone assays TT4, TT3, FT3, FT4, and serum thyroid stimulating hormone TSH) which is not suitable for entering into the study; * The side effects caused by the previous treatment of the subjects did not return to CTCAE <=1; except hair loss and, hyperpigmentation or other tolerable events determined by investigator or laboratory abnormalities allowed by the protocol; * Subjects who are using steroidshave recieved >=15 mg/day glucocorticoid systemically currently within 7 days prior to apheresis; those using inhaled steroids recently or currently are not excluded; * Previously allergic to immunotherapy and related drugs, history of severe allergiespreconditioning drug such as cyclophosphamide, fludarabine, or allergiestocilizumab or allergic to components of CT041CAR-CLDN18.2T injection, allergic to β-lactam antibiotics;the CT041 infusion; * Previously received any chimeric antigen receptor-modified T-cells(including CAR-T、TCR-T) . * Subjects have untreated or symptomatic brain metastases; * Subjects have central or extensivelywith centralcor diffused metastases in lung and .extensiveor diffused metastases in liver;liveror with rapid tumor progression since screening period evaluated by the investigator preconditioning (at baseline)； * The largest target tumor lesion>4cm * Subjects with unstable or active ulcers and gastrointestinal bleeding currently; * Subjects with a history of organ transplantation or awaiting organ transplantation; * Subjects requiring anticoagulant therapy; * Subjects requiring continuous anti-platelet therapy; * Subjects who have undergone major surgery or significant trauma within 4 weeks prior to apheresis, or who are expected to undergo major surgery during the study; * There are no other serious diseases that may limit subjects' participation in this trial; * The investigator assessed that the subject was unable or unwilling to comply with the requirements of the study protocol; * Blood oxygen saturation <= 95% before pre-treatmentapheresis or preconditioning (accept finger oxygen detection method); * Prior to pretreatmentpreconditioning, subjects developed, including but not limited to, new arrhythmias that could not be controlled with drugs, hypotension requiring pressor agent, bacterial, fungal or viral infections that required intravenous antibiotics. Creatinine clearance rate <40mL / min; The investigator judges that the subject is not suitable for continuing the trial. Subjects who use antibiotics to prevent infection can continue the trials if judged by the investigator; * The subject has a central nervous system disease sign or an abnormal neurological test result with clinical significance; * The subject is currently suffered from or have suffered from other incurable malignant tumors within previous 3 years, except in situ cervical cancer or skin basal cell cancer. Sex : ALL Ages : - Minimum Age : 18 Years - Maximum Age : 75 Years - Age Group (Child: birth-17, Adult: 18-64, Older Adult: 65+) : ADULT, OLDER_ADULT Accepts Healthy Volunteers: No

{ "NCT_ID" : "NCT03274219", "Brief_Title" : "Study of bb21217 in Multiple Myeloma", "Official_title" : "A Phase 1 Study of bb21217, an Anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma", "Conditions" : ["Multiple Myeloma"], "Interventions" : ["Biological: bb21217"], "Location_Countries" : ["United States"], "Study_Design" : { "Study_Type" : "INTERVENTIONAL", "Phase" : ["PHASE1"], "Primary_Purpose" : "TREATMENT", "Allocation" : "NA", "Interventional Model" : "SINGLE_GROUP", "Masking" : "NONE" } }

#Study Description Brief Summary Study CRB-402 is a 2-part, non-randomized, open label, multi-site Phase 1 study of bb21217 in adults with relapsed/refractory multiple myeloma (MM). Detailed Description Part A of the study will be Dose Escalation followed by Part B, an expansion cohort. Following consent, enrolled subjects will undergo a leukapheresis procedure to collect autologous mononuclear cells for manufacture of investigational drug product (bb21217). Following manufacture of the drug product, subjects will receive lymphodepletion prior to bb21217 infusion. All subjects will then be followed for up to 60 months in Study CRB-402. All subjects who complete the study, as well as those who withdraw from the study after receiving bb21217 for reasons other than death or meeting the early termination criteria, will be asked to continue to undergo long-term follow-up in a companion study. #Intervention - BIOLOGICAL : bb21217 - autologous T cells transduced ex-vivo with anti-BCMA CAR lentiviral vector encoding the chimeric antigen receptor (CAR) targeted to human BCMA, suspended in cryopreservative solution

#Eligibility Criteria: Inclusion Criteria: * >=18 years at the time of signing informed consent * Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 * Diagnosis of MM with relapsed or refractory disease and have had at least 3 different prior lines of therapy with previous exposure to PI, IMiDs, and a CD38 antibody. Have undergone at least 2 consecutive cycles of treatment for each therapy, unless PD was the best response to the therapy. Refractory to their last line of therapy. * Subjects must have measurable disease Exclusion Criteria: * Subjects with known central nervous system disease * Inadequate hepatic function * Inadequate renal function * Inadequate bone marrow function * Presence of active infection within 72 hours * Subjects with a history of stroke, unstable angina, myocardial infarction, or ventricular arrhythmia requiring medication or mechanical control * Significant co-morbid condition or disease which in the judgment of the Investigator would place the subject at undue risk or interfere with the study; examples include, but are not limited to, cirrhotic liver disease, sepsis, recent significant traumatic injury, and other conditions * Known human immunodeficiency virus (HIV) positivity * Known hepatitis A virus (HAV), hepatitis B virus (HBV) or hepatitis C virus (HCV) positivity with evidence of ongoing infection. * Pregnant or lactating women * Previous history of an allogeneic bone marrow transplantation, treatment with any gene therapy based therapeutic for cancer, or BCMA-targeted therapy * Inadequate pulmonary function defined as oxygen saturation (SaO2) <92% on room air * Subjects who have a history of plasma cell leukemia, active plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS, or clinically significant amyloidosis Sex : ALL Ages : - Minimum Age : 18 Years - Age Group (Child: birth-17, Adult: 18-64, Older Adult: 65+) : ADULT, OLDER_ADULT Accepts Healthy Volunteers: No